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Abstract 
 
The NF-κB family of transcription factors can induce or repress target 
gene expression by binding DNA as homo- or hetero-dimers. In some cancer 
cells the p52  (NF-κB2) subunit, which is derived by proteolytic processing of its 
precursor p100, regulates the expression of genes having a role in cell 
proliferation, such as Cyclin D1 and is also involved in the regulation of G2/M 
phase. Depletion of p100/p52 by siRNA leads to an increase of cells in G2/M 
phase and defects in mitosis. These defects in mitosis can be visualised as 
aberrant chromosome segregation, disruption of the microtubule network and 
poor alignment of chromosomes on the metaphasic plate. Moreover, p100/p52 
depletion results in an increase in multinucleate cells, as well as aberrant 
centrosome structures.  
To elucidate this mechanism, I have investigated p100/p52 regulation of 
various genes involved in the cell cycle and centrosome duplication. I 
discovered that p100/p52 siRNA depletion reduces the expression of a number 
of cell cycle regulators, including Polo-like kinase 4 (PLK4) or Spindle assembly 
abnormal protein 6 (SAS6), a member of the SAS proteins family. PLK4, in 
conjunction with the cyclin-dependent kinase CDK2 and the PLK4 effector 
SAS6, is a key regulator of centriolar duplication. I demonstrated by reporter-
gene and chromatin-immunoprecipitation analyses that the PLK4 promoter is a 
direct target for multiple NF-κB subunits and its activity depends upon NF-κB 
expression. Moreover PLK4 and p100/p52 mRNA and protein expression are 
cell cycle regulated and NF-κB subunits bind the PLK4 promoter in a cell cycle 
dependent manner. 
 These results reveal PLK4 as a new NF-κB target, providing a direct link 
between NF-κB and centrosome duplication with implications for the role of p52 
in tumorigenesis. 
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 1 
1 - Introduction 
 
1.1 The transcription factor NF-κB 
 
1.1.1 Transcription and transcription factors 
Transcription is the cellular process used to convert information encoded 
within the DNA into RNA, which can then act as the template for protein 
synthesis or fulfill structural or regulatory functions. The machinery to allow 
transcription in eukaryotes is extremely complex and well regulated but mainly 
relies on three different RNA polymerase enzymes. These three enzymes share 
structural similarities and have some common subunits, although others are 
unique to the enzyme (Sekine et al, 2012). RNA polymerase I, responsible for 
70% of transcription, is specific to the production of large ribosomal RNA 
(rRNA), whereas RNA polymerase III is in charge of ~10% of transcriptional 
activity and creates small RNAs such as transfer RNA (tRNA) or the 5S rRNA. 
The most studied of RNA polymerases is RNA polymerase II, involved in 20% 
of the cellular transcriptional activity and responsible for the transcription of 
genes translated into proteins (Sekine et al, 2012).  
Usually, a group of proteins called transcription factors binds the DNA on 
a specific sequence within the promoter or enhancer of a target gene and 
thereby regulates its expression. An enhancer is a short DNA sequence 
recognized by transcription factors for regulation of the gene. However, in 
contrast to a regular promoter, it can be localized at the further distance from 
the gene it regulates (Arnosti & Kulkarni, 2005). Besides some general 
transcription factors (TFIIA, TFIIB, TFIID for example) required for accurate 
basal transcription, sequence specific DNA binding proteins (transcription 
factors) are required for regulated, gene specific transcriptional activity. 
Transcription factors can activate or repress transcription via the recruitment or 
interaction with co-regulator proteins (Sekine et al, 2012). These co-regulators 
do not bind directly the DNA, but facilitate the transcription factor dependent 
recruitment of the general transcription machinery, or possess chromatin 
remodeling functions, to regulate the accessibility of the gene’s regulatory 
regions. Co-regulator proteins can act as co-activators (such as p300 and CBP 
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(CREB Binding Protein)) or co-repressors (such as Sin3 or TIF1). Transcription 
factor activity requires extensive regulation, through various mechanisms such 
as abundance, post-translational modifications, cellular localization, 
dimerization or proteolytic degradation (Sekine et al, 2012).  
 
1.1.2 Overview of the NF-κB pathway 
Nuclear factor κB (NF-κB) was discovered twenty-six years ago as a 
nuclear protein that binds to the immunoglobulin κ light chain enhancer in B 
cells (Sen & Baltimore, 1986). NF-κB corresponds to a family of transcription 
factors, which regulate the expression of a wide variety of genes. Perfect 
example on inducible transcription factor, NF-κB’s main role is in the 
development and regulation of immune system (Hayden & Ghosh, 2012). NF-
κB can also be found in other species such as mouse, dog and chicken. NF-κB 
has been well studied in Drosophila melanogaster, where three subunits have 
been described, Dorsal, Dif and Relish, which are involved in embryonic pattern 
formation, immunity, muscle development and hematopoiesis (Govind, 1999). 
NF-κB can also be found in organisms such as Xenopus (Kao 1991) and 
Zebrafish (Correa et al, 2004). Furthermore, a homologue of the NF-κB 
activating protein (NKAP) has been identified in Caenorhabditis elegans (C. 
elegans) although this organism seems to have lost NF-κB subunits (Chen et al, 
2003). This broad range of organisms demonstrates that the NF-κB pathway is 
an ancient and well-conserved evolutionary pathway, which exists in many 
organisms. 
In mammalian cells, the NF-κB family is constituted of 5 members: RelA 
(p65), RelB, c-Rel, NF-κB1 (p105/p50) and NF-κB2 (p100/p52) (Figure 1.1), 
which can induce or repress the expression of target genes by binding DNA as 
homo- or hetero-dimers (Perkins, 2007). The avian viral oncogene v-Rel is also 
an NF-κB protein (Joyce et al, 2001). In unstimulated cells, NF-κB localizes in 
the cytoplasm in an inactive complex with proteins from the IκB (Inhibitors of the 
NF-κB proteins) family (see section 1.1.3). Upon exposure to various stimuli 
such as cytokines, growth factors or viral products such as tumor necrosis 
factor (TNF)-α, interleukin-1 (IL-1) or lipopolysaccharide (LPS) or viral proteins 
(such as Tax or LMP1), IκB is phosphorylated by the IκB kinase (IKK)   
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1.1: the members of the NF-κB and IκB families 
A. All the members of the NF-κB family contain a Rel Homology Domain, which allows 
DNA binding and dimerization. RelA, RelB and c-Rel contain, in their C termini, a 
transactivation domain (TAD), which has sub-domains TA1 and TA2 for RelA and c-
Rel. NF-κB1 is processed from p105 into p50 and NF-κB2 from p100 into p52, which 
results in two shorter proteins lacking the 7 ankyrin repeat domains and the Death 
Domain (DD). 
B. The inhibitor of NF-κB (IκB) family is constituted of IκBα, IκBβ, IκBε and Bcl-3. They 
all contain ankyrin repeat domains. IκBα and IκBβ have a PEST domain (a domain rich 
in Proline, Glutamate, Serine, and Threonine). Adapted from (Perkins, 2007) 
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complex and then degraded, unmasking the nuclear localization signal (NLS) of 
the NF-κB dimers leading to its activation. NF-κB complexes can be induced by 
various stimuli such as DNA damage, cell stress, bacterial products, 
inflammatory cytokines, viral proteins and infection. 
NF-κB subunits act as dimers and almost all combinations of dimers are 
possible. In the literature NF-κB usually refers to the RelA/p50 hetero-dimer, as 
the most commonly observed complex.  RelA homo- and hetero-dimers are 
responsible for much of the observed NF-κB transactivation activity, due to a 
strong transactivation domain in RelA (Karin et al, 2002). RelB can have an 
activating or repressing function (Karin et al, 2002) and can be sometimes 
associated with p50 (Joyce et al, 2001). However, RelB mainly binds to p100 in 
the cytoplasm before translocating to the nucleus once p100 is processed to 
p52 (Karin et al, 2002). RelB/c-Rel association is rare (Joyce et al, 2001) and 
does not bind to the DNA, as it is the case for RelA/RelB heterodimers and 
RelB homo-dimers (Joyce et al, 2001; Karin et al, 2002). c-Rel/p50 hetero-
dimers are less abundant and have a slower response (Karin et al, 2002). 
p50/p50 and p52/p52 homo-dimers, as well as p50/p52 hetero-dimers therefore 
do not act as transcriptional activators by themselves and need the recruitment 
of co-activators (Hoffmann & Baltimore, 2006). Despite the extensive research, 
the biological function of different dimers combinations is still unknown. 
Several mechanisms have been proposed to explain the processing of 
p105 into p50. The best described is the constitutive generation of p50 in un-
stimulated cells resulting from co-translational proteolysis in the C-terminus of 
p105 by the 26S proteasome, liberating p50 (Hayden & Ghosh, 2012). 
Processing of p100 into p52 will be described later. The 26S proteasome is a 
high molecular weight complex responsible for most of protein degradation by 
ATP-dependent proteolysis and is constituted of a 20S catalytic core and a 19S 
regulatory subunit (Frankland-Searby & Bhaumik, 2012). 
The NF-κB family is involved in the regulation of thousands of genes, 
controlling various cellular processes such as the immune and inflammatory 
responses, cell death or cell survival, stress responses, cell adhesion and 
proliferation (Perkins, 2004b). NF-κB itself does not have intrinsic enzymatic 
activity and thus needs to recruit co-activators such as p300 and CBP or co-
repressors such as histone deacetylase (HDAC) proteins to its target genes in 
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order to regulate their transcriptional activity (Hayden & Ghosh, 2012). More 
than 200 regulators or inducers of NF-κB activity have been described. 
Constitutive activation or loss of expression of one or several proteins in the κB 
pathway can cause multiple diseases such as cancer, muscular and 
neurodegenerative diseases and diabetes (type I and II) (Kumar et al, 2004). So 
far, NF-κB has been found involved in 79 diseases, many of those resulting 
from inflammatory responses, such as atherosclerosis and arthritis. Viral 
infection is also well described to induce a NF-κB response. A growing literature 
associates dysfunctional NF-κB activity with cancer, as will be discussed later 
(see section 1.4.2) (www.nf-kb.org).  
The NF-κB subunits contain a number of conserved motifs. DNA binding 
is mediated by a domain called the RHD (Rel Homolgy Domain), which is highly 
conserved between all NF-κB subunits in different species. The RHD domain is 
approximately 300 amino-acids and also permits the dimerization of NF-κB sub-
units. It contains a nuclear localization sequence (NLS) and allows members of 
the IκB family to bind to the Rel proteins in order to keep them inactivated. The 
DNA binding activity of NF-κB dimers via the RHD domains can be controlled 
by modifications such as phosphorylation, oxidation and acetylation (Perkins, 
2006).  
The main difference between all the members of the NF-κB family is in 
their C terminal domains. RelA, RelB and c-Rel have transactivation domains 
(TAD) able to activate the transcription of NF-κB target genes (Karin et al, 
2002). p50 and p52 do not contain a transactivation region and can only 
efficiently regulate gene expression if complexed with Rel sub-units or other 
proteins. 
The ankyrin (Ank) repeat motif is a sequence of 33 amino acids that 
mediates specific protein-protein interactions, discovered for the first time in the 
SW16 protein of Saccharomyces cerevisiae (May & Ghosh, 1997). p105 and 
p100 contain, in their C termini extensions, 7 ankyrin repeat motifs. This domain 
is also contained within the ΙκBs and allows the binding to the NLS of NF-κB 
and consequently its inactivation by sequestration in the cytoplasm (Karin et al, 
2002). However, in case of IκBα-RelA-p50 complexes, cytoplasmic 
sequestration is not absolute, with constant shuttling occuring between the 
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cytoplasm and nucleus. NF-κB NLS is only partially masked, resulting in the 
possible nuclear translocation. Once in the nucleus, the nuclear export signal 
(NES) of IκBα causes the complex to be rapidly exported back to the cytoplasm 
(Hayden & Ghosh, 2012). In p100 and p105, this ankyrin repeat domain also 
interacts with the RHD domain in other NF-κB proteins and acts as a ΙκB-like 
protein, masking the NLS and sequestering the NF-κB dimers in the cytoplasm 
(Joyce et al, 2001). 
 
1.1.3 The IκB family 
The NF-κB complexes are retained in an inactive cytoplasmic form by a 
family of inhibitor proteins. This family of IκB proteins  includes IκBα, IκBβ, IκBγ, 
IκBε and Bcl-3 (Figure 1B) (Perkins, 2007). These proteins possess a series of 
ankyrin repeat motifs that interact with the DNA binding domain of NF-κB 
dimers, as described above (Joyce et al, 2001). However, the number of 
ankyrin repeat motifs does not seem to be involved in the mechanism of NF-κB 
inhibition (May & Ghosh, 1997). ΙκΒγ is a splice variant encoding only the p105 
C-terminus, is specific to lymphoid cells and is able to interact only with 
p105/p50 and p100/p52 homodimers, whereas ΙκΒε is specific to RelA and c-
Rel complexes (Whiteside et al, 1997). The N- and C-terminal regions of IκB do 
not have effects on the ability to bind NF-κB but the deletion of the C-terminal 
domain inhibits the dissociation of DNA-NF-κB dimers and the repression of 
DNA binding by NF-κB (May & Ghosh, 1997). Bcl-3, even though it structurally 
belongs to the ΙκΒ family, is nuclear, can bind to p50 and p52 homo-dimers and 
functions as a transcriptional co-activator (Joyce et al, 2001). The function of 
the ΙκΒ proteins can be independent from NF-κB activation. Atypical members 
of the ΙκΒ family, like Bc-3 or IκBζ, can bind and recruit other co-activators and 
then affect their transcription response (Ghosh & Hayden, 2008; Hayden & 
Ghosh, 2012). ΙκΒ proteins are generally expressed in every cell type. As NF-
κB generates a negative feedback loop by inducing IκBα expression, in the 
absence of IκBα, the termination NF-κB activation after stimulation by the 
cytokine TNFα is delayed compared to normal cells (Klement et al, 1996). 
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Indeed, IκBα contains a nuclear export sequence, which by binding to NF-κB in 
the nucleus, will return it to the cytoplasm (Perkins, 1997). 
ΙκΒα degradation is induced via phosphorylation of the serine residues 
32 and 36, which leads to lysine K48-linked ubiquitination at K20 and K21 and 
degradation via the proteasome. IκBβ and IκBε are activated via similar, 
conserved serine residues. An alternative mechanism has been described for 
the activation via IκBα: in response to the re-oxygenation of hypoxic cells, 
tyrosine Y42 phosphorylation does not induce a proteolytic degradation but 
leads to the dissociation of IκBα from NF-κB and thus its activation (Perkins, 
1997). IκBα can also be responsible for NF-κB inactivation following induction.  
Similar to IκBα, upon stimulation IκBε is phosphorylated at Ser157 and 
Ser161, which induces its degradation by the proteasome (Whiteside et al, 
1997). IκBε is believed to be specific for RelA homo-dimers and c-Rel/RelA 
hetero-dimers. A combined depletion of IκBα and IκBε in mice induces a 
reduction in splenic natural killer (NK) cells numbers, as well as incomplete NK 
cell maturation. This is linked to a hyperactivation of NF-κB. However, single 
depletion of either of these IκB proteins does not affect NK cell production 
(Samson et al, 2004). This has been confirmed with IκBα and IκBε double 
deficiency increasing NF-κB activity and inducing neonatal death, associated 
with a disruption in lymphocyte production (Goudeau et al, 2003).  
IκBβ, despite homologies to IκBα, possesses functional differences. IκBβ 
is subject to slower degradation and resynthesis (Scheibel et al, 2010) and 
does not affect the kinetic of the NF-κB response, in contrast to IκBα (Hoffmann 
et al, 2002). In contrast to IκBα, which when complexed with NF-κB dimers, 
shuttles between the cytoplasm and nucleus, IκBβ-NF-κB complexes stay in the 
cytoplasm (Scheibel et al, 2010). 
Bcl-3 was discovered as a proto-oncogene present in B-cell chronic 
lymphocytic leukemia. Although it has the structure of an IκB protein, it is 
localized to the nucleus and acts as a transcriptional co-activator with p50 or 
p52 homo-dimers. Bcl-3, by association with the p52 protein, forms a functional 
transcription factor complex (Bours et al, 1993) and binds, for example, to the 
promoter of the cyclin D1 gene, regulating its expression. But when Bcl-3 levels 
decrease (e.g. with UV stimulation or activation of p53), the p52/p52 homo-
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dimer associates with HDAC1, leading to the repression of cyclin D1 
transcription and then a decrease in cyclin D1 expression (Rocha et al, 2003). 
The activation of transcription by Bcl-3 depends of its localization in the 
nucleus, which is regulated by ubiquitination (Hayden & Ghosh, 2012). The 
deubiquitinase CYLD has been shown to promote Bcl-3 deubuquitination, 
thereby keeping it inactive in cytoplasm. With CYLD deficiency, Bcl-3 
accumulates in the nucleus with p50 or p52 dimers, activating transcription of 
genes such as cyclin D1 (Massoumi et al, 2006). Bcl-3 has also been shown to 
act as an inhibitor of NF-κB activity, by stabilizing inactive p50 dimers in a DNA 
bound state on a target gene promoter, blocking the binding of more 
transcriptionally active dimers (Hayden & Ghosh, 2012). This system of 
regulation is seen, for example, with the LPS-tolerance. Indeed, Bcl-3 is a 
negative regulator of Toll-like receptor (TLR) signaling. After LPS stimulation, 
Bcl-3 associates with p50 complexes negatively regulating target gene 
transcription, by blocking p50 ubiquitination. In Bcl-3 deficient mice, the 
absence of Bcl-3-p50 complexes induces hypersensitivity to the TLR response 
following LPS stimulation. This makes Bcl-3 regulation the basis of LPS-
tolerance (Carmody et al, 2007).  
IκBζ  (also called MAIL or INAP) has a sequence similar to Bcl-3 
(Kitamura et al, 2000). Associated with p50 complexes, it activates transcription 
of target genes such as IL-6 (Hayden & Ghosh, 2012). After stimulation by 
some stimuli (MyD88- or TRAFF6-dependent signaling pathways), its 
expression can be induced by NF-κB (Eto et al, 2003). IκBζ does not have a 
TAD and can act as a regulator for RelA/p50 dimers upon interaction with the 
p50 subunit (Motoyama et al, 2005).  
Another IκB protein, called IκBNS, is less studied. It was first 
characterized as a promoter of apoptosis in T cells under negative selection but 
can also be found in various cell lines (Fiorini et al, 2002). IκBNS 
overexpression inhibits NF-kB in the same manner as Bcl-3. IκBNS expression 
is induced by IL10 and it binds mainly to p50 and stabilizes p50 homo-dimers at 
the κB sites (Hayden & Ghosh, 2012). 
p105 and p100, in addition to their role as precursors to p50 and p52, 
have also been described acting as IκB-like proteins. Their interaction with NF-
κB dimers requires either direct binding to the RHD of NF-κB proteins or 
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interaction between the p105 and p100 Ankyrin repeats and preformed dimers 
(Savinova et al, 2009). Processing of p105 and p100, by losing their IκB-like C 
terminus, releases specific NF-κB complexes (Xiao et al, 2001). RelB 
associates mainly with p100 and p52 and binding to p100 stabilizes the 
complex (Fusco et al, 2008; Solan et al, 2002). Activation and processing of 
p100 facilitates the exchange on κB sites from the RelA heterodimer to a 
RelB/p52 dimer during dendritic cell maturation. As different NF-κB dimers have 
different transcriptional activity, this induces a different response at later time 
point (Saccani et al, 2003). p100 associates with RelA/p50 dimers in its IκB-like 
C terminus and regulates their activation in response to non-canonical stimuli 
such as LTβR signaling (Basak et al, 2007). p100 also retains NF-κB 
complexes in the cytoplasm, keeping them inactive and influences the pool of 
NF-κB subunits available. Indeed, an increase in p100/p52 levels will enhance 
formation of RelB/p52 complexes, whereas an increase in p52/RelA or p52/p50 
will induce these “canonical” NF-κB dimers activation (Hayden & Ghosh, 2012). 
p105’s IκB-like function was identified as early as 1992 (Rice et al, 
1992). p105, after binding to NF-κB dimers, is phosphorylated and constitutively 
processed to p50 via the ubiquitin-dependent proteasome pathway (Moorthy et 
al, 2006). p105, to be recognized by the proteasome and proteolytically 
processed, needs a Glycine Rich Region (GRR) that acts as a stop signal, 
inducing p50 generation instead of a full degradation of p105 (Hayden & Ghosh, 
2012; Xiao et al, 2001). p105 requires a quick processing tp produce active p50 
dimers. However, in case of slower processing, the p105 C terminus binds to 
stabilize NF-κB dimers and maintains them inactive in the cytoplasm, acting as 
IκB-like protein (Shih et al, 2009).  
 
1.1.4 The IKK family 
As discussed above, to release the NF-κB dimers, ΙκΒ proteins are 
phosphorylated by the IκB kinase complex (IKK), which results in their 
ubiquitination and degradation by the proteasome. The IKK complex constitutes 
of two catalytic subunits (IKKα and IKKβ) and a regulatory protein NEMO (NF-
κB essential modulator, also called IKKγ). The IKKα and IKKβ proteins have 
distinct functions: IKKβ is involved in NF-κB activation through the canonical 
 10 
pathway, whereas IKKα is required for the activation of the non-canonical 
pathway (see below) (Perkins, 2007). After stimulation, IKKα is phosphorylated 
at serines 176 and 180 by NF-κB inducing Kinase (NIK) (Karin et al, 2002), 
inducing the processing of p100 to p52 (Senftleben et al, 2001). IKKβ is 
activated by phosphorylation on serines 177 and 181 by kinases such as the 
TGF-β activated-kinase1 (TAK1) resulting from TAK1 recruitment following 
NEMO-ubiquitination (Perkins, 2007). 
Recently, new functions for IKKs, independent from NF-κB and ΙκΒ, have 
been discovered, suggesting that IKK proteins could have a more widespread 
role. Activation of IKKβ promotes survival and proliferation, inducing anti-
apoptotic (Tang et al, 2001) and proliferative pathways (Widera et al, 2006) in 
response to TNF-α. For example, IKKβ can also inhibit apoptosis and promote 
cell growth by phosphorylation and inhibition of the tumour suppressor FOXO3 
(Hu & Hung, 2005; Tezil et al, 2012). This promotes tumorigenesis and 
enhances chemoresistance (Hu & Hung, 2005), by inducing FOXO3 
sequestration in the cytoplasm after cisplatin treatment in breast cancer cells 
(Tezil et al, 2012). IKKβ can also activate the MAP kinase (MAPK) pathway, 
promoting the cell proliferation. This is achieved by inducing the proteolytic 
degradation of p105 (Perkins, 2007), a subset of which is associated with the 
Tpl2 kinase, which upon p105 degradation is released, leading to MAP kinase 
activation (Perkins, 2007). 
IKKα also has a variety of other substrates. IKKα is notably able to 
regulate cyclin D1 expression, resulting in effects on cell proliferation, 
independently of NF-κB. After UVB stimulation, IKKα activates the p38 and 
ERK MAPK pathways, which lead to repression of cyclin D1 transcription by 
ERK1/2 in addition to p38-dependent proteolysis of cyclin D1 (Song et al, 
2010). By contrast, IKKα is also able to induce its expression, so promoting cell 
proliferation. Indeed, IKKα associates with oestrogen receptor α (ERα) and is 
then able to activate transcription of oestrogen-responsive genes such as cyclin 
D1 or c-myc in breast cancer cells (Park et al, 2005). IKKα can also regulate 
chromatin structure through association with the co-activator complex or by 
functioning as a histone H3 kinase (Perkins, 2007). 
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1.1.5 Canonical pathway of NF-κB activation 
Although various pathways have been shown to activate NF-κB, the two 
most common and best described are: the canonical (classical) and the non-
canonical (alternative) pathway. The first to be described here is the canonical 
pathway and results in the degradation of IκBα and release of RelA/p50 or c-
Rel/p50 heterodimers, which translocate to the nucleus, where they regulate the 
transcription of target genes (Perkins, 2007) (Figure 1.2). Upon stimulation by 
pro-inflammatory cytokines the IKK complex is activated and phosphorylates 
IκBα on the serine 32 and 36 residues. This leads to IκBα polyubiquitination on 
Lysine 21 and 22 residues by the SCF (Skp1/Cul1/F-box) ubiquitin ligase 
family, resulting in its degradation by the proteasome (Karin et al, 2002), 
(Perkins & Gilmore, 2006b). The canonical pathway allows a fast and transient 
response to various stimuli, independent of protein synthesis (Sun, 2011).  
NF-κB classical activation is mainly dependent on IKKβ (Senftleben et al, 
2001). By contrast, IKKα contributes to NF-κB activation but does not seem 
indispensable for the resistance to apoptosis (Baldwin, 2012). To terminate 
canonical pathway activation, NF-κB induces a negative feedback loop 
involving the transcription of target genes such as IκBα and A20. Resynthetized 
IκBα binds NF-κB dimers and promotes their translocation to the cytoplasm as 
an inactive dimer (Perkins & Gilmore, 2006b). In parallel, induction of A20 
deubiquitinase expression results in inhibition of IKK activity (Krikos et al, 1992). 
A20 interacts TRAF6 and RIP1, inactivating IKK complexes and thus stopping 
IκBα degradation, leading to NF-κB inactivation (Shembade & Harhaj, 2012). 
Although the mechanism for NF-κB translocation to the nucleus is not yet 
fully described, it has been suggested to result from the binding with 
karyopherins, proteins responsible for transport between the nucleus and 
cytoplasm (Rothwarf & Karin, 1999). In 2005, Fagerlund et al demonstrated that 
RelA/p50 heterodimers and p50/p50 homodimers could be imported to the 
nucleus by the importin α3 and α4 proteins. Importin α3 and α4 are members of 
the importin α family, constituted of 6 members: α1 (hSRP1α), α3 (Qip1), α4 
(hSRP1γ), α5 (NPI1), α6 and α7 (Fagerlund et al, 2005). Importin α proteins 
contain armadillo repeat motifs that recognize NLS sequence of target proteins, 
and form a heterodimer with the importin β protein that will enable nuclear  
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Figure 1-2: Canonical and non-canonical pathways for NF-κB activation 
Schematic overview of the canonical and non-canonical pathways leading to NF-κB 
activation. The canonical pathway (left side) leads to the activation of RelA-p50 
heterodimers. After stimuli such as TNFα or IL-1, the IKK complex containing NEMO, 
IKKα and IKKβ phosphorylates IκBα on Ser32 and Ser36, inducing ubiquitination and 
proteasomal degradation of IκBα, thus releasing RelA-p50 dimers, which then 
translocate to the nucleus to regulate the target gene transcription. The non-canonical 
pathway (right side) is responsible for p100 processing and p52 activation. Following 
stimuli by CD40 or LPS, NIK phosphorylates a IKKα complex. These kinase then 
phosphorylate p100 on Ser866 ad Ser870, leading to its ubiquitination and p100 
processing into p52. p52, forming a dimer with RelB, translocates to the nucleus and 
then can regulate the transcription of target gene. Other combinations of NF-κB 
dimerization than RelA-p50 or RelB-p52 are also possible. 
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translocation of the target proteins. Importin α3 directly binds to the RelA and 
p50 NLS region and facilitates nuclear translocation only if NF-κB complexes 
are free from IκBα (Fagerlund et al, 2005). 
Aberrant activation of the canonical NF-κB pathway is critical for 
lymphocyte proliferation and survival (Jost & Ruland, 2007) and mediates 
tumorigenesis following inflammation in animal models (Pacifico & Leonardi, 
2006; Pikarsky et al, 2004).  
 
1.1.6 Activation of the non-canonical NF-κB pathway 
The second NF-κB activation pathway, called the non-canonical or 
alternative pathway, results in the processing of p100 to p52 and release of 
p52/RelB hetero-dimers (Figure 1.2). Discovered about 10 years ago, it has 
been the subject of extensive research, as it is significantly different from the 
classical pathway in the composition of IKK complexes and the signaling 
mechanisms involved (Perkins & Gilmore, 2006b; Sun, 2011). As it is also the 
case for the classical pathway, the non-canonical NF-κB activation pathway can 
be aberrantly activated in many tumours. NF-κB subunits can be mutated or 
aberrantly active in tumours, and NF-κB2, is particularly associated with a 
number of lymphomas, notably through chromosomal translocation that 
generates a truncated constitutively active form of the protein (Karin et al, 
2002).  
Stimuli known to induce the non-canonical pathway include CD40 ligand 
(Coope et al, 2002), Lymphotoxin β Receptor (LT-βR) (Dejardin et al, 2002), 
LPS (Mordmuller et al, 2003), viral proteins including Latent membrane protein 
(LMP1) from the Epstein Barr Virus (Atkinson et al, 2003) and the transcription 
factor Stat3 (Nadiminty et al, 2006). Although most of these stimuli are specific 
for the non-canonical pathway, some are also able to activate NF-κB via the 
classical pathway. After stimulation by these inducers, IKKα complexes are 
activated by phosphorylation on Ser177 and Ser188 via NIK (Karin et al, 2002; 
Senftleben et al, 2001). The exact composition of IKKα complexes is still 
unknown but previous studies demonstrated no requirement for IKKβ or NEMO 
(Perkins, 2006). Activated IKKα complexes are involved in p100 processing, 
mechanism described later (see section 1.1.7.). 
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Among the stimuli for the non-canonical pathway (Table 1.3), a common 
characteristic is the role of TNFR superfamily members. TNFR superfamily 
members, also called Death Receptors, are cytokine receptors binding signals. 
It cooperates with adaptator protein such as TRAF or TRADD and can induce 
various responses depending on the stimuli (survival, cell proliferation, 
apoptosis, etc.) (Sun, 2011). 
- The CD40 ligand is a TNF family member expressed on various cell types 
such as B cell, dendritic cells or endothelial cells. It is important for the 
promotion of cell survival and homotypic B cells aggregation, which is 
dependent upon stimulation of p100 processing (Coope et al, 2002; Sun, 2011). 
- The LTβ receptor is a TNFR superfamily member expressed in myeloid and 
epithelial cells and is specific for the lymphotoxin and LIGHT ligands (discussed 
later, see section 1.1.12). Its activation leads to the induction of a number of 
cytokines and secondary lymphoid organogenesis of the spleen, lymph nodes 
and Peyers patches (Dejardin et al, 2002). 
- The RANK receptor, with its ligand RANKL (Receptor activator of NF-κB 
Ligand) activates p100 processing to regulate osteoclast differentiation (Novack 
et al, 2003), suggesting a role for the non-canonical NF-κB pathway in bone 
formation. This has been confirmed with the demonstration of IKKα involvement 
in skeletal, tooth and skin development using knockout mice (Hu et al, 2001; 
Ohazama et al, 2004; Takeda et al, 1999). Interestingly, the same phenotype 
was observed in nfkb1/nfkb2 double knockout mice (Gerondakis et al, 2006). 
The regulation of the non-canonical pathway is dependent on the 
regulation of NIK levels. Indeed, NIK is naturally low (and maintained as such 
by TRAF3) in most cells. De novo protein synthesis is then required to produce 
and accumulate NIK protein (Sun, 2011). In contrast to the classical pathway, 
whose main feature is the rapidity and temporary nature of its response, 
activation of the non-canonical pathway is slow and persistent and can be 
described as context-specific, in response to TNFR stimuli such as CD40 
(Coope et al, 2002), LTβR (Dejardin et al, 2002) or RANK (Novack et al, 2003). 
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Name Receptor/Mediator Cell type References 
BAFF BAFF Receptor Splenic B cells (Coope et al, 2002) 
BLyS BAFF R3 (BR3) 
Diffuse, large B cell 
lymphoma 
(Pham et al, 2011) 
CD30L CD30 Lymphoma cell lines (Nishikori et al, 2005) 
CD40L CD40 / TRAF Murine splenic cells (Coope et al, 2002) 
CD70 CD27 
Peripheral Blood 
Mononuclear cells 
(Ramakrishnan et al, 
2004) 
Human β-defensin-
3 
TLR 1/2 Human monocytes (Funderburg et al, 2011) 
IFN TRAF2 Human fibrosarcoma cells (Yang et al, 2005) 
LPS TLR4 
Human dendritic cells 
B cells 
(Saccani et al, 2003); 
(Mordmuller et al, 2003) 
LTβ 
LTβ-receptor 
TRAF3 
LIGHT 
MEF;  Hela 
Colorectal adenocarcinoma 
cells 
Endothelial cells 
Dejardin 2002; 
(Mordmuller et al, 2003); 
(Bista et al, 2010) 
Notch Notch receptor Lymphoma cells (Schwarzer et al, 2012) 
RANKL RANK Osteoclast precursors (Novack et al, 2003) 
Stat3 N/A Breast cancer cell lines (Nadiminty et al, 2006) 
TWEAK TRAF2/TRAF5 MEF (Saitoh et al, 2003) 
TNF-α 
 
TNFR1 / RIP1 
TNFR2 
Human dendritic cells 
MEF 
T cells 
(Saccani et al, 2003); (Kim 
et al, 2011) (Rauert et al, 
2010) 
Viral products 
LMP1 TRAF2/3 
B cells, epithelial cells 
MEF 
(Atkinson et al, 2003); 
(Song et al, 2010) 
Tax N/A T cells (Xiao et al, 2001) 
vFLIP K13 N/A PEL cell lines 
(Matta & Chaudhary, 
2004) 
 
Table 1-3: Stimuli inducing p100 processing to p52 
List of stimuli known to activate the NF-κB non-canonical pathway and induce p100 
processing to p52 
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1.1.7 Processing of p100 in p52 
The NF-κB2 protein is produced as the precursor p100 but needs to be 
processed to a shorter version, p52, to be activated and trans-located to the 
nucleus. This p100 processing, in addition to producing p52, removes the IκB-
like activity of p100, leading to the nuclear translocation of RelB/p52 complexes 
(Sun, 2011). By contrast to p105, whose degradation to produce p50 happens 
at a high rate constitutively, p100 processing is relatively slow and mainly 
inducible. To process p100 to p52, stable dimers have to be formed. If p100 is 
not able to dimerize, it is completely degraded, with a significant reduction in 
p52 formation (Betts & Nabel, 1996). The activation of IKKα by various stimuli 
leads to the phosphorylation of p100 on serines 866 and 870, resulting in the 
creation of a binding site for β-TrCP, a component of the SCF E3 ubiquitin 
ligase. Mutations on one or both of the Serine 866 and 870 residues completely 
inhibit p100 (Sun, 2011). This site is homologous to the ones found in ΙκΒα and 
p105 (Perkins, 2006). Binding with β-TrCP induces p100 K48 linked 
ubiquitination, on Lysine 856 at the N-terminal region of the β-TrCP binding site 
(Amir et al, 2004). This Lysine 856 residue is analogous to the ubiquitination 
site of IκBα (K22), and mutation of K856 decreases p100 ubiquitination and 
processing (Sun, 2011).  
NF-κB Inducing Kinase (NIK) has been shown to induce p100 processing 
to p52 via stimulation of site-specific phosphorylation and then ubiquitination. 
NIK is naturally mutated in alymphoplasia and nik -/- or nfkb2 -/- mice present 
the same immune deficiencies (Xiao et al, 2001). NIK was first described as a 
MAP kinase kinase kinase (MAP3K), which interacts with the TNF receptor 
associated factor 2 (TRAF2). NIK phosphorylates IKKα in its activation loop, 
activating the phosphorylation and processing of p100 (Sun, 2011; Xiao et al, 
2001). The post-ubiquitination events leading to p100 cleavage to p52 and not 
full degradation are yet to be fully understood, although some elements are 
described. p100 ubiquitination triggered by NIK induces its recruitment to the 
proteasome via the interaction of the p100 Death Domain (DD) with S9, a non 
ATPase subunit located in the lid of the 19S proteasome (Fong et al, 2002b; 
Sun, 2011). Even though the final mechanism for p100 processing remains 
unclear, Fong et al demonstrated in 2002 that the DD is essential for NIK-
induced p100 processing, making a further link between the processing and S9 
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binding (Fong et al, 2002b). Disruption of the Ankyrin repeat domain or the DD 
induces constitutive processing of p100 (Liao & Sun, 2003). It is still unknown 
how the DD and Ankyrin repeats inhibit p100 processing but one hypothesis is 
that through the Ankyrin repeats interacting with the RHD, p100 adopts a 
conformation that blocks processing by masking p100 NLS (Sun, 2011). 
Heusch demonstrated that inhibition of the proteasome by agents such 
as MG115 blocks p52 generation (Heusch et al, 1999). Recent results show 
that p100 sumoylation is involved in ubiquitination and processing (Vatsyayan 
et al, 2008). SUMO (for Small Ubiquitin-like Modifier) modifications are 
reversible and SUMO proteins can be removed by SUMO-specific proteases. In 
some human cell lines and mouse fibroblasts, a small quantity of p100 is 
naturally found conjugated to SUMO1 and a mutation in the sumoylation site 
decreases inducible processing. Moreover, basal sumoylation has been found 
to be necessary for p100 phosphorylaton but the detailed mechanism of how 
SUMO proteins regulate p100 processing still has to be fully understood 
(Vatsyayan et al, 2008).  
An additional domain, the Glycine Rich Repeat Region (GRR), from 
amino acids 346 to 377, acts as a “stop-transfer signal” and is also necessary 
for the cleavage, which happens after the amino acid 405. This GRR, also 
found in p105, has been shown to be essential for p105 processing in p50 (Lin 
& Ghosh, 1996). The poor efficiency of p100 processing compared to p105 can 
also be explained by the peptide sequence around the cleavage site, situated 
downstream GRR and responsible for p52 production, and rather than the GRR 
itself (Heusch et al, 1999). 
As mentioned above, constitutive p100 processing is extremely low. 
p100 contains a domain, called the Processing-Inhibitory Domain (PID), 
situated downstream the Ankyrin repeat region, in the same region than DD 
(amino acids 777 to 859), which negatively regulates p100 processing to p52 
(Xiao et al, 2001). 
 
1.1.8 Other NF-κB activation pathways 
In addition to the canonical and non-canonical NF-κB pathways, some 
atypical activation mechanisms have been described, although their efficiency 
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is slower and weaker than the classical pathways (Rothwarf & Karin, 1999). 
These atypical pathways, in response to stimuli such as genotoxic stress, UV or 
hypoxia can be both IKK dependent or independent and usually activate the 
“classical” NF-κB complex of RelA/p50 hetero-dimers (Perkins & Gilmore, 
2006b). 
After genotoxic stress resulting from treatment with drugs such as 
etoposide or exposure to ionizing radiation, NEMO protein alone translocates to 
the nucleus where it is sumoylated. There, the sumo modification is replaced by 
mono-ubiquitination at the same site in an ATM (ataxia telangiectasia mutated)-
dependent manner before relocation back to the cytoplasm, where together, 
NEMO and ATM activate IKK complexes. However, the cell type distribution of 
this activation pathway remains unclear (Perkins, 2007). 
Different mechanisms have been described for the atypical activation of 
NF-κB in an IKK-independent manner, After stimulation by ultra-violet (UV) light 
or expression of the Her2/Neu oncogene, the C terminus of IκBα can become 
phosphorylated by the casein kinase II (CK2) leading to its degradation (Perkins 
& Gilmore, 2006b), activating NF-κB dimers. After UV stimulation, IκBα 
phosphorylation by CK2 is dependent on the p38-MAP kinase pathway. 
Inhibition of the p38-MAP pathway increases UV-induced cell death, 
demonstrating its importance during the UV-stress response (Kato et al, 2003). 
In 2010, Tsuchiya et al showed that after UV irradiation, IκBα degradation 
happens after phosphorylation in its C terminus PEST domain by CK2, through 
interaction with p38. IKKβ is required for UV-induced IκBα proteolysis and NF-
κB activation but not its kinase function. In this particular case, IKKβ acts as an 
adaptor protein for IκBα degradation, as it can associate either with β-TrCP to 
promote N terminal ubiquitination of IκBα or with the kinases CK2 and p38 to 
promote its degradation through C terminal phosphorylation (Tsuchiya et al, 
2010).  
Amplification or overexpression of the Her2/Neu oncogene is altered in 
30% of breast cancers (Pianetti et al, 2001) and results in PI3K-Akt activation of 
CK2, which phosphorylates IκBα, inducing its degradation by calpain (Romieu-
Mourez et al, 2002). This IKK-independent NF-κB activation can be blocked by 
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the receptor or tumor suppressor PTEN in breast cancer cells (Pianetti et al, 
2001). 
IκBα can also be phosphorylated on Tyr42 by the c-Src kinase after 
hypoxia/reoxygenation and hydrogen peroxide stimulation, inducing its 
degradation (Perkins & Gilmore, 2006b; Rothwarf & Karin, 1999). Surprisingly, 
in bone marrow cells, NF-κB activation after TNF-α stimulation comes from this 
Tyr42 phosphorylation and atypical pathway, and not from the canonical 
pathway (Abu-Amer et al, 1998). 
Finally, late time point activation of NF-κB can occur in response to drugs 
such as doxorubicin in an IKK-independent manner but the exact mechanism 
still has to be elucidated (Perkins & Gilmore, 2006b; Tergaonkar et al, 2003). 
 
1.1.9 DNA binding 
To regulate their target genes, NF-κB subunits bind to a specific DNA 
sequence of 9-11 base pairs called a κB site: GGG RNN YYC C, where R is a 
purine (adenine or guanine), N can be any base pair and Y represents a 
pyrimidine (cytosine or thymidine) (Natoli et al, 2005). Although this sequence is 
considered as the classical κB site, it is highly degenerate, which considerably 
increases the number of κB sites possible in the genome. For example, c-Rel 
homo-dimers show a high affinity for the sequence AGA AAT TCC found in the 
CD28 response element of IL2 enhancer. RelB/p52 hetero-dimers bind 
specifically on the κB site RGG AGA YTT R on genes encoding chemokines 
such as CXCL13 or CCL19 (Natoli et al, 2005). RelA/p52 hetero-dimers show 
specificity for sequences such as GG RNN YYC C (Perkins, 1997). The p50 
subunit has a high affinity for the κB sites GGG ACT TTC C (for the Ig κ chain 
enhancer and HIV-1 LTR) and GGG ATT CCC C in the MHC class I H2-K 
enhancer, whereas p52 only recognizes the latter and RelA homo-dimers have 
a very low affinity for both. By contrast, RelA binds preferentially to sequences 
ending with TTT CC, such as the palindrome GGA AA TTC C (Perkins, 1997). 
Alteration of the κB consensus binding site by mutation causes changes in the 
structure and affinity of the site therefore attracting different NF-κB dimers 
(Natoli et al, 2005). This specificity of binding has the potential to allow genes 
with variant κB sites to be regulated by different NF-κB complexes, although the 
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binding of a specific NF-κB complex is not encoded in the κB site itself 
(Hoffmann et al, 2003). 
Natoli reported an estimation of 1.4 x 104 potential κB sites in the human 
genome but admitted that this was probably inaccurate and the final number 
should be closer to 1.5 x 105, although not all would be localized in promoters 
(Natoli et al, 2005). This large variability of potential κB sites, which can 
differentially respond to different stimuli, has yet to be fully understood and 
explained. However, work in Drosophila melanogaster has suggested one 
possibility (Minakhina & Steward, 2006). In this species, sites with weak affinity 
were found to require a high quantity of Dorsal, whereas κB sites with a high 
affinity only required a low quantity of protein available. Since, different 
quantities of NF-kB subunits are found in the various organs of Drosophila, 
therefore a difference in affinity will induce a different response (Minakhina & 
Steward, 2006).  
 
1.1.10 Post transcriptional modifications of NF-κB 
Multiple post-transcriptional modifications that regulate NF-κB activity 
have been described. For example phosphorylation of RelA on S276, which can 
be carried out by PKA, MSI or MSII, is required for the interaction with the 
p300/CBP complex and the activation of transcription (Hayden & Ghosh, 2012). 
IKKα and IKKβ act as kinases for RelA and phosphorylate it on S536 (Sakurai 
et al, 1999). Interestingly, RelA S536 phosphorylation, occurring mainly in the 
cytoplasm (Moreno et al, 2010), allows transcription of specific target genes, 
such as IL-8, in cells stimulated by PMA and ionomycin (Buss et al, 2004; 
Sasaki et al, 2005). S536 phosphorylation is independent of IκBα (Sasaki et al, 
2005) but can be dependent on IKKβ in human multiple myeloma cells upon 
HDAC inhibitor stimulation (Dai et al, 2011). This promotes translocation to the 
nucleus and enhances RelA acetylation (Dai et al, 2011). RelA S536 can be 
used as a prognostic marker for colorectal cancer (Lewander et al, 2012) and is 
linked to epileptic vulnerability in rat (Ryu et al, 2011). Phosphorylation of T505 
by the checkpoint kinase Chk1 inhibits RelA transactivation activity, which leads 
to the repression of the anti-apoptotic gene Bcl-xL by inducing association with 
HDAC1 (Rocha et al, 2005b). This T505 phosphorylation is maximal during the 
S phase of the cell cycle, as Chk1 is activated by the DNA replication 
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checkpoint (Barre & Perkins, 2007). Interestingly, RelA S536 modification can 
be linked to the cell cycle. In unstimulated U20S cells, this phosphorylation 
occurs specifically during the G2 phase of the cell cycle (S536 phosphorylation 
is low during G1 phase), whereas IKKβ is also responsible for RelA Ser468 
phosphorylation in G1 phase. This change of phosphorylation sites during the 
cell cycle is thought to be involved in the switch from RelA dependent activation 
to repression of target gene expression (Barre & Perkins, 2007). 
RelA can also be subject to many other modifications, such as 
acetylation on lysine residues such as K310 by the p300 and CBP co-
activators. However, this only occurs if S276 is phosphorylated, making the 
S276 residue mandatory for HAT recruitment (Hayden & Ghosh, 2012; Zhong 
et al, 2002). 
Only a few phosphorylation sites (and no other modifications) have so far 
been found in the RelB subunit. Phosphorylation on T84 and S552 initiates 
RelB degradation by the proteasome (Marienfeld et al, 2001). RelB S368 
phosphorylation, not required for nuclear translocation, is involved in RelB/p100 
dimerization (Maier et al, 2003). Cells expressing a non-phospho mutant of 
S368 RelB displayed a shorter p100 half-life compared to wild-type RelB, 
suggesting than RelB is involved in regulating p100 processing (Maier et al, 
2003). Phospho-proteomic studies identified a few more phosphorylation sites 
on the Ser37 and Ser73 residus (Dephoure et al, 2008; Olsen et al, 2010). 
Some lysine residus (K295, 297, 327 and 330) have been involved in the 
regulation of RelB activity and stability (Leidner et al, 2008). 
The post-transcriptional modifications described to date for p100/p52 
have been shown to mainly regulate p100 processing to p52 and can be found 
described in section 1.1.7. It has also been shown that Ser866 phosphorylation, 
required for p100 processing, is inhibited in S phase and is dependent on IKKα 
for G1 and G2 phase basal phosphorylation (Barre & Perkins, 2007). It can also 
be induced by DNA damaging agents such as cisplatin or UV in U2OS cells 
(Barre et al, 2010c). In addition, some phospho-proteomic studies found 
additional p100/p52 phosphorylation sites during mitosis (figure 1.4), on serine 
residues 22, 23, 222, 226, 429, 759, 762, 811, 816 (Dephoure et al, 2008; 
Olsen et al, 2010). 
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Figure 1-4: Modification sites in p100/p52 
Schematic representation of the modifications sites identified in p100/p52. The 
phosphorylation sites that are targets of IKKα, required for p100 processing are 
represented in orange. In grey is the ubiquitination site in the β-TrCP binding site that is 
required for processing. The mitotic phosphorylation sites identified by (Dephoure et 
al, 2008) are represented in yellow. Adapted from (Perkins, 2006). 
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Although the full functionality of these phosphorylation sites is not yet studied, 
mostly due to the recentness of the reports, some elements are known. For 
example Olsen et al suggested possible kinases for some phosphorylation 
sites: Ser23 is part of a motif for the kinase CK2, while Ser816 might be target 
for the kinases CK1 or GSK3β (Olsen et al, 2010). Interestingly, our laboratory 
also published in 2010 that GSK3β is responsible for Ser222 phosphorylation, 
regulating the p52 dependent activation or repression of the Skp2 promoter and 
p52 dimerization (also discussed later) (Barre & Perkins, 2010). This Ser222 
phosphorylation by GSK3β would require primary phosphorylation at Ser226, 
but the kinase involved is still unknown (Barre et al, 2010c) Some further 
analysis will be necessary to fully understand the influence of p52 
phosphorylation sites and how post-transcriptional modifications affect the NF-
κB response (Barre & Perkins, 2010b). 
Modifications of the c-Rel and p105/p50 subunits have been reported 
(Perkins, 2007) but they will not be discussed here, as they have not been 
linked to the cell cycle, the major topic of this thesis. 
 
1.1.11 NF-κB target genes 
In the past 25 years of research on NF-κB, hundreds of target genes 
have been identified and described. These can be categorized as 14 types of 
target genes: chemokines/cytokines and modulators, immunoreceptors, 
proteins involved in antigen presentation, cell adhesion molecules, acute phase 
proteins, stress response genes, cell surface receptors, regulators of apoptosis, 
growth factors/ligands and modulators, early gene responses, transcription 
factors and their regulators, viruses, enzymes and others (www.nfkb.org). 
However, in 2002, Karin suggested that most of these could be grouped and 
proposed the existence of only four types of target genes for NF-κB (Karin et al, 
2002). The first group concerns genes involved in cell proliferation, such as 
Skp2 (Schneider et al, 2006) or cyclin D1 (Schumm et al, 2006). The second 
includes target genes involved in the regulation of apoptosis such as Bcl-2 
(Catz & Johnson, 2001) or Bcl-xL (Chen et al, 1999). The third group contains 
genes with an immunoregulatory function and that are involved in the 
inflammatory response, such as TNF-α (Shakhov et al, 1990) or IL-6 
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(Libermann & Baltimore, 1990). The final group of NF-κB target genes is those 
actually involved in the positive, such as RelB (Bren et al, 2001) or negative 
regulation of NF-κB activity, which includes IκBα (Sun et al, 1993), nfkb1 and 
nfkb2 (Lombardi et al, 1995; Ten et al, 1992) and A20 (Shembade & Harhaj, 
2012). 
Although these hundreds of NF-κB target genes, only some are known to 
be p52 specific target genes. p52 can regulate the expression of genes having 
a role in cell proliferation, such as Cyclin D1 (Barre & Perkins, 2007; Schumm et 
al, 2006). NF-κB and specifically p52 protein/protein interactions have been 
described in abundance in the literature but will not be discussed here. 
 
1.1.12 Opposing roles for NF-κB subunits 
As more studies about NF-κB are published, it is becoming clearer that 
NF-κB dimers can act as activators or repressors of the same target genes, 
depending on the conditions (Campbell & Perkins, 2004b). 
The first reports of NF-κB dependent repression of transcription 
concerned RelA regulation of apoptosis. Following activation via the canonical 
pathway, in response to stimuli such as TNF-α, LPS or ionizing radiation, 
RelA/p50 complexes associate with co-activator complexes containing 
p300/CBP, which leads to the induction of anti-apoptotic genes and promotes 
cell survival (Sheikh & Huang, 2003). However, it has been shown that following 
stimulation by UV-C, drugs such as daunorubicin, doxorubicin, cisplatin or 
activation by the tumour suppressor ARF, RelA complexes associate with the 
co-repressor HDAC1 and induce the repression of anti-apoptotic genes, 
promoting cell death (Campbell et al, 2004; Rocha et al, 2003).  
Previous works in our laboratory proposed a switch in function from 
proto-oncogene to tumour suppressor-like activity for the p52 subunit, 
depending on its phosphorylation at Ser222 after DNA damage (Barre & 
Perkins, 2010). It is however important to note that p52 has not yet been 
identified as a tumor suppressor but its behavior can be consistent with a tumor-
suppressor-like function. After stimulation by cisplatin in U2OS cells, Akt is 
active, which inhibits GSK3β activity and thus allows the formation of 
unphosphorylated Ser222 p52/Bcl-3 complexes. These complexes, with the 
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help of p53, increase Skp2 (S-phase kinase associated protein 2) expression, 
repressing p27kip1 and ultimately suppressing autophagy (Barre & Perkins, 
2010). By contrast, in UV-C stimulated cells, the inactivation of Akt allows 
GSK3β to phosphorylate p52 at Ser222, disrupting p52/Bcl-3 complexes and 
enabling the formation of p52/c-Rel complexes, which repress Skp2 expression 
in association with HDAC1, increasing cell death via autophagy (Barre & 
Perkins, 2010). Barre et al showed in 2010 that this p52 duality does not only 
apply to autophagy but can also be found in the regulation of genes involved in 
the cell cycle and cell death (Barre et al, 2010c). This was illustrated with the 
cyclin D1 promoter, where p52 can change from an activator to a repressor, 
depending on the induction of p53 (Rocha et al, 2003b; Schumm et al, 2006). 
Similar results demonstrating the duality of NF-κB function have been 
reported by other laboratories. For example, another study recently illustrated 
the dual role of the RelB subunit. This showed that the non-canonical pathway 
could be activated by the binding to the LTβ receptor of LIGHT, a member of 
the TNF super-family. This led to the activation of RelB/p52 dimers and the 
regulation of various genes, including the chemokine pro-inflammatory 
CXCL12. LIGHT ultimately leads to the activation of CXCL12. However, TNF-α 
upregulates p100 and RelB expression through the canonical pathway. This 
activation of RelB by TNF reduces the basal expression of CXCL12, inhibiting 
the upregulation of CXCL12 by LIGHT via RelB (Madge & May, 2011). 
In 2006, Strozyk et al demonstrated that NF-κB’s anti-apoptotic or pro-
apoptotic role relies on the type of DNA damage. When epithelial carcinoma 
cells were irradiated with UV-B, NF-κB was activated by IL-1, thus inducing an 
increase in TNF-α expression followed by an increase of apoptosis (Strozyk et 
al, 2006). By contrast, in the case of DNA strand breaks, no IL-1-dependent NF-
κB activation occurred, and the usual anti-apoptotic role for NF-κB ensued 
(Strozyk et al, 2006). This difference in NF-κB activation was confirmed in 
another study.  Here, DNA damage inducing agents such as aphidicolin or 
hydroxyl-urea induced ATM activation, which induced pro-apoptotic NF-κB 
(Habraken 2006). By contrast, replication stress had also been shown to 
activate the ATR (ATM- and Rad3- related) kinase, which was shown to 
compete with ATM and associate with but not activate NEMO, thus delaying 
NF-κB activation (Wu & Miyamoto, 2008b). However, in this study replication 
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stress was still found to lead to a pro-apoptotic role for NF-κB, notably through 
the repression of the anti-apoptotic gene Bcl-xL, whereas double strand breaks 
induced the anti-apoptotic role of NF-κB. The differences in the NF-κB response 
to DNA damage reported in different studies likely result from changes in cell 
context. For example, the growth conditions used and the activity of parallel 
signaling pathways such as p53. A definitive explanation for what regulates the 
outcome of NF-κB activation after DNA damage has still to be provided. 
All of these articles and other demonstrate that, despite the large amount 
of research into the role NF-κB role in cells after stimulation, more is necessary, 
since it is becoming clearer that NF-κB effects can vary upon the cellular 
context and nature of the stimulation. 
 
1.2 The cell cycle 
 
One of the main features of tumour cells is their ability to proliferate rapidly 
and in an uncontrolled way. To understand how this can happen, it is necessary 
to understand first how cells normally replicate their genetic material and divide 
into viable daughter cells. After mitogenic stimuli, cells leave their quiescent 
stage (G0) and enter into the cell cycle. In mammalian cells, the cell cycle is 
separated four phases: a gap phase G1, follows by the DNA synthesis phase (S 
phase). A second gap phase (G2 phase) precedes the mitosis (M phase). Once 
in the cell cycle, the cell progresses through G1 phase to S phase, when DNA 
replication occurs. Then, the cell enters into G2 phase, which allows a 
checkpoint to ensure DNA is correctly replicated, before the entry into M phase 
(Figure 1.5.A). 
During M phase, mitosis occurs, which ends with the separation of the 
two daughter cells through a mechanism called cytokinesis. Mitosis can be 
separated into five distinct phases, based on cellular morphology. In prophase, 
cells organize their cytoskeleton in order to have a microtubule network called 
the mitotic spindle (Figure 1.5.B). At the same time, the DNA duplicated during 
S phase begins to condense into chromatids. Nuclear envelope break down 
signals the end of this phase.  
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Figure 1-5: Cell cycle and mitosis 
A. Schematic overview of the cell cycle and the Cyclin-CDK complexes involved in its 
regulation. Adaptation from (Herrup & Yang, 2007) 
B. Hela cells were immunostained for α-tubulin (green) to detect the mitotic spindle and 
DAPI (blue) to detect DNA. The images shown are a representation of the five phases 
during mitosis. Images taken from (Bakal et al, 2005) 
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The next step is prometaphase, a sub-step defined by kinetochore 
attachment to the spindle. This is followed by proper metaphase, during which 
the chromosomes align in a “metaphase-plate” (Bharadwaj & Yu, 2004). 
Anaphase is the step where the two chromatids separate and moves to the 
opposite pole. The chromatids decondense during the next step, telophase, 
while the nuclear envelope re-forms and the mitotic spindle disassembles. At 
this stage, a ring of actin-myosin begins to form. The last step of mitosis, which 
some researchers consider to be still within telophase, is cytokinesis, with the 
separation of the two daughter cells (Jackson et al, 2007). 
 
1.2.1 The regulation of the cell cycle 
A family of protein kinases, the cyclin-dependent-kinases (CDKs) drive 
progression through the cell cycle. CDK activity is modulated by mitogens and 
growth factors or by signalling pathways, which includes, in some contexts, NF-
κB (Joyce et al, 2001). The CDKs become active after forming complexes with 
regulator proteins, called the cyclins (Figure 1.5.A) (Herrup & Yang, 2007).  
The cyclin D family contains cyclin D1, cyclin D2 and cyclin D3. Cyclin 
D1 is widely expressed in mammalian cells and its expression can vary during 
the cell cycle. This is controlled by the rate of gene transcription and is induced 
following exposure to mitogenic stimuli, through an extensive range of 
transcription factors including NF-κB. The other cyclins, D2 and D3, are more 
tissue-specific and are required in late G1 or S phase respectively (Joyce et al, 
2001). After detection of proliferative signals, Cyclin D associates with CDK4 or 
CDK6 and allows progression through G1 phase. Here, the Cyclin D1-CDK4 
complex phosphorylates the retinoblastoma protein Rb. This relieves repression 
of the E2F transcription factor which is required for synthesis of cyclin E and 
entry into S phase. The accumulation of CDK2-Cyclin E allows the G1/S 
transition (Malumbres & Barbacid, 2001) and the accumulation of cyclin A 
regulates S phase. Cyclin A and cyclin E are both under the control of the E2F 
transcription factor. Cyclin A continues to increase in S phase and in the 
beginning of G2 phase, followed by an increase in the cyclin B1 level, which is 
involved in the start of M phase (Joyce et al, 2001).  
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In order to make sure that the cell cycle produces two viable daughter 
cells identical to the mother cell, checkpoints are required during the cell cycle 
to ensure mistakes are corrected prior to cell division. Two families of inhibitor 
proteins regulate the activities of the CDKs: the CDK Interacting Protein / CDK 
Inhibitory Proteins (CIP/KIP) and the Inhibitors of CDK4 (INK4) family. Members 
of the INK4 family (p16INK4a, p15INK4b, p18INK4c and p19 INK4d) specifically 
inhibit CDK4 and CDK6 (Denicourt & Dowdy, 2004) (Figure 1.5.A). The CIP/KIP 
family is composed of p21Cip1, p27Kip1, and p57Kip2 and can inhibit a large 
spectrum of cyclin-CDK complexes (Denicourt & Dowdy, 2004). Among this 
family, p21 is one of the most studied, since it is a target gene of the p53 
tumour suppressor, and one of the main effectors of cell cycle arrest following 
DNA damage (Weiss, 2003). 
After cellular stress or DNA damage, the cell cycle can also be arrested 
by other types of proteins, specific to the type of damage. For example, the 
ATM kinase is activated following double-strand DNA breaks whereas the 
related ATR kinase is more specific to the arrest of DNA replication forks 
(Shiloh, 2001). Following DNA damage, ATM/Chk2 and ATR/Chk1 kinase 
pathways are activated and can lead to cell cycle arrest, either at the G1/S 
transition or G2/M checkpoint. This regulation occurs in a manner dependent or 
independent of the tumor suppressor p53. Indeed, DNA damage response 
leads to activation of p53, which induces the expression of CDK inhibitor 
p21waf1, resulting in arrest in G1 or G2 phases (Poehlmann & Roessner, 2010). 
However Chk1 and Chk2 kinases are also able to directly phosphorylate 
Cdc25a and Cdc25c, leading to an accumulation of inactive CDK2/cyclin E and 
CDK1/cyclin B complexes, arresting the cell cycle in G1 and G2 phases 
respectively (Niida & Nakanishi, 2006; Poehlmann & Roessner, 2010). 
The DNA damage response can induce cell cycle arrest through the 
MAPK (mitogen activated protein kinases) pathways. ERK induces arrest in G1 
phase through a direct, p53-independent, activation of p21waf1. It also 
inactivates Cdc25c, blocking entry in mitosis (Poehlmann & Roessner, 2010). 
JNK signaling effects on the G1/S transition, following DNA damage, involves 
p53 phosphorylation and p21waf1 activation, whereas JNK-mediated G2/M arrest 
requires either CDC25c activity regulation, or p21waf1 activation (Poehlmann & 
Roessner, 2010). Finally, the p38 MAPK arrests cells in G2 phase through p53 
phosphorylation, whereas multiple mechanisms are involved in its G1/S arrest, 
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including p53 and p21waf1 activation, or even a direct phosphorylation of cyclin 
D1, regulating its degradation (Poehlmann & Roessner, 2010). 
 
1.2.2  NF-κB and the regulation of the cell cycle 
Several studies show that NF-κB can have an effect on cellular growth 
by inducing cell cycle arrest (Joyce et al, 2001). Overexpression of RelA or c-
Rel arrests cells at the G1/S transition in pro-B cells and HeLa cells, 
respectively (Bash et al, 1997; Sheehy & Schlissel, 1999), although these 
effects can be due to p53 activation following NF-κB over-expression. RelA and 
p50 are able to induce cell cycle arrest in epithelial cells, notably through the 
induction of p21 (Seitz et al, 2000) whereas p21 is induced in lymphoma cells 
by RelB over-expression and in HeLa cells by RelB/p50 heterodimers (Bren et 
al, 2001). 
However, NF-κB can also stimulate cell proliferation. The cyclin D1 gene 
is one of the best-known NF-κB target genes involved in cell cycle regulation 
during G1 phase (Barre & Perkins, 2007). This gene contains three κB sites in 
its promoter, where all the NF-κB sub-units can bind to up- or down-regulate 
cyclin D1 expression, depending on p53 activation (Guttridge et al, 1999), 
(Rocha et al, 2003). Cyclin D2 and D3 also have κB response elements in their 
promoters (Bharti et al, 2004). Interestingly, cyclin A also appears to be a 
potential RelA target gene (Joyce et al, 1999). Cyclin B1 also possesses a κB 
site in its promoter and its expression has been shown to correlate with NF-κB 
expression, even if the exact mechanism or binding by NF-κB is not yet 
demonstrated (Cude et al, 2007). 
NF-κB has also been shown to indirectly regulate cell proliferation. For 
example, c-Myc promotes proliferation and can be regulated by the RelB/p52 
heterodimer (Demicco et al, 2005). Similarly, IKKα, which is responsible for the 
activation of the NF-κB non-canonical pathway, promotes the transcription of 
the skp2 gene through RelB/p52 dimers. Skp2 promotes the degradation of the 
CDK inhibitor p27, allowing cell cycle progression (Schneider et al, 2006). IKKα 
is also involved in the regulation of cyclin D1 independently of NF-κB, through 
being recruited to its promoter by oestrogen receptor α (ERα) in breast cancer 
cells, which leads to increase cyclin D1 expression (Park et al, 2005). 
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An active role for NF-κB in mitosis has not yet been identified, although 
some studies suggest that NF-κB can regulate mitosis either, directly or 
indirectly. For example NF-κB is activated after stimulation by several drugs 
acting on the microtubule cytoskeleton, such as taxol (stabilization of the 
microtubules) or nocodazole (depolymerization) (Das & White, 1997; Mistry et 
al, 2004; Rosette & Karin, 1995). These drugs act on NF-κB through the 
activation of IKKα and IKKβ (Mistry et al, 2004). However the exact mechanism 
involved is still unclear. Furthermore, a few articles link IKK proteins to mitotic 
progression. In 2006, Prajapati et al demonstrated that IKKα, but not IKKβ, 
siRNA treatment induces an increase in cell number in G2/M and this effect 
involves cyclin B1 and PLK1 regulation. They also demonstrated that IKKα 
associates and phosphorylates AuroraA on T288, indicating a possible 
mechanism for regulation of G2/M progression regulation (Prajapati et al, 2006). 
However, in 2007, Irelan et al found that IKKβ depletion deregulates AuroraA 
stability and leads to the formation of multipolar spindle and defective 
chromosome segregation (Irelan et al, 2007). This has been confirmed using an 
IKK inhibitor, resulting in blockage of AuroraA and CDK1 activity and induction 
of cyclin B1 degradation, as well as defective chromosome segregation 
(Blazkova et al, 2007). Together, these studies have defined a role for NF-κB in 
G1/S but more literature is emerging also linking NF-κB to mitosis, although 
definite mechanisms have not yet been explained. 
 
1.3 The centrosome 
 
1.3.1 Centrosome duplication cycle 
Centrosomes are small organelles, near the centre of the cell in the 
periphery of the nucleus (Doxsey, 2001). Centrosomes are composed of two 
centrioles and pericentriolar material (PCM), which permits the nucleation of 
microtubules (Figure 1.6.A and 1.6.B) (Doxsey, 2001). During most of the cell 
cycle, centrioles are perpendicular to each other but are not completely similar: 
although they both are composed of nine triplets of microtubules, at the end of 
the mother centriole, appendages can be observed that are not present in the 
daughter centriole (Nigg, 2002).   
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Figure 1-6: Centrosome structure and centrosome cycle 
A.The centrosome. The centrosome is constituted of two centrioles perpendicular to each 
other and some pericentriolar material (PCM). Each centriole is composed of nine 
triplets of microtubules. At the end of one centriole, the mother centriole, can be 
observed appendages allowing anchoring of the microtubules and this is not present in 
the daughter centriole. Schematic representation taken from (Fukasawa, 2005).  
B. Electron microscopy picture of a centrosome. Taken from (Nigg, 2002).  
C. The centrosome duplication cycle. The centrosome duplication cycle can be 
separated in various phases linked to the cell cycle. During the G1 phase, the two 
centrioles are separated, before being duplicated in S phase. In G2 phase the newly 
formed centrioles elongate and mature to form two functional centrosomes, before the 
centrosomes separate in mitosis. Taken from (Nigg, 2002). 
 
  
A. 
C. 
B. 
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These appendages allow anchoring of the microtubules. During the cell 
cycle, the centrioles duplicate and appendages appear on the daughter 
centriole in G2 phase (Figure 1.6.C) (Nigg, 2002). During mitosis, centrosomes 
are involved in the formation of the mitotic spindle, while during interphase, they 
form a structure called the Microtubule Organising Centre (MTOC) (Cuschieri et 
al, 2007). The MTOC is involved in vesicle transport and the formation of cell 
shape, as well as cellular polarity. Several proteins are involved in the following 
processes: anchoring (ninein, centriolin, dynactin), nucleation (γ-tubulin, 
pericentrin, polo-kinases, aurora-kinases) and release (katanin) (Badano et al, 
2005).  
Regulatory mechanisms are required to make sure that centrosomes 
duplicate only once per cell cycle. Maintaining the right number of centrosomes 
is necessary for genomic stability, although the formation of the mitotic spindle 
can occur without centrosomes under some circumstances (Doxsey, 2001). 
Among these mechanisms, various proteins involved in centriole duplication 
have been described (Table 1.7). These include γ-tubulin whose depletion 
blocks centriole duplication or induces problems in centriolar structure 
(Raynaud-Messina et al) and the Ser/Thr kinases CDK2 and PLK4, which also 
affect centrosome duplication (Bettencourt-Dias & Glover, 2007).  
Mechanisms are required to make sure that centrosomes duplicate only 
once per cell cycle. Indeed, deregulation of the centrosome duplication cycle 
leads to multipolar spindle and increases chromosome abnormalities and 
multinucleate cells. One of these mechanisms involves the enzyme separase 
being required during anaphase to separate the sister chromatids. This link 
between centrosomal duplication and anaphase is important, as deregulation 
could lead to excess number of centrosomes and dysfunctional spindles (Tsou 
& Stearns, 2006).  
 A ring of γ-tubulin forms the junction between the PCM and the 
microtubules. The microtubules are mainly composed of α- and β- tubulin 
proteins organised in a polarised tube with the negative extremity bound to the 
PCM and the positive one to the kinetochores. This tube is very dynamic and it 
alternates between polymerization and depolymerization, which permits 
microtubule movements in the cell (O'Connell & Khodjakov, 2007).  
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Protein Function Assays and phenotypes Reference 
PLK4 centriole duplication 
RNAi, mutations => no duplication 
Overexpression => amplification 
(Habedanck et 
al, 2005) 
SAS6 Centrosome duplication 
RNAi => no duplication 
Overexpression => amplification 
(Leidel et al, 
2005), (Strnad 
et al, 2007) 
CDK2 cell cycle regulation 
Dominant negative mutant, 
inhibition => no duplication 
Hyperactivation => amplification 
(Meraldi et al, 
1999), 
(Duensing et 
al, 2006) 
(Adon et al, 
2010) 
Centrin Centriole duplication RNAi => no duplication 
(Salisbury et 
al, 2002) 
CP110 CDK substrate RNAi => no duplication (Chen et al, 2002) 
Nucleophosmin Substrate for CDK2/cyclin E RNAi => amplification 
(Lim et al, 
2002) 
γ-tubulin 
Nucleation and 
orientation of 
microtubules 
RNAi => no duplication (Dammermann et al, 2004) 
CEP135 Organization of microtubules 
Inhibition, RNAi => 
disorganization of microtubules 
Overexpression => accumulation 
of particules 
(Ohta et al, 
2002) 
p53 tumor suppressor Mutations => Amplification (Shinmura et al, 2007) 
 
 
Table 1-7: Proteins involved in centrosome duplication in Homo Sapiens 
Non-exhaustive list summarizing the main proteins for which a change in 
expression affects centrosome duplication in human cells. Adapted from 
(Bettencourt-Dias & Glover, 2007) 
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The contact with the kinetochore halts the microtubule dynamics and leads to 
the capture of a chromosome, as well as the beginning of the growth of the 
mitotic spindle (O'Connell & Khodjakov, 2007).  
Mitosis is subject to a high level of regulation in order to permit its correct 
resolution. Indeed, aneuploidy and chromosome rearrangements are common 
in most human cancers (Nigg, 2002) and, usually, a deficiency in cell cycle 
checkpoints leads to faulty chromosome segregation, followed by the 
development of genomic rearrangements (Gisselsson, 2005). It is well known 
that several mitotic kinases are involved in tumorigenesis, due to their central 
role in the regulation of the cell cycle checkpoints. For example, the mitotic 
kinase Aurora-A, which in normal cells is required for centrosome maturation, 
mitotic spindle organization, G2/M transition and cytokinesis, is over-expressed 
in many primary tumours and is involved in cellular transformation (Nigg, 2002). 
Furthermore, mutations have been detected in genes involved in the spindle 
checkpoint, in a number of cancers (Bharadwaj & Yu, 2004). 
 
1.3.2 The spindle checkpoint 
As described previously, mitosis can be separated into five phases: 
prophase, metaphase, anaphase, telophase and cytokinesis (Figure 1.5.B). At 
the end of metaphase, the cells have to pass a checkpoint before anaphase 
can begin, to be sure that the chromosome segregation only occurs when the 
two daughter cells can receive the same partition of genetic material 
(Bharadwaj & Yu, 2004). This mechanism is called the spindle checkpoint, 
which detects a lack of attachment or tension at kinetochores and if activated 
prevents chromosome segregation (Bharadwaj & Yu, 2004). The spindle 
checkpoint is well characterized and requires the proteins Mad1, Mad2, BubR1 
(also named Mad3 in yeast), Bub1, Bub3 and Mps1 (Figure 1.8) (Bharadwaj & 
Yu, 2004). If a lack of attachment or tension is detected, protein complexes 
containing Bub1, BubR1 and Mad2 bind to kinetochores and induce a stop in 
anaphase. These complexes bind and inhibit Cdc20, which is essential for the 
activation of the anaphase promoting complex/cyclosome (APC/C).  
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Figure 1-8: The spindle checkpoint 
During the metaphase-anaphase transition, APC/C is activated by release from a 
complex with BubR1, Bub3 and Mad2, leading to Securin ubiquitination. The 
degradation of securin activates separase, which cleaves cohesin keeping the sister 
chromatids together, thus allowing their separation. If the sister chromatids are not 
properly attached to the mitotic spindle, APC/C is kept inactive, and securin is 
stabilized to preserve chromatid cohesion and delay mitotic progression into anaphase. 
Taken from (Bharadwaj & Yu, 2004). 
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APC/C is a multi-subunit E3 ubiquitin ligase that allows the proteosomal 
degradation of a large number of cell cycle regulators through their 
ubiquitination. This ubiquitination permits the activation of the enzyme 
separase, which induces the destruction of the link between sister chromatids. 
APC/C can also trigger the degradation of cyclins, promoting the exit from 
mitosis (Malmanche et al, 2006). Once the spindle checkpoint is passed, each 
set of sister chromatids migrate to the opposite spindle pole (anaphase). The 
ring’s assembly in telophase is mediated by the serine/threonine kinase ROCK, 
an effector protein of the GTPase RhoA (Glotzer, 2005). In animal cells, around 
20 conserved proteins, found in the contractile ring, regulate cytokinesis. These 
proteins participate in the RhoA pathway and are responsible for expansion of 
the membrane and breakage of the cytoplasmic bridge (Glotzer, 2005). A failure 
in cytokinesis can lead to multinucleate cells, with an abnormal number of 
centrosomes. 
 
1.3.3 The PLK family 
Named after the polo gene of Drosophila melanogaster, the members of 
the polo-like kinase (PLK) family have been identified in many organisms, from 
yeast to mammals (Nigg, 1998). 
The PLK family is constituted of five serine - threonine kinases in 
mammalian cells, all sharing a high sequence homology in their N-terminal 
kinase catalytic domain and usually containing two polo-box domains (only one 
in PLK4’s case) (Figure 1.9) (de Carcer et al, 2011). PLK1, the most studied 
member of the family, has been found in multiple organisms, from yeast (called 
Cdc5) to Drosophila (called Polo) and is an essential gene as null mutants in 
yeast and Drosophila are lethal (de Carcer et al, 2011). PLK1 and PLK4 are 
mostly expressed in highly proliferative tissues, whereas PLK2, PLK3 and PLK5 
can also be found in non-proliferative cells such as the nervous system (for 
PLK2 and PLK5) or respiratory organs such as lungs, trachea or bronchus (for 
PLK3) (de Carcer et al, 2011). Preliminary results show that PLK1 can act as an 
oncogene in human hepatocellular carcinoma, while PLK2, PLK3 and PLK4 
(also known as SAK) are more likely to act as tumour suppressors (Pellegrino et 
al, 2010). 
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Figure 1-9: The PLK family member 
Schematic representation of the five PLK family members. Kinase domains are shown 
in yellow, polo box domains in blue and the Polo Binding motif in red. Key residues 
such as the Lysine acceptor and T-loop Threonine in the kinase domain are 
represented, as well as the key residues for substrate recognition within the Polo Box 
domain. Based on (de Carcer et al, 2011) 
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The PLK proteins are involved in centrosome maturation and bipolar 
spindle formation, the activation and inactivation of CDK1/cyclin B1 complexes, 
co-ordinating the spindle assemble and promoting the exit from mitosis (Figure 
1.10) (Nigg, 1998). PLK proteins are essential regulators of the APC/C complex 
and PLK absence blocks the destruction of mitotic cyclins (Kotani et al, 1998). 
PLK mRNA and protein levels vary during the cell cycle, mainly in abundance, 
localization and activity: PLK1 levels increase to reach a maximum in activity 
and phosphorylation during M phase (Winkles & Alberts, 2005). PLKs possess 
multiple phosphorylation sites whose functions are not yet fully understood 
(Nigg, 1998). PLK1 substrates are found during most of the cell cycle (Luo & 
Liu, 2012). Indeed Hbo1, a histone transferase, (Wu & Liu, 2008) and Orc2, a 
component of the ORC complex facilitating DNA replication, (Song et al, 2011) 
are both involved in S phase progression and are published PLK1 substrates 
(Luo & Liu, 2012). G2/M PLK1 target proteins are either involved in centrosome 
duplication, for the centrioles elongation, maturation and separation, or the 
regulation of the cell cycle (Luo & Liu, 2012). Two of these substrates are 
essential G2/M regulators whose phosphorylation by PLK1 promotes their 
nuclear translocation during prophase: Cdc25 (Toyoshima-Morimoto et al, 
2002) and cyclin B1 (Toyoshima-Morimoto et al, 2001). Specific mitotic PLK1 
substrates involve proteins required for the recruitment to the kinetochores (Luo 
& Liu, 2012), such as INCENP (Goto et al, 2006) and BubR1 (Elowe et al, 
2007).  
PLK2 is localized to the centrosome and reaches a maximum in 
expression and activity during the S phase of the cell cycle. By contrast PLK3 
mRNA peaks in G1 phase, however its protein expression remains stable 
during the whole cell cycle, suggesting an alternative regulation not yet 
elucidated (de Carcer et al, 2011). PLK3 allows cyclin E accumulation and 
Cdc25a activation, leading to DNA replication. PLK3 has been shown to be 
activated after genotoxic stress, in a p53-dependent manner (de Carcer et al, 
2011). 
PLK5 is the most recent PLK protein described. In humans a stop codon 
mutation changes the reading frame, removing the kinase domain, whereas the 
mouse PLK5 gene encodes the full length protein.  
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Figure 1-10: Functions of the PLK proteins during the cell cycle 
Schematic overview of the PLK proteins and their moment of action during the cell 
cycle. PLK1 is involved in mitotic entry, centrosome separation and maturation, spindle 
formation, chromosome segregation and cytokinesis. PLK2 and PLK4 regulate 
centriole duplication, whereas PLK3 is involved in DNA replication. PLK2, PLK3 and 
PLK5 also have non-proliferative roles, such as neuron differentiation and synaptic 
homeostasis. DDR = DNA damage response; SAC = spindle assembly checkpoint. 
Taken from (de Carcer et al, 2011) 
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Both human and mouse express a functional PLK5 protein, however the 
human gene seems to initiate translation after the codon-stop, expressing a 
shorter kinase domain (de Carcer et al, 2011) Overexpression of PLK5 arrests 
cells in G0/G1 and increases p21 expression, independently of any kinase 
activity (de Carcer et al, 2011b). 
PLK4 is an atypical member of the polo-like kinase family. Instead of the 
second normal polo-box domain found in other PLK proteins, PLK4 contains a 
larger crypto polo-box, with a weaker homology to other polo-boxes (figure 1.9) 
(Sillibourne & Bornens, 2010b). Unlike other PLKs, this crypto polo-box domain 
is unable to dimerize, as is seen for the other PLKs, suggesting that PLK4 is not 
regulated in the same manner (Sillibourne & Bornens, 2010b). Maximally 
expressed in actively dividing tissues, PLK4 is a key regulator of centriole 
duplication and will be described later in more details (see Chapter 4).  
 
1.3.4 NF-κB and regulation of centrosome duplication 
So far, no published reports link NF-κB to PLK4 or PLK2 and only one 
study found a relationship between NF-κB and PLK3. In 2005, Li and coworkers 
found that the RelA subunit directly binds PLK3 promoter and activates its 
transcription. They previously stated that RelA induces a pro-apoptotic 
response via the p53-pathway in response to doxycycline-induced superoxide 
(Fujioka et al, 2004). In 2005, they followed by showing that in HCT116 cells, 
after doxyxline treatment, NF-κB is activated and induces PLK3 expression. 
PLK3 then associates with and phosphorylates p53, leading to p53-dependent 
apoptosis (Li et al, 2005b). They also demonstrated that PLK3 depletion by 
siRNA in HCT116 cells suppresses doxycycline-induced apoptosis; whereas the 
opposite effect is obtained after PLK3 overexpression (Li et al, 2005b). 
Although this PLK3-mediated induction of apoptosis can be either p53 
dependent or independent, RelA induction of PLK3 is required in both cases (Li 
et al, 2005b). Some studies do link PLK1 with NF-κB but once again only from a 
RelA perspective, in case of cell detachment from the extra-cellular matrix 
(ECM) in oesophageal squamous cell carcinoma (ESCC) cells, leading to 
anoikis. ESCC cells detachment triggers NF-κB-dependent PLK1 induction, 
which through the stabilization of β-catenin, promotes anoikis resistance (Lin et 
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al, 2011). Interestingly, two studies by Higashimoto in 2008 and Zhang in 2010 
illustrated a potential activation feedback loop, as they found that PLK1, by 
formation of a complex with NEMO and the phosphorylation of IKKβ, could 
decrease IKK activation by TNFα. This reduced IκBα phosphorylation and 
degradation, which then reduced NF-κB activation (Higashimoto et al, 2008; 
Zhang et al, 2010). 
Interestingly, Bcl-3, the IκB protein that can function as a co-activator for 
p52 homodimers, was found to regulate cell proliferation, induce centrosome 
amplification and aneuploidy in Hela cells (Zamora et al, 2010). Inducible by 
DNA damage, Bcl-3 inhibits p53 activation (Kashatus et al, 2006). Although 
Zamora and coworkers did not link their study with p53 status, they 
demonstrated that induction of centrosome amplification; reduced cell 
proliferation and aneuploidy are caused by Bcl-3 depletion. These results are 
associated with a DNA damage response and a G2/M checkpoint delay 
(Zamora et al, 2010). 
NF-κB, and in particular the RelA and p50 sub-units, can also regulate 
some genes involved in mitotic progression. Wu and co-workers suggested that 
NF-κB can control the expression of BRCA2, a tumour suppressor whose 
mutation leads to ovarian and breast cancers, by regulating its promoter (Wu et 
al, 2000). ERK5 has been shown to induce IκB phosphorylation and 
degradation via ribosomal S6 kinase 2 (RSK2) and thus promotes NF-κB 
activation. This ERK5-NF-κB pathway delays mitotic entry and de-regulates 
cyclin B1, cyclin B2 and PLK1 expression (Cude et al, 2007). Mutations in the 
NF-κB site in the PRC1 promoter modify its basal activity (Li et al, 2004). Since 
PRC1 is a regulator of cytokinesis, this provides an additional route through 
which NF-κB might regulate mitosis. RelA also interacts with the centrosomal 
P4.1-associated protein (CPAP) (Koyanagi et al, 2005), which is a component 
of the centrosomal complex. This interaction was identified after a yeast two-
hybrid screen and then confirmed in MCF—7 breast cancer cells (Koyanagi et 
al, 2005). 
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1.4 Cancer 
 
1.4.1 The Hallmarks of cancer 
Cancer is a multi-step disease characterized by various genetic 
alterations, which promote the transformation of normal cells into malignant 
cells. More than a hundred cancers have been described, and a lot of sub-types 
can be found associated with specific organs (Hanahan & Weinberg, 2000) but 
the common characteristic is that genetic modifications induce a loss of function 
in tumor suppressor genes and/or a gain of function of tumor promoter genes, 
also called oncogenes. Hanahan and Weinberg suggested in 2000 that all 
cancer cells have six characteristics compared to normal cells, which are briefly 
described below (Figure 1.11).  
- Self-sufficiency in growth signals. Some tumours, due to the activation of 
oncogenes such as Ras, are able to produce their own growth signals.  
- Insensitivity to anti-proliferative signals: in order to pass through processes 
such as cellular quiescence or differentiation, cancer cells are able to modify 
the response to anti-proliferative signals and in this case, this results in 
uncontrolled growth. 
- Evasion of apoptosis: this ability can sometimes be linked to uncontrolled 
proliferation. In normal cells, excessive proliferation results in programmed cell 
death. But in cancer cells, resistance to apoptosis can be acquired, through a 
variety of processes, such as mutation of the tumor repressor p53.  
- Limitless replicative potential: normally, after a certain number of doublings, 
cells undergo senescence. To overcome this, tumour cells acquire limitless 
replicative potential. This can frequently occur by up-regulation of telomerase 
resulting in maintenance of telomere length and cell immortalisation.  
- Angiogenesis: angiogenesis is the process necessary to grow new blood 
vessels. This is regulated by a balance between angiogenesis inducers (like 
vascular endothelial growth factor VEGF) and inhibitors (thrombospondin-1, for 
example). Tumor cells have the ability to shift this balance in order to increase 
angiogenesis. 
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Figure 1-11: The Hallmarks of Cancer 
The six first hallmarks of cancer as described by Hanahan in 2001 were constituted of: 
1-evading apoptosis; 2-self sufficiency to growth signals; 3-insensitivity to anti-growth 
signals; 4- tissue invasion and metastasis; 5- limitless replicative potential; 6-sustained 
angiogenesis. To these 6 characteristics, four other hallmarks were described later: 7- 
Genome instability and mutations; 8- Tumour promoting inflammation; 9- 
Reprogramming energy metabolism; 10- Evade Immune destruction 
Adapted from (Hanahan & Weinberg, 2011). 
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- Tissue invasion and metastasis: the ability of tumour cells to invade adjacent 
tissues and settle in another place, forming metastases, is a major issue in 
oncology and is responsible for 90% of human cancer deaths. This process 
frequently involves cell adhesion molecules, whose expression can become 
altered in malignant cancer cells. 
 
A decade later, due to the advances in cancer research, Hanahan and 
Weinberg updated their first review by the addition of four more characteristics, 
two of which are well established (bringing the list to eight hallmarks of cancer) 
and two of emerging importance (Figure 1.11) (Hanahan & Weinberg, 2011). 
These were: 
- Mutations and genome instability (established hallmark): genomic instability 
increases the probability that occurring mutations will enhance tumor formation 
and promotion (for example the mutation of the BRCA1 gene in breast cancer).  
Telomeric DNA loss also plays a role in the karyotype instability, by promoting 
the amplification or deletion of chromosomic DNA sections, which leads to a 
possible unlimited replication. 
- Tumor promoting inflammation (established hallmark): the tumor-associated 
inflammatory response allows the progression and enhancement of tumor 
growth, by providing various essential molecules to the micro-environment, 
such as growth factors and cytokines 
- Reprograming of energy metabolism (emerging hallmark): even with oxygen, 
cancer cells are able to change their glucose metabolism and then their energy 
production. This will support increased cell proliferation. 
- Evasion of the immune destruction (emerging hallmark): cells and tissues are 
permanently monitored by the immune system, allowing the recognition and 
destruction of a majority of cancer cells. This means that the remaining tumors 
have found a way to bypass this surveillance, but the full mechanism involved is 
still to be fully understood 
In addition to all these characteristics, the micro-environment has been 
shown to have a great influence on tumour growth. Here, different non-tumour 
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cell types can synthetize and provide various molecules such as growth factors 
to the tumour (Hanahan & Weinberg, 2011). 
 
1.4.2 NF-κB in cancer 
Usually, in normal conditions, NF-κB activation is a response mechanism 
to infection and inflammation. However, as described earlier in this chapter and 
to a larger extent in the literature, NF-κB, in association with other transcription 
factors such as AP-1, complex composed of pronto-oncogenes such as c-Fos 
and c-Jun (Kawai & Akira, 2006), can act as a tumour promoter in cancer cells. 
In this context, aberrantly activated NF-κB can be linked to all the “hallmarks of 
cancer” described by Hanahan (Hanahan & Weinberg, 2011), promoting tumor 
survival (Perkins, 2012). However, the effect of individual NF-κB subunits is still 
to be fully understood. Constant NF-κB activation in tumor cells usually derives 
from permanent activation of the IKK complex or a deficiency in a negative 
feedback loop (Perkins, 2012). 
The first demonstrated link between NF-κB and cancer was when v-rel, a 
c-Rel homologue found in the avian reticuloendothelial virus, was shown to 
induce B-cells tumours in chicken (Gilmore, 1999), although this study was 
performed before the link between Rel and NF-κB was known. The c-Rel 
subunit seems to be the most oncogenic sub-unit, as c-Rel overexpression but 
not any of the other NF-kB subunits promotes tumour formation in chickens 
(Karin et al, 2002). The c-Rel gene is found amplified in approximately 23% of 
lymphomas. Almost half of B-cell non-Hodgkins’ lymphoma have amplified c-
Rel, which is usually associated with poor prognosis (Rayet & Gelinas, 1999). c-
Rel mutations are found quite frequently. For example, the S525P change in B 
cell lymphoma, found in 2.4% of samples tested, affects an IKK phosphorylation 
site and increases c-Rel’s in vitro transforming activity (Perkins, 2012). 
Although not much mutated in cancer, NF-κB are frequently found 
aberrantly active. The RelA and p50 subunits are found constitutionally 
activated in 37% and 28% respectively of prostate cancers, whereas it is the 
case in almost 19% of prostate cancers for the p52 subunit, despite the fact that 
they could not be associated with any particular pathologic characteristics (Seo 
et al, 2009). Among other cancer types (Prasad et al, 2010), NF-κB was found 
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aberrantly activated in breast cancer (Sovak et al, 1997), and in leukemia and 
lymphoma (Karin et al, 2002). 
Only a few mutations have been detected in the other NF-κB sub-units in 
cancer. One point mutation in RelA was described in a case of multiple 
myeloma, which changed the glutamate 495 residue to aspartate, which was 
reported to reduce RelA DNA-binding and transactivation activity, although the 
mechanism behind this is unclear (Trecca et al, 1997). Four other point 
mutations in RelA (T55S, E498K and Q132 in lung cancer, E127 in ovarian 
cancer) have been detected without any effect described yet (Perkins, 2012). 
Any effect of point mutations in RelB, which are mostly silent and found in 
ovarian cancer, are still not known (Perkins, 2012).  
NFkB2 was identified as a gene found translocated in B-cell lymphoma, 
lyt-10-Cα (Neri et al, 1991). This involves a chromosomal translocation of the 
NFkB2 locus (10q24), associated with B and T cell lymphoma, chronic 
lymphocytic leukaemia (CLL) and multiple myeloma (Karin et al, 2002). NFkB2 
translocation occurs in 2% of B and T cell lymphomas, and these lead to a C-
terminal truncation of p100 and constitutive processing of p52 (Perkins, 2012). 
This translocation will also lead to a reduction in the IκB like function of p100, as 
a consequence of loss of the PID domain in rearranged p100 proteins (Xiao et 
al, 2001). Partial loss of the Ankyrin repeat in p100 due to this rearrangement 
also reduces its IκB activity although as long as 2 out of the 7 Ankyrin repeats 
are present, p100 is able to function as an IκB-like protein when transiently 
transfected into cells, leading to the conclusion that Ankyrin repeats are not the 
only mechanism for the IκB like function of p100 (Xiao et al, 2001). The C-
terminal deletion of the nfkb2 gene in mice results in aberrant production of p52. 
This leads to increased lymphocyte proliferation and gastric hyperplasia in mice 
(Ishikawa et al, 1997). 
Viral proteins are involved in cancers such as Burkitts lymphoma or 
Hodgkins disease. For example, the EBV protein LMP-1 can cause cell 
transformation, cell proliferation and is required for lymphoblastoid cell line 
establishment (Atkinson et al, 2003). They can also induce p100 processing to 
p52 (Atkinson et al, 2003). The significance of NFkB2 mutations found in lung 
cancer is not yet understood, although the location of one of them (V519F) in 
p100 is thought not to affect p52 activation, whereas the V281L mutation, 
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situated in the dimerization domain, could affect p52 dimerization affinity and 
specificity ((Perkins, 2012), Catalogue of Somatic Mutations in Cancer 
(COSMIC) Database).  
In human breast cancer, the cyclin D1 gene is amplified in 15% of cases, 
while the protein is over-expressed in 30-50% of tumors, thereby increasing 
their proliferation (Fu et al, 2004). It is now well known, that NF-κB sub-units 
regulate cyclin D1 expression (Guttridge et al, 1999) and this regulation, in 
breast cancer, seems to go through the non-canonical pathway (Demicco et al, 
2005). Moreover, immunostaining experiments showed that p52, the co-
activator Bcl-3, and cyclin D1 but not RelA are over-expressed in breast tumour 
tissues (Cogswell et al, 2000). IKKα can also be activated in mammary 
epithelium (Cao et al, 2001), which leads to the processing of p100 to p52. 
Inactivation of the Nfkb2 gene induces specific defects in B cell functions and in 
the architectural development of peripheric lymphoid organs (Xiao et al, 2001). 
After stimulation by infectious agents such as bacterial or viral products, 
NF-κB is activated in inflammatory cells. This leads to the release of 
inflammatory cytokines, growth and survival signal, as well as angiogenic 
factors in the tumour micro-environment (Karin, 2006). This results in NF-κB 
activation in malignant cells, regulating the expression of cell cycle genes, anti-
apoptotic genes and invasive protease (Karin, 2006), thus enabling the tumor 
progression.  
 
1.4.3 NF-κB knockout mice 
Due to the involvement of NF-κB in the immune response as well as 
cancer and inflammatory diseases, NF-κB mice knockout have been 
extensively studied (Gerondakis et al, 1999; Gerondakis et al, 2006; Hoffmann 
& Baltimore, 2006)) but will be briefly described here.  
Interestingly, RelA is the only subunit required for embryonic development 
and post-natal survival. Indeed, RelA -/- mice died at the embryonic stage E14 
of fatal liver apoptosis after sensitization to TNF-α (Gerondakis et al, 1999; 
Hoffmann & Baltimore, 2006). Mice lacking the RelB subunit are viable but 
present multiple pathological lesions and defects in immunity (Gerondakis et al, 
1999). c-Rel knockout mice exhibit major defects in B and T cells development, 
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whereas nfkb1 -/- mice induce defects mainly in the B cell population 
(Gerondakis et al, 2006). Nf-kb2 -/- mice, the most relevant to my thesis, are 
able to develop normally but present disruptions in splenic and lymph node 
architecture (Caamano et al, 1998). They also display negative regulation of 
dendritic cell maturation (Speirs et al, 2004). NFkB2 has a role regulating naïve 
T cell function and limits nuclear translocation of RelA/p50 heterodimers 
(Gerondakis et al, 2006). 
 Double knockout nfkb1/nfkb2 mice have also been studied and display a 
more severe phenotype that single subunit knockout. Although their 
embryogenesis occurs normally, these mice develop abnormalities after birth, 
such as growth retardation or craniofacial malformations. B cell development is 
also blocked in nfkb1 -/- nfkb2 -/- mice (Gerondakis et al, 2006). 
 
1.5 Preliminary data 
 
As described above, p52 is able to regulate the expression of genes 
having a role in cell proliferation, such as Cyclin D1 (Barre & Perkins, 2007; 
Schumm et al, 2006). Unpublished data by K.Schumm showed that p52 is also 
involved in the regulation of G2/M phase in U2OS osteosarcoma cells.  
Transient depletion of p52 with siRNA oligos leads to an increase in G2/M 
phase cells and defects in mitosis ((Schumm et al, 2006) and unpublished 
observations). A significant lengthening of mitosis has also been detected 
visually after p52 siRNA treatment in U2OS cells expressing a YFG-H2B fusion 
protein, allowing chromosome separation in mitosis to be seen using a 
deconvolution microscope. Here, live cell imaging showed that cells lacking p52 
could stay in metaphase for over 1h (whereas normal mitosis usually last 30 
minutes to 1h in U2OS cells) before pursuing mitosis. Defects in chromosome 
segregation and alignment on the metaphasic plate were also observed, as 
chromosomes stayed attached to the outside of the cell and failed to line up on 
the metaphasic plate. When progression through anaphase and telophase 
finally happened, formation of micronuclei, which could come from 
chromosomes left behind, was detectable. Some cells were also seen 
appearing to go into apoptosis but managing to survive and progress though 
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mitosis (unpublished observation by K.Schumm, 2006). Moreover, p52 siRNA 
depletion resulted in an increase in multinucleate cells, as well as aberrant 
spindle formation.  
An immunofluorescence study showed that p52 could be associated with 
the centrosome structure in U2OS cells in interphase and during mitosis. During 
metaphase, p52 was found in the center of the ring formed by α-tubulin, 
whereas during telophase, p52 localized in the MTOC. Colocalization between 
p52 and γ-tubulin was also observed during prophase, metaphase and 
telophase in U2OS cells, HT1080 cells (immortalized human fibrosarcoma) and 
HFF cells (immortalized human foreskin fibroblasts) (K.Schumm, unpublished 
observations). 
U2OS cells stably expressing a shRNA against p100/p52 were created 
and immunofluorescence observation showed a significant increase in 
multinucleate cells compared to a control shRNA U2OS cell line. Electron 
microscopy revealed aberrant centrosome structures in the p100/p52 depleted 
stable cell lines. Moreover, these cells were sick, proliferated slowly and died 
after few passages compared to control cells (K.Schumm, unpublished 
observations). 
Unpublished studies on the mechanism involved revealed that p52 could 
regulate the expression of genes involved in G2/M progression, such as 
Survivin. Survivin, a chromosome passenger protein, involved in the spindle 
checkpoint, is also a p53 target gene (Mirza et al, 2002). Furthermore, an 
increase in the mRNA levels encoding other proteins required for the spindle 
checkpoint, such as BubR1 or Mad2, was also seen after p52 depletion, 
although there is no evidence for direct regulation.  
These data and unpublished observations by K.Schumm linked p52 with 
the centrosome structure and G2/M progression. However, further analyses 
were necessary to explain the role of the NF-κB p52 subunit in centrosome 
duplication. 
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1.6 Aims of the thesis 
 
The aim of this thesis was to elucidate how p52 affects centrosome 
structure. To achieve this, I first studied the ability of p52 to regulate various 
genes involved in the cell cycle and the centrosome duplication. I found that 
some essential genes, such as PLK4 or its effector SAS6, were regulated by 
NF-κB subunits. I then showed that this regulation happens via a direct 
interaction of NF-κB subunits with the PLK4 promoter and that PLK4 promoter 
activity depends on NF-κB expression. I then investigated whether this 
regulation is cell cycle dependent. 
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2 Materials and Methods 
 
2.1 Cell culture 
2.1.1 Tissue culture cell lines and growth condition 
U2OS are a human osteosarcoma cell line obtained from the Europan 
Collection of Cell cultures (ECACC). Cells of passage 6-28 were used. These 
cells are functionally null for p16INK4A and p14ARF due to hypermethylation of 
their promoter. They also contain a functional p53. 
Hela are a human adenocarcinoma cell line obtained from the ATCC, and are 
functionally null for p53 due to the expression of the Human Papilloma Virus 
proteins E6 and E7.  
H1299 cells, also obtained from the ATCC, are human non-small-cell lung 
carcinoma cells derived from a lymph node metastasis. H1299 cells do not 
express p53 due to a homozygous partial deletion. 
Dr.Jorge Caamano (University of Birmingham) provided Mouse Embryonic 
Fibroblasts (MEF) wild-type (wt) cells. nfκb2 null MEF cells were obtained from 
Dr. Ron Hay’s laboratory in Dundee. 
All cell lines were maintained at 37°C, 5% CO2 in Dulbecco's modified Eagle's 
medium (Lonza) supplemented with 10% filtered fetal calf serum (FCS, 
Invitrogen), 1 U/mL penicillin, 1 µg/mL streptomycin (Lonza) and 2mM L-
glutamine (Lonza), unless stated otherwise. All cells were subcultured when 
they reached ~80% confluency by washing with phosphate buffered saline 
(PBS, Lonza), treating with trypsin-EDTA and replating to ~20% of confluency. 
 
2.1.2 Frozen cell storage 
For long-term storage, cells of ~80% confluency were washed with PBS, 
detached using trypsin-EDTA and pelleted at 1000 revolutions per minute (rpm) 
for 5 minutes. The cell pellet was re-suspended in filtered FCS with 10% 
dimethyl sulphoxide (DMSO) and transferred to frozen storage vials. Cells were 
incubated at room temperature (RT) for 15 minutes before freezing slowly at -
80°C and transferred to liquid nitrogen storage. Cells were recovered by 
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thawing a vial in a 37°C waterbath and plating on 10cm plates (Helena) in the 
required growth media. 
 
2.1.3 RNAi transfection 
Small Interfering RNA (siRNA) knockdown of specific mRNA was carried out as 
follows. Quantities are for a transfection of a 15cm plate and were scaled down 
relative to the size of the plate for smaller transfections. Cells were seeded at 
4x106 cells and transfected a few hours later. 5nM (final concentration) of 
siRNA were mixed with 1 mL of Opti-MEM media (Invitrogen) and 25 µL of 
Interferin reagent (Polyplus) according the manufacturer’s instructions. The mix 
was left for 10-15 minutes at room temperature before adding drop-wise over 
the surface of the cells already covered by media. The cells were harvested 48h 
later as described in the corresponding experiment, unless stated otherwise. 
For some transfections, a pool of siRNAs was used with a final concentration of 
5 nM of total siRNA added to the transfection mix. The sequences for the 
siRNAs used are shown below: 
control = CAGUCGCGUUUGCGACUGG 
p100/p52-A = CAGCCUAAGCAGAGAGGCU 
p100/p52-B = CUACGAGGGACCAGCCAAG 
p100/p52-C = GAUGAAGAUUGAGCGGCCU 
RelA-1 = GCUGAUGUGCACCGACAAGUUTT 
RelA-2 = GCCCUAUCCCUUUACGUCATT 
RelB = UUGGAGAUCAUCGACGAGU 
cRel = AUUGUGAAGGGCGAUCAGCA 
p105/p50 = NNGGGGCUAUAAUCCUGGACU 
pan-NF-κB = AAGGUGCAGAAAGAGGACA 
PLK4-A = GGACCUUAUUCACCAGUUA 
PLK4-B = UGAAGGACUUGGUCUUACA 
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2.1.4 DNA transfection 
The cationic polymer polyethylenimine (PEI) was used for transfection of DNA 
into mammalian cell lines. This technique relies upon endocytosis of the 
DNA/PEI complexes (Durocher et al, 2002). Quantities shown below are for the 
transfection of a 15cm plate and were scaled down relative to the size of the 
plate for smaller transfections. Cell were seeded at 4x106 cells and transfected 
more than 6 hours later. 1mL of Opti-MEM were mixed with 5 µg of DNA and 25 
µL of PEI and the mix was left 15 minutes at RT before adding drop-wise over 
the surface of the cells already covered by media. The cells were harvested as 
described 48h later, unless stated otherwise. 
 
2.1.5 CDK1 inhibitor 
When required, cells were treated with the CDK1 inhibitor RO-3306 (Biomal) at 
10 µM. The inhibitor was made up at a 1000X concentration in DMSO, and cells 
were simultaneously treated by DMSO alone as a control. 
 
2.1.6 Cell synchronization 
Various techniques were performed to synchronize U2OS cells: 
Taxol (Sigma): cells were treated with 5 µM Taxol for 24 hours, washed 3 times 
in PBS and released in normal DMEM media. 
Nocodazol (Sigma):  cells were treated with 2 mM Nocodazol for 20 hours, 
washed 3 times in PBS and released in normal DMEM media. 
Aphidicolin (Calbiochem): cells were treated with 1 nM Aphidicolin for 12 hours, 
washed 3 times in PBS and released in normal DMEM media. 
Serum Starvation: cells were grown in DMEM medium with 0.5% FCS 
overnight, washed 3 times in PBS and released in normal DMEM media. 
Hydroxy-urea (Sigma): cells were treated with 2 mM hydroxyl-urea (HU) 
overnight, washed 3 times in PBS and released in normal DMEM media. 
Double thymidine block (Sigma): cells were treated with 2 mM thymidine for 18 
hours, washed 3 times in PBS and released in normal DMEM media for 9 
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hours, treated a second time with 2 mM thymidine for 14 hours, washed 3 times 
in PBS and released in normal DMEM media. 
Cells were then analyzed by FACS (Fluorescence Activated Cell Sorted) 
analysis to confirm synchronicity. 
 
2.1.7 Cell proliferation assay 
U2OS cells in 24 well plates were transfected in duplicate with siRNA, using the 
previously described conditions. 24 hours later, the cells were washed, 
detached with trypsin-EDTA and the duplicates were combined in the same well 
of a 6 well plate. The next day, cells were once again transfected with siRNA, 
using the previously described conditions. 24 hours later, the cells were 
washed, detached with trypsin-EDTA, counted and replated in 96 well plates at 
a concentration of 2, 000 cells per well. More than 6 hours later, the proliferation 
at day=0 (D0) was read using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega) and a 96 well plate reader (POLARstar Omega, 
BMG Labtech). Following readings (D1, D2, etc.) were each taken 24 hours 
after the previous one. 
 
2.1.8 Immunofluorescence 
U2OS cells grown on cover slides were fixed for 30 minutes using 3.7% 
paraformaldehyde. After 3 washes in PBS, cells were permeabilised for 5 
minutes at room temperature (RT) with PBS-Triton X100 (1%), washed 3 times 
in PBS and blocked in PBS – Tween (0.1%) – BSA (5%) for 1 hour at RT under 
agitation. Primary antibodies were diluted in PBS - Tween 0.05% - BSA 1% for 
1 hour at RT (See Table 2.2 for antibodies dilutions). The slides were then 
washed 3 times in PBS – Tween (0.05%) before being incubated with 
secondary antibodies for 1h at RT in the dark. After 3 more washes in PBS-
Tween 0.05%, slides were incubated with mounting medium containing DAPI 
(Vector Vectashield) for 5 minutes and then sealed and stored at -20°C. Slides 
were viewed on a Leica confocal imaging spectrophotometer system (TCS-
SP2) and analyzed with Volocity imaging software at the University of Bristol. 
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2.1.9 Fluorescence Activated Cell Sorting (FACS) 
Adherent and detached cells were harvested, pooled, washed once in PBS, and 
fixed in ice-cold 70% Ethanol at -20°C for at least 16 hours. The cells were then 
washed twice in PBS – Tween (0.05%) and resuspended in PBS containing 50 
µg/ml of propidium iodide and 50 µg/ml of RNAse A. Cells were stained for 20 
minutes at RT in the dark. Cells were then analyzed for cell cycle distribution 
with a BD FACSCanto II (6c) (Becton Dickinson) and FlowJo analyzing 
software. Red fluorescence (≥ 585 nm) was evaluated on a linear scale and 
pulse width analysis was used to exclude cell doublets and aggregates from the 
analysis. Cells with DNA content between 2N and 4N were designated as being 
in the G1, S, or G2/M phase of the cell cycle. Cells with a DNA content less 
than 2N were designated as Sub-G1. The number of cells in each stage of the 
cell cycle was expressed as a percentage of the total cumber of gated cells. 
 
2.1.10 Reporter gene assay 
Cells in 6 well plates were harvested by removing media and washing with 
PBS. 600 µL of Passive Lysis Buffer (PLB, Promega) were added to each well 
and left to incubate for 15 minutes at RT under agitation. Lysed cells were then 
removed to eppendorfs and centrifuged at 19, 350 g for 5 minutes. The 
supernatant was then assayed using the Luciferase Assay System (Promega) 
in a Lumat LB9507 luminometer (Bethold Technologies). Results were 
normalized to protein concentration and all experiments were performed a 
minimum of three times before calculating means and standard deviation as 
shown in the figures. 
 
2.1.11 Chromatin ImmunoPrecipitation (ChIP) 
At 70-80% confluency, cells were washed once in PBS and fixed for 10 minutes 
at RT with 1% formaldehyde in PBS. The crosslinking was blocked with a 5 
minutes incubation in cold PBS- 0.125 M Glycine. The cells were washed twice 
in PBS, lysed in 500 mL of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl 
pH 8.1, 1 mM phenylmethylsulfonyl fluoride, 1 mg/mL leupeptin, 1 mg/mL 
aprotinin) and incubated for 10 minutes at 4°C. Samples were sonicated 6 times 
(30 sec ON, 30 sec OFF, 5 Amp), followed by centrifugation at 14000 rpm for 
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10 minutes at 4°C. 20 µL of the supernatant was kept apart, diluted by 1:10 
(Dilution buffer: 1% triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.1, 150 mM 
NaCl, 0.1% NP40, 0.05% deoxycholate) and stored at 4°C as “Input”. The 
remaining supernatant was diluted three times and precleared for 2h at 4°C with 
2mg of sheared salmon sperm DNA (ssDNA) and 30 µL of beads (1:1 mix of 
protein A- and protein G-sepharose, 50% slurry) per 500 µL. 
Immunoprecipitation was performed overnight with 1 µg of specific antibody at 
4°C. The immune complexes were captured by addition of 30 µL of beads (1:1 
mix of protein A- and protein G-sepharose, 50% slurry) and 2 µg of ssDNA for 
1h at 4°C. Immunoprecipitates were washed sequentially for 5 minutes each in 
Wash Buffer 1 (0.1% SDS, 1% Triton-X-100, 2 mM EDTA, 20 mM Tris-HCl 
pH8.1, 150 mM NaCl), Wash Buffer 2 (0.1% SDS, 1% Triton-X-100, 2 mM 
EDTA, 20 mM Tris-HCl pH8.1, 500 mM NaCl), Wash Buffer 3 (0.25 M LiCl, 1% 
NP40, 1 deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH8.1) and TE Buffer (10 
mM Tris-HCl and 1 mM EDTA). Complexes were eluted with 200 µL of Elution 
Buffer (1% SDS, 0.1 M NaHCO3) for 1h at room temperature and pelleted at 
2000 rpm for 5 minutes at RT. To reverse the crosslinks, the supernatants and 
the inputs (which were adjusted to 1% SDS, 0.1 M NaHCO3) are incubated at 
65°C for at least 6h. The proteins were removed with a phenol choloroform 
extraction; DNA was then extracted by ethanol precipitation and diluted in 100 
µL of TE buffer. 5 µL was used for the PCR reactions. 
PCR conditions were as follows: 95°C for 3 minutes and then 35 cycles of 95°C 
for 40 sec, 55°C for 40 sec, 72°C for 40 sec followed by an additional 7 minutes 
at 72°C. Quantitative PCR data were generated on a Rotor-Gene 3000 (Corbett 
Research) using the following experimental settings: Hold 95°C 7 min; Cycling 
(45 cycles of 95°C for 20 sec; 55°C for 20 sec; 72°C for 20 sec with 
fluorescence measurement); Melting Curve 55–99°C with a heating rate of 1°C 
every 5 sec. All values were calculated relative to Inputs levels and normalized 
to IgG levels using the Pfaffl method (Pfaffl, 2001). All experiments were 
performed a minimum of three times before calculating means and standard 
deviation as shown in figures. Human and mouse primers used for ChIP-PCR 
are as stated in Table 2.1 
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Table 2-1: Primers used for ChIP assays 
Name Sequence sense Sequence antisense 
Human primers 
PLK4-2634 GTC-CTA-TCA-AAA-CAG-CTA-GGT-TG GAT-GAA-TTT-ATT-GGG-ATG-TAG-CC 
PLK4-1947 GAG-GGG-TTT-GCT-GAG-GAG-CAG CAC-GTG-ATA-TTG-TTT-GTC-TCT-C 
PLK4-1256 TAC-GGT-ATG-TGA-TCC-TGT-ACT-AG CAT-ACA-CTA-TGC-TCT-TAT-ACC-CC 
Gapdh CGG TGC GTG CCC AGT TG GCG ACG CAA AAG AAG ATG 
Mouse primers 
PLK4-21 GCT ACG GTC AGT CGT ACA CTG GTG ACG TCA GCA CAC TCT CCA C 
PLK4+135 GCC TCT AAG AAG TGG AGA GTG CCA TCA GGA CGC CTT CTC TAC 
PLK4+329 GGA GAG GAT CGA GGT GAG G CCG CTT TAC TAG TGT CAC TG 
 
2.2 Protein and RNA extracts 
 
2.2.1 Protein extracts 
The cells were harvested, pooled, washed once in PBS and lysed using a Total 
Lysis Buffer (25 mM HEPES, 300 mM KCl, 0.2 mM EDTA, 10% Glycerol, 0.1% 
NP-40, 1 mM PMSF, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 
5 nM NaF, 500 µM Na3VO4). Cells were lysed by vortexing for a few seconds 
before incubating on ice for 15 minutes before centrifugation at 19 350 g for 15 
minutes at 4°C. 
 
2.2.2 Western Blotting 
Proteins were separated by molecular weight using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Protein samples were boiled for 5 minutes in an 
appropriate volume of 5x SDS buffer (5% SDS, 50% glycerol, 312.5 mM Tris, 
25% β-mercapthoethanol, trace Bromophenol Blue, pH 6.8) and briefly 
centrifuged prior to loading on a gel. Samples were first run through a 5% w/v 
stacking gel (5% acrylamide, 0.2 M Tris pH 6.8, 0.1% SDS, 0.1% w/v 
ammonium persulfate (APS), and 0.1% v/v tetramethylethylenediamine 
(TEMED)). The resolving gel following contained 10% w/v acrylamide, 0.25 M 
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Tris pH 8.8, 0.1% SDS, 0.1% APS, 0.04% TEMED. Gels were run between 80 
and 150 volts depending on the size of the gel and the level of separation 
required. The proteins were then semi-dry transferred to a polyvinylidine 
difloride (PVDF) membrane in PVDF transfer Buffer (20% methanol, 48 mM 
Tris, 39 mM Glycine, 0.02% SDS) at 21 volts for 30 minutes – 1.5 hours 
depending on the size of the protein being transferred. Membranes were 
blocked for one hour in tris buffered saline (TBS)-tween (20 mM Tris pH7.6, 150 
mM NaCl, 0.1% tween) supplemented with 5% powered milk, washed once with 
TBS-Tween and incubated overnight at 4°C with primary antibodies (see table 
2.2 for dilutions). Antibodies are diluted to the appropriate dilution in TBS – 
Tween 0.25% - BSA 2% - sodium azide (NaAz) 0.1%. The membrane was 
washed 3 x 10 minutes in TBS-Tween and incubated in secondary antibody, 
conjugated with the Horseradish Peroxidase (HRP) in TBS-Tween – 5% milk for 
1h at RT before washing as before. Specific antibodies were visualized using 
enhanced-chemiluminescence (ECL) solution (Pierce) and exposed to 
autoradiography film. The membrane was probed for additional proteins by 
stripping away the first set of antibodies in Stripping Buffer (62.5 mM Tris, 2% 
SDS, 100 mM β-mercaptoethanol, pH 6.7) for 30 minutes at 55°C. The 
membrane was then washed in TBS-Tween, blocked and reprobed as 
described before. 
 
2.2.3 Antibodies 
Primary antibodies, as well as concentration or dilution, are used as stated in 
Table 2.2. 
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Table 2-2: Primary antibodies 
ChIP stands for Chromatin Immuno-Precipitation, IF for Immuno- Fluorescence 
Antibody Company Western Blot ChIP IF 
p52 Monoclonal Upstate 1/1000 1 µg 1/100 
p52 Polyclonal (sc-848) Santa Cruz 1/1000 1 µg 1/100 
p52-pS222  1/400   
RelA polyclonal (sc-372) Santa Cruz 1/1000 1 µg  
RelB polyclonal (sc-226) Santa Cruz 1/1000 1 µg  
cRel polyclonal (sc-71) Santa Cruz 1/1000 1 µg  
p50 (06-886) Upstate 1/1000 1 µg  
PLK4 Cell Signalling 1/500   
CDK2 Santa Cruz 1/1000   
Cyclin B1 Santa Cruz 1/1000   
Cyclin A Santa Cruz 1/1000   
Cyclin E Santa Cruz 1/1000   
Cdc2 CRUK 1/1000   
β-actin Sigma 1/10000   
RNApol II Santa Cruz  1 µg  
Ac-Histone H3 Upstate  1 µg  
HA CRUK  1 µg  
IgG Sigma  1 µg  
Cyclin D1 Santa Cruz 1/1000   
γ-tubulin Sigma   1/500 
α-tubulin Sigma   1/500 
Centrin2 Abcam   1/1000 
CDK1 CRUK 1/1000   
CDK4 Santa Cruz 1/1000   
 
Secondary antibodies used for Western Blotting were: 
Anti-mouse IgG HRP-conjugate (Upstate, 12-349) 
Anti-rabbit IgG HRP-conjugate (Sigma, AO545) 
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Secondary antibodies used for Immunofluorescence were as follow: 
Rhodamine RedX-conjugated donkey Anti-rabbit IgG (Jackson Laboratories, 
711295152) 
FITC Anti-mouse IgG (BD Pharmingen, 554001) 
 
2.2.4 RNA extracts 
For reverse transcriptase PCR, mRNA was extracted with the Total RNA kit 
(Peqlab), according to manufacturers instructions. Briefly, DNA was first 
removed by binding to a column. After centrifugation, the filtrate from the 
column containing the RNA was diluted with an equivalent volume of 70% 
Ethanol before loading on a RNA binding column. After three washes with the 
provided buffers and drying the column, the RNA was eluted using 50 µL of TE 
buffer and quantified using a Thermo Scientific NanoDrop2000c 
spectrophotometer with the analysis software NanoDrop2000. 
 
2.2.5 Reverse transcription 
1 µg of RNA sample was reverse transcribed using the Quantitect Reverse 
Transcription Kit (QIAgen; 205313) according the manufacturer’s instructions. 
Briefly, the genomic DNA was first removed by a 2 minutes incubation at 42°C 
using an appropriate buffer. The cDNA was then generated by adding Reverse 
transcriptase and its buffer, with a mix of primers to the RNA. This was 
incubated for 15 minutes at 42°C, followed by a 3 minutes incubation at 95°C to 
inhibit the enzyme. The cDNA stock was diluted by to a concentration of 5 
ng/µL and 5µl (25ng) was used for PCR with GoTaq flexi DNA polymerase 
(Promega; M8305). 
 
2.2.6 Quantitative Polymerase Chain Reaction (PCR) 
Quantitative PCR was performed using GoTaq flexi DNA polymerase 
(Promega; M8305), with 3 nM of MgCl2, Sybr Green (Sigma) and 0.4 µM of 
each primer. 
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Quantitative PCR data were generated on a Rotor-Gene 3000 (Corbett 
Research) using the following experimental settings: Hold 95°C 7 min; Cycling 
(45 cycles of 95°C for 20 sec; 58°C for 20 sec; 72°C for 20 sec with 
fluorescence measurement); Melting Curve 50–99°C with a heating rate of 1°C 
every 5 sec. All values were calculated relative to untreated levels and 
normalized to GAPDH levels using the Pfaffl method (Pfaffl, 2001). All 
experiments were performed a minimum of three times before calculating 
means and standard deviation as shown in figures. Human and mouse primers 
used for PCR are as stated in Table 2.3: 
 
Table 2-3: primers used for PCR 
Gene Sequence sense Sequence antisense 
Human primers 
Nf-κb2 (p100) GGG CAG ACC AGT GTC ATT GAC CCA TGC CGA TCC AGC AGA G 
RelA CTC-GGT-GGG-GAT-GAG-ATC-TTC CCG-GTG-ACG-ATC-GTC-TGT-ATC 
RelB CAT-CGA-GCT-CCG-GGA-TTG-T CTT-CAG-GGA-CCC-AGC-GTT-GTA 
cRel AGA GGG GAA TGC GTT TTA GAT ACA CAG GGA GAA AAA CTT GAA AAC ACA 
p50 TCC-CAT-GGT-GGA-CTA-CCT-GG ATA-GGC-AAG-GTC-AGG-GTG-C 
PLK4 GAT CAT TTG CTG GTG TCT A ACC TCA TTT TGG ACT CTC TG 
SAS6 GAA TGA GCA TTG AAC TAC A GGT GAG TTA TCC AAA ATA GC 
Cyclin B1 ATA-AGG-CGA-AGA-TCA-ACA-TGG-C TTT-GTT-ACC-AAT-GTC-CCC-AAG-AG 
Cyclin D1 CCA TTC CCT TGA CTG CCC GAG GAC CAG CCT CTT CCT CCA C 
CDK2 ATC TCT CGG ATG GCA GTA GTT GTG TAC AAA GCC AGA AAC 
GAPDH GGT CGT ATT GGG CGC CTG GTC ACC CAC ACC CAT GAC GAA CAT GGG GGC 
Centrin2 GAA CTG GCA CCA TAG ATG T TTT CCT GTC CCT TCC TTA T 
CDK1 AAA CTA CAG GTC AAG TGG TAG CC TCC TGC ATA AGC ACA TCC TGA 
CDK4 AGA GTG TGA GAG TCC CCA ATG CAA ACA CCA GGG TTA CCT TG 
cyclin A CGC TGG CGG TAC TGA AGT C GAG GAA CGG TGA CAT GCT CAT 
cyclin E TTA CCC AAA CTC AAC GTG CAA GCT CAA GAA AGT GCT GAT CCC 
γ-tubulin TAC AAC CCA GAG AAC ATC TA CAT CTG CTT CTC GGT CTA T 
Mouse primers 
Nf-κb2 (p100) CTA-ATG-TGA-ATG-CCC-GGA-CC GAG-CAG-CAT-TTA-GCA-GCA-GAG 
PLK4 AGG-AGA-AAC-TAA-TGA-GCA-CCA-CA TGG-CTC-TCG-TGT-CAG-TCC-AA 
GAPDH GCTACACTGAGGACCAGGTTG 
 
GCCCCTCCTGTTATTATGGGG 
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2.3 Molecular Biology techniques 
 
2.3.1 Escherichia coli growth conditions 
Escherichia coli (E.coli) bacteria were grown in Luria-Bertani (LB) medium (1% 
bacto-tryptone, 0.5% bacto-yeast extract, 1% NaCl, pH 7.0) and LB agar plates 
(as for LB medium with 15 g of agar added prior to autoclaving. 
 
2.3.2 Transformation of competent E. coli cells 
Competent E. coli cells (Subcloning Efficiency DH5α competent cells, 
Invitrogen) were transformed with plasmid DNA using the heat shock method. 
Approximately 100 ng of plasmid DNA or 10 µL of ligation was added to 50 µL 
of competent cells and incubated on ice for 30 minutes. The cells were then 
heat shocked at 42°C for 90 seconds and immediately placed on ice for 2 
minutes to recover. 500 µL of LB medium was then added and cells were 
shaken for 1 hour at 37°C to allow the bacteria to recover and produce the 
antibiotic resistance marker. The mixture was then spread onto the LB plates 
containing the required antibiotic (Ampicillin was used at 100 µg/mL, Kanamycin 
at 50 µg/mL) and grown overnight at 37°C. 
 
2.3.3 Minipreparation of plasmid DNA 
For small-scale preparation, plasmid DNA was extracted from a 3 mL overnight 
culture grown from a single colony in LB medium with the required antibiotic. 
DNA was extracted using the Wizard® Plus SV Minipreps DNA Purification 
System (Promega) according to manufacturers instructions. Briefly, the 
overnight culture was centrifuged at 3272 g and the pellet containing the 
bacteria was lysed after resuspension. The bacterial lysate was precipitated 
and centrifuged, the supernatant being then loaded on a DNA binding column. 
After three washes with the appropriate buffers, the DNA was eluted in 100 µL 
TE buffer. 
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2.3.4 Maxipreparation of plasmid DNA 
For large-scale experiments, plasmid DNA was extracted from a 300 mL 
overnight culture grown from a single colony in LB medium with the required 
antibiotic. Preparation of DNA was extracted using the Pureyield maxiprep kit 
(Invitrogen) according to manufacturers instructions. To describe the system 
briefly, the overnight culture was centrifuged at 3272 g and the pellet containing 
the bacteria is lysed. The bacterial lysate was precipitated and the whole 
suspension (containing DNA and bacterial lysate) was loaded on a DNA binding 
column, containing a filter that retains debris, previously correctly equilibrated. 
After three washes, the DNA was eluted with the elution buffer, precipitated with 
isopropanol, washed with 70% ethanol and then resuspended in 300 µL of TE 
buffer. 
 
2.3.5 Quantification of DNA and RNA 
The DNA or RNA concentration was quantified by measuring the optical 
absorbance at 260 nm with the Thermo Scientific NanoDrop2000c 
spectrophotometer with the analysis software NanoDrop2000. The 
concentration was calculated using the formula A260 1.0 = 50 µg/mL for double 
strand DNA or A260 1.0 = 40 µg/mL for RNA. 
 
2.3.6 Agarose Gel electrophoresis 
DNA products were resolved using 1-2% agarose gels (depending of the size of 
the fragment of interest) containing Tris-acetate Buffer (TAE, 40 mM Tris-
acetate, 1 mM EDTA) and SYBR Safe DNA gel Stain (Invitrogen). Gel loading 
buffer (30% glycerol, 0.25% bromophenol blue, 0.25% xylene cyanol) was 
added to each sample and the gel was run at 120V for up to 1 hour at RT. DNA 
was visualized using a luminescent Image Analyzer LAS-4000 (Fujifilm). To 
verify the size of the DNA, a 1 Kbp or 100 bp DNA ladder (Invitrogen) was run 
alongside. Fragments for use in subcloning were excised using a clean scalpel. 
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2.3.7 Purification of DNA fragments from agarose gels 
DNA fragments were purified using the QIAquick gel extraction kit (Qiagen) 
according to manufacturers instructions. For this purpose, small sized agarose 
bands containing the DNA to extract were melted at 65°C in a buffer with beads 
which bind to the DNA. After few washes, beads were dried and DNA was 
eluted with 30 µL TE buffer. 
 
2.3.8 Digestion of DNA with restriction endonucleases 
When required for subcloning, DNA digestion was performed at required sites 
using recombinant enzymes and buffers supplied by New England Biolabs or 
Promega, according to manufacturers instructions. Digestion was typically 
performed in a 20 µL volume, using 0.5 µL of the required enzyme and 
incubating for 1 hour at 37°C. 
 
2.3.9 Phosphatase treatment of linearized DNA 
To prevent self-ligation of the DNA vector after digestion, the 5’ phosphate 
groups were removed by the addition of Shrimp Alkaline Phosphatase (SAP, 
Promega), according to manufacturers instructions. This consisted of the 
addition of 1 µL of shrimp alkaline phosphatase enzyme and its buffer to the 
digested buffer and incubation for 15 minutes at 37°C. 
 
2.3.10 Ligations 
Ligations were performed using New England Biolabs T4 DNA ligase according 
to manufacturers instructions. A 1:5 ratio of vector:insert was used. Ligations 
were performed in a 20 µL volume using 0.5 µL enzyme and incubated at 16°C 
overnight. For each ligation, a control experiment without insert was set up to 
evaluate the level of self-ligation of the plasmid backbone. 
 
 66 
2.3.11 DNA sequencing 
DNA sequencing was performed by the sequencing service in Dundee (College 
of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using ABI 
3730 Capillary DNA Sequencers. 
 
2.3.12 Plasmids 
For all plasmids used in the study, see Table 2.4 
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Table 2-4: Plasmids used in the study 
Name Source Description 
RNAi plasmids 
pSilencer scramble NDP lab 
U6 plasmid containing a scramble 
RNAi oligo 
 
pSilencer p100 NDP lab 
U6 plasmid containing a p100/p52 
RNAi oligo 
 
pSilencer RelA NDP lab 
U6 plasmid containing a RelA RNAi 
oligo 
 
pSilencer RelB Rocha lab 
U6 plasmid containing a RelB RNAi 
oligo 
 
pSilencer cRel Rocha lab 
U6 plasmid containing a cRel RNAi 
oligo 
 
pSilencer p50 Rocha lab 
U6 plasmid containing a p105/p50 
RNAi oligo 
 
pSilencer panNF-κB Rocha lab 
U6 plasmid containing a RNAi oligo 
against all NF-κB subunits 
 
RSV Expression plasmids 
pRcRSV-NRC/MS NDP lab 
pRcRSV basic plasmid (Invitrogen) 
with multiple cloning site insertion 
 
pRcRSV-p52 NDP lab 
p52 in pRcRSV-NRC/MS 
 
pRcRSV-RelA NDP lab 
RelA in pRcRSV-NRC/MS 
 
pRcRSV-RelB NDP lab 
RelB in pRcRSV-NRC/MS 
 
pRcRSV-cRel NDP lab 
cRel in pRcRSV-NRC/MS 
 
pRcRSV-p50 NDP lab 
p50 in pRcRSV-NRC/MS 
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Table 2.4 (continued): Plasmids used in the study 
HA Tagged Expression plasmids 
pCMV-HA NDP lab pCMV5 Eukaryotic Expression plasmid encoding an HA Tag 
HA-p52 NDP lab 
pCMV5 plasmid encoding HA tagged 
p52 
 
HA-52-DBM NDP lab 
pCMV5 plasmid encoding HA tagged 
p52 with 2 aa substitutions 
(R52A/R54A) 
 
HA-p52-S222A NDP lab 
pCMV5 plasmid encoding HA tagged 
p52 with 1 aa substitution (S222A) 
 
HA-p52-S222D NDP lab pCMV5 plasmid encoding HA tagged p52 with 1 aa substitution (S222D) 
Luciferase reporter plasmids 
prPLK4-2634-1256 Dundee Cell Products 
smaller version of the prPLK4-wild 
type promoter, going from the ⎢B site 
-2634 up to shortly after the 
transcription start. 
prPLK4-full length Dundee Cell Products 
PLK4 promoter (4621 bp) inserted in 
pGL3 basic vector 
 
prPLK4-Δ3537 This study 
SacI deletion in prPLK4, deleting the 
⎢B site -3537, from 1 to 937 bp 
 
prPLK4-Δ1256 This study 
KpnI deletion in prPLK4, deleting the 
⎢B sites -3537 to -1256 from 1 to 
3263 bp 
 
prPLK4-+1 Dundee Cell Products 
shortest version of the prPLK4 
promoter, starting after the ⎢B site -
1256 and finishing shortly after the 
transcription start point, thus deleting 
all ⎢B sites  
 
prPLK4-2634-1256 Dundee Cell Products 
smaller version of the prPLK4-wild 
type promoter, going from the ⎢B site 
-2634 up to shortly after the 
transcription start. 
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3 Results Chapter 1:  
Characterization of p52 regulation of the cell cycle 
 
3.1 Introduction 
 
Previous data in the lab showed that the p52 NF-κB subunit could 
localize to the centrosome during interphase and various stages of mitosis. 
Furthermore U2OS cells stably expressing p100/p52 shRNA displayed 
centrosome structure defects. p52 is also involved in G2/M progression in 
U2OS cells as p52 depletion leads to defects in mitosis. These are visualized 
by disruption of the microtubule network, defects in chromosome segregation, 
increase in multinucleate cells, aberrant chromosome structure, as well as poor 
chromosomal alignment on the metaphasic plate (K.Schumm, unpublished 
data). The first goal of this PhD project was to reproduce and confirm the 
centrosomal localization of p52. Using U2OS cells transiently transfected with 
control or p100/p52 siRNAs, any defects in mitotic spindle were investigated.  
The p52 NF-κB subunit, by regulating the expression of genes involved 
in cell proliferation, can regulate cell growth and proliferation (Schumm et al, 
2006). Effects of NF-κB in general and p52 in particular on the cyclin D1 
promoter have been well described. Indeed, p52 co-operates with its co-
activator Bcl-3 to regulate cyclin D1 expression (Schumm et al, 2006). This is 
illustrated, in many cell lines, by the down-regulation of cyclin D1 expression in 
the absence of p52, or its activation by p52/RelB recruitment upon TNF-α 
stimulation (Witzel et al, 2010). We decided to confirm these results using 
transient transfection of p100/p52 siRNA and to extend the analysis to the 
expression of other cyclins (cyclin A, cyclin B1, cyclin E) and CDKs (CDK1, 
CDK2, CDK4). 
As defects in the centrosome structure were previously observed after 
p100/p52 depletion, I was also interested in investigating the regulation of 
genes involved in centrosome duplication. Indeed, some key effectors tightly 
regulate the centrosome duplication cycle. Alterations in their expression can 
inhibit centrosome duplication or promote over-amplification and thus lead to 
multinucleate cells. CP110 siRNA for example blocks reduplication (Chen et al, 
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2002), whereas p53 mutations induce centrosome amplification (Shinmura et al, 
2007).  
Among the list of proteins involved in centrosome duplication (Figure 
1,7), we focused on PLK4, CDK2, SAS6, AuroraA and γ-tubulin, as the key 
regulators of this process. The expression of some of these genes was 
downregulated upon p52 depletion. PLK4 expression seemed the most 
affected; therefore its regulation was investigated upon depletion or over-
expression of other NF-κB subunits. 
 
3.2 Results 
 
3.2.1 Co-localization of p100/p52 with the centrosome 
The first experiment performed was to confirm p100/p52 localization to 
the centrosome. U2OS cells were fixed with paraformaldehyde and labeled with 
antibodies against p100/p52 and γ-tubulin to detect the centriole. DAPI was 
used to detect DNA and differentiate cells in interphase from cells in various 
mitotic phases (Figure 3.1). As shown with the three cell images presented in 
Figure 3.1, p100/p52 localized to the centrosome. Co-localization was also 
observed in the case of a multinucleate cell (middle panel). This data confirmed 
previous findings and created a solid basis for the project.  
U2OS cells were then transiently transfected with a p100/p52 or control 
siRNA, to investigate any effect on the centrosome structure. The mitotic 
spindle was labeled with an α-tubulin antibody. Results showed that the 
centrosome structure was not affected by p52 depletion in this transient assay 
(Figure 3.2, top panel). The CDK1 inhibitor RO-3306 was also used to delay the 
progression through mitosis and to possibly enhance the p52 effect. However, 
no effect on the mitotic spindle was observed, whether p52 was present or 
deleted in cells treated with RO-3306 (Figure 3.2, bottom panel). Western 
blotting was performed to confirm the efficiency of siRNA transfection. These 
results demonstrated that p52 does not seem to affect the mitotic spindle in 
U2OS cells, in contrast to the previous results.  
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Figure 3-1: p52 co-localizes to the centrosome 
U2OS cells were plated the night before imaging, fixed with paraformaldehyde 
the next day, and then labeled with antibodies as described in material and 
methods. Cells were labeled with antibodies for p100/p52 (red), γ-tubulin 
(green) and and stained with DAPI to reveal DNA (blue). 
3 different cells, representative of the population, are shown. Insets show an 
enlargement of the centrosome area. 
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Figure 3-2: p52 transient depletion does not affect the mitotic spindle 
U2OS cells were subjected to transient siRNA transfection. After 48h, cells were 
treated for 2h with the CDK1 inhibitor R0-3306 or DMSO, fixed with 
paraformaldehyde, and then labeled with α-tubulin antibody (green) and stained 
with DAPI to reveal the DNA as described in material and methods. Cells shown 
are representative of the population for each treatment. Protein expression is 
shown to demonstrate the efficiency of the siRNA transfection. 
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However, it is important to note that many previous effects were seen in 
stable cell lines expressing p100/p52 shRNA, where the cells overcame p52’s 
other effects on the cell cycle. This will be discussed further in the discussion 
section of this capter. 
 
3.2.2 p52 affects cyclin and CDK gene expression 
It is well known that NF-κB is involved in the regulation of the cell cycle 
and the p52 subunit was previously reported to regulate cyclin D1 expression 
as well as participate in G1/S progression by our lab and others (Guttridge et al, 
1999; Schumm et al, 2006). To more fully characterize this p52 effect, we 
decided to look at the expression of all cyclins and CDKs after p100/p52 siRNA 
depletion (Figure 3.3). A decrease in cyclin D1 expression following p100/p52 
knockdown was detected with both mRNA (Figure 3.3.A) and protein (Figure 
3.3.B), confirming previously published data. No significant effect was seen on 
cyclin A, cyclin E and cyclin B1 mRNA or protein expression, although cyclin E 
seemed to present a slight decrease in protein expression. In the same manner, 
CDK1 expression did not appear to be dependent of p52. By contrast, p52 
depletion reduced the mRNA and protein expression of CDK4, involved in early 
G1, and CDK2, required during the G1 and S phases. FACS analysis of cellular 
DNA context in Figure 3.3.C demonstrated that the loss of CDK4 may not be 
due to a overall reduction of the number of cells in G1 phase, as the DNA 
profiles were similar for control cells and cells depleted of p52. This confirms the 
importance of p52 during the G1/S transition and S phase progression. 
Interestingly, as no effect was detected on the Cyclins and CDK responsible for 
G2/M transition, this would indicate that any effect seen on the mitotic spindle 
and chromosome arrangement by p52 depletion may not be linked to an 
incorrect G2/M progression, suggesting another type of p52 regulation for the 
mitotic spindle. 
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Figure 3-3: p52 depletion affects the expression of cyclin and CDK genes 
U2OS cells were subjected to transient siRNA transfection and after 48h, cells 
were lysed. A. mRNA were analyzed by quantitative PCR, compared to a 
housekeeper gene and related to the expression with siRNA control. Errors bars 
show the standard error of at least 3 independent experiments B. Protein 
expression was detected by Western Blot. C. DNA profile after siRNA 
transfection was analyzed by flow cytometry 
Error bars show the standard error of at least 3 independent experiments.  
* P<0,05 ; *** P<0,001 
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3.2.3 Genes involved in the centrosome duplication 
To further investigate any p52 effect on centrosome duplication and 
function, I decided to look at the expression of genes involved in centrosome 
duplication, such as PLK4, AuroraA, SAS6 and γ-tubulin following p100/p52 
depletion. U2OS cells were transiently transfected with control or p100/p52 
siRNAs and mRNA levels were determined by RT-PCR. Figure 3.4 
demonstrates that, upon p52 depletion, γ-tubulin expression did not significantly 
vary, thus providing a negative control. However, CDK2 (as already detected in 
Figure 3.3), PLK4, AuroraA and the PLK4 effector SAS6 mRNA expression 
were significantly reduced in the absence of p52, however with different P-
values. The loss of CDK2 upon p100/p52 depletion was observed previously in 
Figure 3.3. The loss of PLK4 expression was the strongest as the mRNA levels 
were reduced by 80% upon p100/p52 depletion. As SAS6 has been identified 
as one of the PLK4 effectors, the loss in SAS6 mRNA could be linked to the 
loss of PLK4. AuroraA expression was reduced by 50% after p100/p52 
depletion. These effects provide a potential direct link between NF-κB and the 
regulation of the centrosome, as well as with the spindle checkpoint, which has 
not been shown previously.  
Although PLK4 substrates have not all been identified, PLK4 can 
cooperate with CDK2 to enable correct centriole duplication (Habedanck et al, 
2005). PLK4 causes the activation of down-stream regulators, such as SAS6, a 
coiled-coil protein recruited to the centriole (Rodrigues-Martins et al, 2007). 
Regulation of PLK4 gene expression has not been studied in much detail to 
date, and no link has been previously made with NF-κB. We therefore decided 
to focus the rest of the project on the regulation of PLK4 expression by NF-κB. 
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Figure 3-4: p52/p100 depletion affects the expression of various genes 
involved in centrosome duplication 
U2OS cells were subjected to transient siRNA transfection. After 48h, cells were 
lysed and the RNA extracted. mRNA expression was analyzed by quantitative 
PCR, compared to a housekeeper gene and related to the expression with 
siRNA control. Errors bars show the standard error of at least 3 independent 
experiments. * P<0,05 ; ** P<0,001; *** P<0,0001 
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3.2.4 NF-κB affects PLK4 expression 
 
NF-κB depletion reduces PLK4 expression 
To begin studying the role of NF-κB in the regulation of PLK4 expression, 
a siRNA that targets all NF-κB subunits simultaneously (siRNA Pan-NFκB) (van 
Uden et al, 2011) was transfected into U2OS cells (Figure 3.5). Protein 
expression analysis showed that after simultaneous depletion of all NF-κB 
subunits, PLK4 protein levels were reduced (Figure 3.5, left panel). This was 
confirmed at the mRNA level by qPCR, where PLK4 mRNA decreased by more 
than 50% after Pan-NF-κB siRNA treatment (Figure 3.5, right panel). Western 
blot (left panel) and RT-PCR (data not shown) confirmed the transfection 
efficiency by showing that the levels of the different NF-κB subunits were all 
reduced.  
Individual siRNAs were then used to determine the influence of each NF-
κB subunit on PLK4. As can be seen in Figure 3.6, all NF-κB subunits 
independently reduced PLK4 levels, at both the protein (Figure 3.6, left panel) 
and mRNA (Figure 3.6, right panel) levels. However, this decrease did not 
happen with the same efficiency for all subunits. c-Rel depletion seemed to 
most affect PLK4 protein and mRNA levels, with PLK4 mRNA decreased by 
80% after c-Rel knockdown. A significant decrease in PLK4 mRNA levels was 
also obtained after p100/p52 or RelB siRNA depletion. The effect on protein 
levels differed between subunits. Nevertheless an effect for all subunits was still 
seen. RelA depletion seemed to completely inhibit PLK4 protein expression, but 
the effect on mRNA was not as strong. Interestingly, RelA depletion also inhibits 
the expression of the other NF-κB subunits. In the absence of p50, protein 
levels remained unaffected but mRNA levels were reduced by 50%. The 
difference between mRNA and proteins levels might be due to the poor quality 
of commercial antibodies or to difficulties detecting low basal levels of PLK4 
protein.  
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Figure 3-5: NF-κB depletion affects the expression of PLK4 in U2OS cells 
U2OS cells were subjected to transient siRNA transfection against all NF-κB 
subunits. After 48h, cells were lysed and the proteins and RNA extracted. 
Protein levels were analyzed by Western Blot (left panel). mRNA expression 
(right panel) was analyzed by quantitative PCR, compared to a housekeeper 
gene (GAPDH) and related to the expression of the siRNA control. Results are 
the average of at least 3 independent experiments. 
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Figure 3-6: NF-κB subunit depletion affects the expression of PLK4 in 
U2OS cells 
U2OS cells were subjected to transient siRNA transfection against various NF-
κB subunits. After 48h, cells were lysed and the proteins and RNA extracted. 
Protein levels were analyzed by Western Blot (left panel). mRNA expression 
(right panel) was analyzed by quantitative PCR, compared to a housekeeper 
gene (GAPDH) and related to the expression of the siRNA control. Results are 
the average of at least 3 independent experiments. 
 
 
  
co
nt
ro
l 
Pa
n-
N
Fk
B
 
p1
00
/p
52
 
R
el
B
 
p5
0 
PLK4 
p100 
p52 
RelA 
RelB 
R
el
A 
cR
el
 
ac#n%
cRel 
p50 
siRNA 
0"
0.2"
0.4"
0.6"
0.8"
1"
1.2"
control" p100/p52" RelA" RelB" cRel" p50"
siRNA"
m
RN
A%
re
la
#v
e%
ab
un
da
nc
e%
PLK4%expression%
 80 
 
Another hypothesis is that further post-transcriptional regulation could 
induce such differences between mRNA and protein levels. I have confirmed 
the overall effect of NF-κB subunit depletion on PLK4 mRNA and protein levels 
in other cell lines such as Hela cells and H1299 cells (data not shown). 
Therefore, this data confirms that NF-κB depletion reduces PLK4 
expression and that all subunits are involved in its regulation, although not all 
subunits seem to regulate PLK4 expression with the same efficiency.  
 
NF-κB overexpression increases PLK4 expression 
To confirm the NF-κB effect on PLK4 protein levels, Hela cells were 
transfected with plasmids to overexpress the different NF-κB subunits. As seen 
in Figure 3.7, subunits over-expression also induced an increase in PLK4 
protein level. It is also notable that, although the overexpression efficiency did 
not seem significant for most NF-κB subunits, the effect on PLK4 protein levels 
was very strong. However, in the case of p52 overexpression, the results were 
not as convincing but the efficiency of the transfection was also less than in the 
case of other subunits. Nonetheless, this result confirms that PLK4 expression 
is regulated by NF-κB. 
 
Depletion or overexpression of NF-κB subunits, individually or 
simultaneously, in various cell lines allowed me to determine that PLK4 is likely 
to be a NF-κB target gene. PLK4 could therefore provide the previously 
identified link between the p52 subunit and regulation of mitotic spindle 
formation. 
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Figure 3-7: NF-κB subunit overexpression increases the expression of 
PLK4 in Hela cells 
Hela cells were subjected to transient DNA transfection to overexpress NF-κB 
subunits. After 48h, cells were lysed and the proteins extracted. Protein levels 
were analyzed by Western Blot. 
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3.2.5 p52 and PLK4 affect cell proliferation 
Our lab has previously shown that the p52 NF-κB subunit can reduce cell 
proliferation in cells transiently depleted of p100/p52 (Schumm et al, 2006). 
PLK4 is known to be essential for centrosome duplication and error free 
division. Therefore, to determine if loss of PLK4 could contribute to p52 effects 
on proliferation, U2OS cells were transiently transfected with siRNAs against 
p100/p52 or PLK4. MTT-MTS assays were performed to determine cell 
proliferation (Figure 3.8, left panel). Western blotting was used to verify the 
efficiency of transfection (Figure 3.8, right panel). As can be seen in the 
proliferation assay (Figure 3.8), the p100/p52 siRNA decreased the proliferation 
of U2OS cells, and the effect can be seen even at Day 1. PLK4 depletion also 
inhibited cell proliferation, significantly stronger than p52 alone.  
These experiments confirm the importance of p52 and PLK4 to the 
correct progression through the cell cycle, at least in U2OS cells, and thus the 
necessity for tight regulation of both. 
 
3.3 Discussion 
 
Previous unpublished results in the Perkins lab showed that the p52 NF-
κB subunit could associate with the centrosome in U2OS cells in interphase and 
during mitosis. To characterize the p52 effect on the cell cycle, my first 
experiment was to repeat and validate such data. To this extent, U2OS cells 
were observed by confocal microscopy, after immunostaining for p100/p52 and 
γ-tubulin (Figure 3.1). Observations showed that p100/p52 does indeed localize 
to the centrosome for cells in interphase. However, no co-localization of 
p100/p52 with the centrosome has been seen for cells in mitosis (data not 
shown). It is possible that incorrect experimental conditions were used, or 
p100/p52 localization to the centrosome in mitosis happened in only a low 
percentage of cells and therefore would have been missed in these conditions. 
Further experiments will be performed to validate the proposed p52 localization 
to the centrosome.  
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Figure 3-8: p52 and PLK4 affect cell proliferation 
U2OS cells were transiently transfected with control, p100/p52 or PLK4 siRNAs 
and a MTT/MTS proliferation assay (left panel) was performed, as in Material 
and Methods. Western Blot (right panel) is shown for the siRNA transfection 
efficiency. 
Error bars shows the standard deviation of at least 3 independent experiments. 
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Nonetheless, our experiments confirmed p100/p52 localization to the 
centrosome in cells in interphase. Further investigation will determine whether 
p100/p52 associates with centrosomal proteins. A technique recently 
developped in the lab allows the visualization by microscopy of the skeleton of a 
cell, as well as the internal structures but with no cytoplasm, therefore 
eliminating all cytoplasmic proteins (Kuznetsov et al, 2008). Optimization of this 
technique to specially envision the centrosome would allow us to more precisely 
observe the association of p100/p52 or other NF-κB subunits with the 
centrosome, by reducing the cytoplasmic NF-κB background.  
The p52 NF-κB subunit has also been previously reported to regulate the 
expression of genes involved in the cell cycle, such as cyclin D1 (Barre & 
Perkins, 2007; Schumm et al, 2006). Analysis of various cyclins and CDKs 
showed regulation of their expression by p52 (Figure 3.3). Cyclin D1 was used 
as a control for this experiment, even though the decrease in mRNA and protein 
expression after p100/p52 siRNA depletion was not as strong as in already 
published results (Schumm et al, 2006). However, it is interesting to note that 
p52 regulates CDK4 and CDK2 expression, both of which are involved in the 
progression of G1 phase. It has been reported before that p52 depletion 
induces a decrease of cells in S phase and a small accumulation of cells in G1 
(Schumm et al, 2006). So far, these results have been attributed to the 
regulation of cyclin D1 expression but it is possible that CDK2 and CDK4 also 
play a role in p52 regulation of the cell cycle. Appart from cyclin D1, my studies 
of cyclin expression did not show any effects of p100/p52 siRNA depletion, 
whether on the mRNA or protein levels. These results clarify p52 regulation of 
genes involved in the cell cycle and reveal more of its ability to regulate G1 
phase. 
Another way to determine the p52 effect on the centrosome structure 
and defects in the mitotic spindle is to study the expression of genes involved in 
centrosome duplication after p100/p52 depletion. For this PhD project, we 
decided to focus on some of them: PLK4, SAS6, CDK2, AuroraA and γ-tubulin. 
mRNA analysis showed that p100/p52 siRNA depletion induced a significant 
decreased in expression of those genes, with the exception of γ-tubulin. 
Interestingly, PLK4 and SAS6 down-regulation has been shown to inhibit 
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centriolar duplication (Bettencourt-Dias & Glover, 2007), whereas AuroraA 
siRNA treatment of Hela cells resulted in incorrect centriolar separation, 
incomplete cytokinesis and chromosome misalignement on the metaphasic 
plate (Marumoto et al, 2003). My data showing a decrease in the expression of 
those genes upon p100/p52 siRNA treatment directly links p52 to the regulation 
of centrosome duplication and suggests a possible mechanism to explain the 
defects in centrosome structure observed previously, which will be addressed 
later in the main discussion.  
Due to the lack of published data concerning regulation of its expression, 
I decided to focus my research on NF-κB regulation of PLK4. siRNA depletion 
of all the NF-κB subunits simultaneously showed a decrease in PLK4 mRNA 
and protein levels (Figure 3.5). This result was confirmed after separate 
depletion of the NF-κB subunits in U2OS cells (Figure 3.6), Hela cells and 
H1299 cells (data not shown). Although all NF-κB subunits reduced PLK4 
expression, c-Rel appeared to have the strongest effect on mRNA levels 
(Figure 3.6). However, this did not seem to be the case at the protein level, 
suggesting additional post-transcriptional regulation. Overexpression of the NF-
κB subunits increased PLK4 protein levels in Hela cells (Figure 3.7), confirming 
NF-κB regulation of PLK4 expression. Although the increase in NF-κB subunit 
expression was low, a clear induction of PLK4 was detectable, with the 
exception of p52 overexpression. One hypothesis for such a strong effect on 
PLK4 expression after an apparently moderate increase in NF-κB subunit 
expression is that the low increase in NF-κB subunit expression may reflect 
transfection efficiency. If only 20 or 30% of the cells were transfected, only a 
small effect would be seen on NF-κB expression by western blot, as levels 
would remain high in the rest of untransfected cells. By contrast, as PLK4 basal 
levels are very low, an effect on its expression in the 20% of the cells that were 
transfected would be more easily detected and seen as a significant increase. 
These results will need to be confirmed by increasing the efficiency of 
transfection and quantification by q-PCR. 
Previous results also revealed defects in the mitotic spindle after 
p100/p52 depletion in U2OS cells. My attempts to confirm these results were 
unsuccessful, as when U2OS cells were transiently depleted for p100/p52, no 
effects could be seen on the mitotic spindle (Figure 3.2). The use of a CDK1 
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inhibitor, which delays entry in mitosis and thus could possibly enhance a 
potential p52 influence, did not show any effect on the mitotic spindle. A 
possibility to explain such different results could arise from the fact that previous 
results were obtained using U2OS cells stably expressing p100/p52 shRNA, 
whereas my results were obtained after a transient depletion. p52, as a 
regulator of the cell cycle (Schumm et al, 2006), is required for correct cell cycle 
progression in U2OS cells and such stably depleted cells would have to 
overcome the absence of p52 to proliferate. The defects in mitotic spindle could 
then be coming from the cells adaptation to proliferating under these conditions. 
However, these results need to be treated carefully, as no kinase assay on 
CDK1 activity was performed to check the CDK1 inhibitor efficiency. 
Nonetheless, results obtained on proliferation assays support this hypothesis. 
Indeed, U2OS cells transiently depleted for p100/p52 or PLK4 showed a 
decrease in proliferation rate (Figure 3.8). The decrease in proliferation 
detected after p100/p52 siRNA is confirmed by previously published data 
(Schumm et al, 2006) but a stronger effect was detected after PLK4 depletion. 
A similar effect was previously found in PLK4 +/- MEFs (Swallow et al, 2005), 
emphasizing PLK4’s influence on cell proliferation. As PLK4 depletion also 
induced defects in centrosome structure (Bettencourt-Dias & Glover, 2007), it is 
possible that PLK4 in involved in p52 regulation of the cell cycle and 
centrosome structure.  
Together, my data suggest that PLK4 is a NF-κB target gene. This has 
been recently confirmed with another project in the laboratory. Human primary 
fibroblasts were transiently depleted for the p52 or RelB NF-κB subunit and 
subjected to a micro-array analysis (data not shown, personal communication 
with A.Iannetti). In these conditions, PLK4 expression was found down-
regulated after both p52 and RelB siRNA depletion (Figure 3.9). Other genes 
involved in centrosome duplication and the cell cycle were also altered by p52 
and RelB absence, such as CENPE, BubR1. These results confirm our data 
and highlight NF-κB’s involvement in centrosome duplication regulation in 
multiples cell types. Although no further investigation has yet been pursued 
regarding regulation of centrosome duplication in fibroblasts, it will be 
interesting to confirm and quantify biochemically such results, as these cells 
validate my results in a “non-tumour” cell line. 
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Figure 3-9: Micro-array data after p100/p52 depletion in human fibroblasts 
List of cell cycle associated genes seen to be significantly down-regulated (>1.5 
fold) following a microarray analysis of human fibroblasts after p100/p52 siRNA 
depletion (Alessio Iannetti, unpublished data). Genes shown are involved in the 
cell cycle progression, centrosome duplication and the mitotic checkpoint.  Most 
of these genes have not been previously described as NF-κB targets.  
 
  
Gene 
Name 
Protein Name Function 
Regulation 
by NF-κB 
Reference 
CCNA2 Cyclin A2 Cell cycle   
CCNB1 Cyclin B1 Cell cycle   
CCNB2 Cyclin B2 Cell cycle   
CDK1 Cyclin-dependent kinase 1 Cell cycle   
CDK4 Cyclin-dependent kinase 4 Cell cycle   
CDK6 Cyclin-dependent kinase 6 Cell cycle Yes 
(Iwanaga et al, 
2008) 
CDK7 Cyclin-dependent kinase 7 Cell cycle   
PLK4 Polo-like kinase 4 Centrosome duplication   
CCP110 
Centriolar coiled-coil protein 
110kDa 
Centrosome duplication   
BUB1 
budding uninhibited by 
benzimidazoles 1 homolog 
(yeast) 
Mitotic checkpoint   
CDC20 
cell division cycle 20 homolog 
(S. cerevisiae) 
Mitotic checkpoint   
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3.4 Conclusion 
 
This results chapter focused on the characterization of p52’s effects on 
the cell cycle regulation. These data showed p100/p52 colocalization with the 
centrosome and the regulation of the expression of various cyclins and CDKs. 
Moreover, the p52 NF-κB subunit regulates the expression of a number of 
genes involved in the regulation of centrosome duplication. One of these genes, 
PLK4, a key factor for centriolar duplication, was also regulated by the other 
NF-κB subunits. 
Our next goal was then to determine whether the NF-κB regulation of 
PLK4 expression happens through a direct or indirect mechanism. 
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4 – Results Chapter 2: PLK4 regulation 
 
4.1 Introduction 
 
As seen in Chapter 3, NF-κB regulates the expression of various genes 
involved in centrosome duplication, including the polo kinase PLK4. However, it 
is still unclear whether this regulation is direct or required the activity of other 
transcription factors. 
PLK4 belongs to the PLK family, sharing sequence homology and a 
kinase domain in its N terminus but has the characteristic of possessing only 
one polo box domain. PLK4 is a short-lived protein and contains 3 PEST 
sequences, one in the N-terminus and two in the C-terminus. Deletion and 
mutation experiments showed that only the first motif is responsible for PLK4 
stability, by creating a SCF binding site, which can trigger PLK4 ubiquitinylation 
and degradation by the proteasome (Sillibourne & Bornens, 2010b), via the 
SCF subunit Cullin1 (Korzeniewski et al, 2009). PLK4 auto-phosphorylation also 
seems to be involved in protein stability and thus regulates its activity to prevent 
aberrant centrosome amplification (Holland et al, 2010).  
PLK4, present in proliferative tissue, is thought to act as a tumor 
suppressor or as an oncogene, depending on the tumor context (Pellegrino et 
al, 2010). Furthermore, PLK4 is aberrantly amplified in colorectal cancer 
(Macmillan et al, 2001) but is down-regulated in human hepatocarcinoma and 
associated with poor survival prognosis (Liu et al, 2012). Recent data also 
identifies PLK4 as a key factor regulating centriolar duplication. Indeed, 
overexpression of PLK4, specifically the auto-phosphorylated form on Ser305 
(Sillibourne et al, 2010), induces over-amplification of centrosomes (Rodrigues-
Martins et al), while depletion reduces centriole number (Bettencourt-Dias et al, 
2005). PLK4 works in concert with the cyclin-dependent kinase CDK2, CP110 
and the PLK4 effector SAS6 to ensure correct centrosome duplication 
(Habedanck et al). Interestingly, PLK4 null mice die during gestation due to 
massive mitotic arrest cause by an accumulation of cyclin B1 in anaphase and 
telophase, suggesting that PLK4 is required for cyclin B1 degradation and 
mitotic exit (Hudson et al, 2001). PLK4 heterozygous knockout mice present 
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centrosome amplification, aneuploidy together with multipolar spindle formation 
and develop 15 times more spontaneous liver and lung cancer compared to 
wild-type mice (Ko et al, 2005).  
Very few studies to date have looked at PLK4 transcriptional regulation. 
Results published in 2005 demonstrate that PLK4 is indirectly regulated by p53, 
likely through the recruitment of HDAC repressors. PLK4 overexpression also 
reduces apoptosis induced by p53 but no further study yet has been published 
to explain the mechanism involved (Li et al, 2005). It has also been 
demonstrated that Sak, the mouse homologue of PLK4, binds to p53 but the 
mechanism for the interaction is not known (Swallow et al, 2005). 
In this chapter, I determined whether NF-κB directly or indirectly 
regulates PLK4 expression, by performing chromatin-immunoprecipitation 
(ChIP) analyses on the putative κB sites previously identified in the PLK4 
promoter in a number of human cell lines, as well as in murine fibroblasts. In 
addition to investigate the mechanism of NF-κB regulation of the PLK4 
promoter, luciferase reporter plasmids were created, carrying various deletions 
of the PLK4 promoter. PLK4 promoter activity was monitored with using 
luciferase assays, combined with the overexpression or downregulation of NF-
κB subunits. 
 
4.2 Results 
 
4.2.1 The PLK4 promoter 
To determine the mechanism of regulation of PLK4 by NF-κB, it was 
essential to establish if NF-κB binds to the PLK4 promoter directly or if the 
regulation is indirect. To begin this analysis, the PLK4 promoter, between -4000 
and +2000 bp from the initiation site, was subjected to a computational analysis 
using the MatInspector software to identify putative NF-κB sites. NF-κB sites 
usually follow the consensus GGG RNN YYC C (with R being a purine 
(adenosine or guanine) and Y a pyrimidine (cytosine or thymidine) nucleotide) 
(Natoli et al, 2005).  
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Analysis of the PLK4 promoter allowed the identification of seven 
potential NF-κB sites, as shown in Figure 4.1. Four of these sites were situated 
before the initiation site, at positions -3587, -2634, -1947, -1256 and three are 
placed shortly after the initiation site at positions +397, +480 and +760. These 
putative NF-κB sites were used to determine whether PLK4 is a direct or 
indirect NF-κB target gene and to investigate the mechanism behind NF-κB 
regulation of PLK4. 
 
4.2.2 PLK4 is a direct NF-κB target gene 
PCR primers were designed around each of the putative NF-κB sites 
identified above and chromatin-immunoprecipitation assays (ChIP) were 
performed to determine NF-κB binding to the PLK4 promoter. For the rest of 
this thesis, the primers around the putative sites prPLK4-2634, prPLK4-1947 
and prPLK4-1256 will mainly be used, as these κB sites displayed the strongest 
and more reproducible results. ChIP assays in U2OS cells (Figure 4.2.A) and 
Hela cells (Figure 4.2.B) show that all NF-κB subunits bind to the PLK4 
promoter. In U2OS cells, primers for GAPDH were used as a control to confirm 
the specificity of binding. The p50 subunit seemed to bind stronger than RelB 
however quantification would be necessary to confirm this observation. In Hela 
cells (Figure 4.2.B), all subunits were also bound to the three sites studied in 
the PLK4 promoter. p52, along with RelB and c-Rel, seemed to have stronger 
binding than RelA or p50. These differences in binding, which could correspond 
to the stronger effects seen on the mRNA level upon siRNA knockdown (Figure 
3.6), suggested preferential involvement of some NF-κB subunits over others.  
To quantify NF-κB binding to the PLK4 promoter, qPCR was performed 
after ChIP assays in U2OS cells (Figure 4.3) and in H1299 cells (Figure 4.4). In 
U2OS cells, as can be seen in Figure 4.3.A, p52 was bound to all three κB sites 
tested prPLK4-2634, prPLK4-1947 and prPLK4-1256. Significant binding was 
also detected for RelA and RelB for the prPLK4-2634 and prPLK4-1256 sites. 
p50 subunit binding was statistically significant only on the prPLK4-1256 site. Of 
all the NF-κB subunits RelB seemed to have the strongest binding for the 
prPLK4-1947 site, although this was not statistically significant.  
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Figure 4-1: Potential NF-κB binding sites on the human PLK4 promoter 
Schematic representation of the PLK4 promoter and its potential NF-κB binding 
sites, identified with a computational analysis using the Mat-Inspector software 
(the human PLK4 promoter analyzed correspond at -4000 bp before the 
transcription starting site, up to +2000 bp). Below are shown the sequence for 
the NF-κB consensus binding site, as well as the sequences for these potential 
NF-κB sites. 
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Figure 4-2: The PLK4 promoter is a NF-κB target 
U2OS cells (A) or Hela cells (B) were fixed by parafornaldehyde and processed 
for a ChIP assay, using antibodies against NF-κB subunit, RNApolII as a 
positive and IgG as a negative control. PCR was performed with primers for the 
-2634, -1947 and -1256 NF-κB sites, and Gapdh as a negative control (A.). 
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Figure 4-3: The PLK4 promoter is a NF-κB target 
U2OS cells were fixed by paraformaldehyde and processed for a ChIP assay, 
using antibodies against NF-κB subunits and IgG as a negative control. qPCR 
was performed with primers for the PLK4 NF-κB binding sites -2634, -1947 and 
-1256. A. Graphic representation where the errors bars are representative of 
the Standard Error. * P<0.05. B. Scattered plot representation of results 
showing the diversity of binding observed. 
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As can be seen in Figure 4.3.B, high variability in the results was seen 
and despite multiple repeats, could not be reduced. Several populations could 
be found, some with strong binding and some with a lot milder binding, such as 
p52 binding on the prPLK4 -2634 site for example. This variability in U2OS cells 
was also found in H1299 cells to some extent. As seen in Figure 4.4.A and 
4.4.B, NF-κB subunits also bind to the PLK4 promoter in H1299 cells, with the 
notable exception of p52. The strongest binding observed was for RelB and 
p50. However, not enough repeats were performed to apply statistical analysis 
to this data.  
These results indicate that PLK4 is a direct NF-κB target gene and that 
all NF-κB subunits can bind to the PLK4 promoter. However, at this point, no 
definitive quantification of relative subunit binding was possible, as will be 
discussed later. 
 
4.2.3 p52 binding on the PLK4 promoter is reversible 
To verify the specificity of the p52 antibosy used to assess binding to the 
PLK4 promoter, U2OS cells were transiently transfected to deplete p52 
expression with control or p100/p52 siRNAs. ChIP assays, quantified by qPCR 
were performed on the κB sites previously studied. Figure 4.5.A shows that 
indeed, the p52 binding to the PLK4 promoter detected is reversible, as it can 
be observed that in the case of the p100/p52 siRNA, p52 binding is lower than 
for the siRNA control with all prPLK4 κB sites. The reduction was approximately 
50% compared to the control transfection, which roughly corresponded to the 
efficiency of the siRNA knockdown itself. This demonstrates the specificity of 
the p52 binding detected earlier in Figures 4.2, 4.3 and 4.4.  
Further experiments also confirmed this p52 antibody specificity in Hela 
cells, as illustrated in Figure 4.5.B. Here, the same type of experiment was 
performed with transfection of control or p100/p52 siRNAs followed by ChIP 
assays quantified by qPCR. The same result was found with p52 binding to the 
various κB sites in the PLK4 promoter being reduced, between 50% and 70% 
compared to Hela cells treated with a control siRNA. 
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Figure 4-4: NF-κB binding on the PLK4 promoter in H1299 cells 
H1299 growing cells were fixed by paraformaldehyde and processed for a ChIP 
assay, using antibodies against NF-κB subunits and IgG as a negative control. 
qPCR was performed with primers for the PLK4 NF-κB binding sites -2634, -
1947 and -1256. A. Graphic representation where the errors bars are 
representative of the Standard Error. B. Scattered plot representation of results 
showing the diversity of binding observed. 
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Figure 4-5: p52 binding on the PLK4 promoter is reversible 
U2OS (A.) and Hela (B.) cells were subjected to transient siRNA transfection, 
with either control or p100/p52 siRNA. After 48h, the cells were processed for a 
ChIP assay, as described in Material and methods. qPCR was performed on 
the -2634, -1947 and -1256 binding sites. Error bars show the standard error of 
at least 3 independent experiments.  
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4.2.4 PLK4 is a target for exogenously expressed p52 
Another way to check the specificity of p52 binding to the PLK4 promoter 
is to introduce a HA-tagged, exogenous form, of p52 within the cells, and to 
detect binding with an antibody against the tag. U2OS cells were thus 
transiently transfected to express either exogenous HA-tagged p52 or a DNA-
binding mutant (DBM) (Schumm et al, 2006), alongside an empty HA control 
vector. ChIP assays using an HA antibody were then performed and quantified 
for binding to the  -2634, -1947 and -1256 κB sites.  
Exogenous p52 demonstrated a 7 fold higher binding compared to the 
background HA antibody control with the empty vector for the -2634 and -1947 
κB sites; and by 3 fold for the -1256 κB site on the PLK4 promoter (Figure 4.6). 
Interestingly, when cells were transfected with the p52 DBM mutant, p52 
binding on the promoter was not completely abolished but reduced by 50%. 
These results indicate that p52 clearly binds to the PLK4 promoter and this 
binding can be reduced by a DNA binding mutant. As the decrease in binding is 
not complete, this suggests that p52 recruitment can also result from interaction 
with other transcription factors through DNA-independent protein-protein 
interaction.  
 
4.2.5 PLK4 is a NF-κB target gene in mouse 
Previous data demontrated that PLK4 is a NF-κB target gene in multiple 
human cell lines: U2OS cells (Figures 4.2 to 4.6), Hela cells (Figures 4.2.B. and 
4.5.B) and H1299 cells (Figure 4.4). However, to further validate the model, I 
investigated whether this was also the case in another mammalian model. I 
therefore examined the mouse sequence for PLK4 and its promoter. Analysis 
with the MatInspector software determined only three putative κB sites between 
region -4000 bp and +2000 bp of the mouse PLK4 promoter, with only one 
situated before the transcription start point at -21 bp (Figure 4.7.A). The last two 
sites were situated shortly after the transcription start, at position +135 and 
+329. Similarly to the human promoter, primers were designed around all of 
these putative κB sites and were used for ChIP assays. 
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Figure 4-6: Exogenous p52 binds the PLK4 promoter 
Hela cells were subjected to transient DNA transfection, with plasmids coding 
for exogenous p52 or the p52 binding mutant (DBM), both HA tagged. After 
48h, the cells were processed for a ChIP assay, as described in Material and 
methods. qPCR was performed on the -2634, -1947 and -1256 binding sites . 
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Figure 4-7: PLK4 is a NF-κB target gene in mouse 
A. Schematic representation of the PLK4 promoter in the mouse. Putative NF-
κB binding sites are shown with red circles, with the sequence for the putative 
κB sites written on the right. MEF wild type (B.) and nfkb2 -/- (C.) growing cells 
were fixed with formaldehyde and processed for a ChIP assay, using antibodies 
against NF-κB subunits, RNApolII as a positive and IgG as a negative control. 
PCR was performed with primers for each potential NF-κB binding region. D. 
Growing cells (MEF wild type or nfkb2 -/-) were lysed and the RNA extracted. 
mRNA expression was analyzed by quantitative PCR, compared to a 
housekeeper gene (GAPDH) and related to the expression with MEF wild type. 
Error bars show the standard error of at least 3 independent experiments.  
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NF-κB binding to these various sites was first studied in wild-type mouse 
embryonic fibroblasts (MEF) with ChIP assays using antibodies against each 
NF-κB subunit, as well as RNA pol II as a positive control and IgG as a negative 
control (Figure 4.7.B). It can be seen that p52 seemed to be the only NF-κB 
subunit to bind all three putative sites, while RelA only bound to -21 and +329; 
and p50 only to +135. RelB and c-Rel did not appear to bind the PLK4 promoter 
in wild type MEF, which is interesting considering RelB had the strongest binder 
in human cancer cells. 
To confirm the specificity of binding, untreated nf-kb2 -/- MEFs were 
used. Figure 4.7.C shows that in nf-kb2 -/- MEFs, p52 binding was completely 
abolished, validating the previous assay and confirming the specificity of the 
signal. Interestingly, in the absence of p52, RelB and c-Rel seem to be able to 
bind the PLK4 promoter. Further experiments will be required to quantify this 
NF-κB binding and determine if p52 has a negative effect on c-Rel and RelB 
binding. During cell cultivation, it became clear that the nf-kb2 -/- MEFs were 
growing faster than the wild type MEFs (data not shown). As p52 is required for 
cell cycle progression of U2OS cells and p100/p52 depletion reduces cells in S 
phase, this suggests that nf-kb2 -/- MEFs had to overcome the absence of p52 
to allow proliferation.  
Given the previous effects seen with p52 on PLK4 expression, I 
investigated PLK4 expression in nf-kb2 -/- MEFs compared to wild type MEFs. 
Both cell types were cultured and analyzed for mRNA expression by qPCR 
(Figure 4.7.D). Q-PCR analysis showed that in nf-kb2 -/- MEFs, p100 
expression is indeed reduced compared to wild type. It is notable that the basal 
level is lower than 50% for the control but not completely absent. This might be 
due the mouse knockout being created by deletions of crucial exons but still 
allowing mRNA transcription of the rest of the gene. Interestingly, in contrast to 
human cells, where siRNA depletion of p100/p52 reduced PLK4 expression 
(Figure 3.4), in nf-kb2 -/- MEFs, the PLK4 levels were twice as high than in wild 
type MEFs. This is consistent both with the observed increase in proliferation, 
as a decrease in PLK4 reduces proliferation (Figure 3.8) and also with the fact 
that p52 is required for proper PLK4 regulation. Moreover, this implies that p52 
can also be a negative regulator of PLK4 expression, and that other NF-κB 
subunits can compensate for its absence. 
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4.2.6 Luciferase constructs of the PLK4 promoter 
The data above demonstrates that PLK4 is a NF-κB target gene but so 
far, the mechanism behind this was unclear and it was difficult to predict which 
homo- or heterodimers were involved. To begin to address this issue, five 
constructs of the PLK4 promoter, driving expression of a luciferase reporter 
gene, were designed (Figure 4.8.A). The first construct consisted of the full 
length PLK4 promoter, containing all seven putative κB sites identified earlier. 
prPLK4-Δ3587 has a deletion of the most distal κB site, -3587, while prPLK4-
Δ1256 has all sites up to the initiation start site removed and contains a minimal 
promoter starting 300 bp before the transcription initiation start (Figure 4.8.A). In 
the construct prPLK4-+1, the only promoter region remaining flanked the 
transcription initiation point (see Material and Methods), whereas the prPLK4-
2634-1256 was designed to contain only the three main κB sites (-2634, -1947 
and -1256) including the transcription initiation start. These various constructs 
were used to clarify the importance of the various κB sites and NF-κB binding 
preferences. 
Before looking at the NF-κB effect on these plasmids, it was necessary 
to check the basal activation of the various constructs. U2OS cells were 
transiently transfected with the different plasmids and luciferase assays were 
performed to check the activity of the promoter. Normalizing the results to 
harvested protein level, Figure 4.8.B shows that, although the deletion of the     
-3587 κB site did not have any effect on the basal activation of the PLK4 
promoter, other mutations decreased the activity by approximately 40%. This 
means that the -3587 site is probably not involved in the regulation of basal 
PLK4 activity but all other κB sites are, although no single deletion is enough to 
completely shut down PLK4 activity. 
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Figure 4-8: Luciferase constructs for the PLK4 promoter 
A. Schematic overview of the various PLK4 promoter constructs used for the 
luciferase assays. Constructs prPLK4-full length, prPLK4-+1 and prPLK4-2634-
1256 were made by Dundee Cell Products. Constructs prPLK4-D3537 and 
prPLK4-D1256 were generated by restriction enzyme digestion (SacI and KpnI 
respectively) and ligation, using the prPLK4-full length as template, as 
described in Material and Methods. B. Basal activation for the various luciferase 
constructs, relative to prPLK4-full length. Error bars show the standard error of 
at least 3 independent experiments. 
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4.2.7 NF-κB subunit regulation of the PLK4 promoter 
To look at the effect of NF-κB on the PLK4 promoter, U2OS cells were 
transfected with plasmids overexpressing (Figure 4.9.A) or down-regulating 
(Figure 4.9.B) the various NF-κB subunits and luciferase assays were 
performed. With the exception of the p100/p52 shRNA, published previously 
(Schumm et al, 2006), all NF-κB subunits shRNAs have been validated by our 
collaborator’s lab (Rocha lab, Dundee, personal communication). 
Overexpression of the NF-κB subunits showed that all of them increased PLK4 
promoter activity to varying levels (Figure 4.9.A). p52, RelA and RelB doubled 
the activity, whereas c-Rel and p50 increased the activity three fold. Curiously, 
down-regulating the NF-κB subunits did not have the opposite effect. Deletion 
of p100/p52, c-Rel or p50 did not affect the average activity of the PLK4 
promoter, while RelA deletion slightly reduced its activity. Despite being small, 
this decrease was significantly different to the control. Interestingly, RelB 
depletion by shRNA had a similar effect to its overexpression: full length PLK4 
promoter activity increased by two fold whether RelB was overexpressed 
(Figure 4.9.A) or absent (Figure 4.9.B).  
The increase in promoter activity after RelB depletion contradicts the 
effect seen on PLK4 mRNA expression, when RelB siRNA depletion decreased 
PLK4 mRNA levels (Figure 3.6). The cause of duality of this effect by the RelB 
subunit is not known. 
U2OS cells were also depleted for all NF-κB subunits simultaneously 
using the pan-NF-κB shRNA, along with the luciferase reporter plasmid and 
luciferase assays were performed. However, no effect could be detected 
compared to the control (data not shown), suggesting that the effects of 
independent NF-κB subunits could neutralize each other.  
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Figure 4-9: NF-κB subunits effects on the PLK4 promoter 
A. Overexpression of NF-κB subunits. U2OS cells were subjected to 
transient DNA transfection to overexpress NF-κB subunits, together with a 
plasmid encoding the luciferase reporter gene, under the control of the full 
length PLK4 promoter. B. NF-κB depletion. U2OS cells were subjected to 
transient DNA transfection to down-regulate NF-κB subunits, along with a 
plasmid encoding the luciferase reporter gene, under the control of the full 
length PLK4 promoter. 48h later, cells were processed for a luciferase assay. 
Results were normalized to protein yield and then shown relative to a plasmid 
control. Error bars show the standard error of at least 3 independent 
experiments. * P<0,05; ** P<0,001; *** P<0,0001 
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4.2.8 Cooperation between NF-κB subunits 
In order to identify the composition of possible the NF-κB dimers most 
actively regulating the PLK4 promoter, U2OS cells were transfected with the 
PLK4 promoter luciferase reporter and a combination of NF-κB subunit 
expression plasmids. Figure 4.10.A shows that the strongest effect on luciferase 
assays was seen with c-Rel and p52 co-expression. When p52 was present in 
combination with RelB and p50, the effect was larger than when p52 was in the 
presence of RelA. RelA had a more potent effect with p50 (Figure 4.10.B), but 
RelA effects were generally weaker than with other subunits. Indeed, the 
strongest activation of the PLK4 promoter was obtained after co-expression of 
c-Rel with RelB (Figure 4.10.C) or with p50 (Figure 4.10.D). It is interesting to 
note that p52 usually increased PLK4 promoter activity by only two fold, 
whereas any involvement of c-Rel or RelB usually increased activity by at least 
three fold at least (with the exception of RelA) (Figure 4.10).  
This data suggest that c-Rel and RelB could be the main components of 
the NF-κB dependent regulation of PLK4 promoter activity. 
 
4.2.9 Depletion of multiple NF-κB subunits 
As RelA and RelB were the only subunits giving a significant effect on 
PLK4 promoter activity after depletion by shRNA, to identify the influence of the 
other subunits on this effect, U2OS cells were co-transfected with different 
shRNA expressing plasmids in order to down-regulate two NF-κB subunits 
simultaneously. Luciferase assays were then performed to determine PLK4 
promoter activity. However, no matter which combination of NF-κB subunits 
was tried with RelA or RelB depletion, no further effect was seen on full length 
PLK4 promoter activity (Figure 4.11.A. and 4.11.B.). The strongest cooperative 
effect was seen with simultaneous RelB and p50 depletion, although this was 
not statistically significant and would need further validation. By contrast, 
despite the fact that single depletion of c-Rel or p50 did not affect PLK4 
promoter activity (Figure 4.9.B. and Figure 4.11.C), a simultaneous depletion of 
these subunits increased PLK4 promoter activity (Figure 4.11.C). Once again, it 
is interesting to note that depletion increased PLK4 promoter activity, in the 
same way as the over-expression.   
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Figure 4-10: NF-κB subunits cooperatively induce the PLK4 promoter 
U2OS cells were subjected to transient DNA transfection to overexpress various 
combination of NF-κB subunits, along with a plasmid encoding the luciferase 
reporter gene under the control of the full length PLK4 promoter. A. 
overexpression of p52, with the other NF-κB subunits. B. overexpression of 
RelA, with the other NF-κB subunits. C. overexpression of RelB, with the other 
NF-κB subunits. D. overexpression of cRel, with the other NF-κB subunits. Error 
bars show the standard error of at least 3 independent experiments. * P<0,05; 
** P<0,001; *** P<0,0001 
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Figure 4-11: shRNA depletion of multiple NF-κB subunits 
U2OS cells were subjected to transient DNA transfection to down-regulate 
various combination of NF-κB subunits, along with a plasmid encoding the 
luciferase reporter gene, under the control of the full length PLK4 promoter. 48h 
later, cells were processed for a luciferase assay. Results were normalized to 
protein yield and then shown relative to a plasmid control. A. and B. RelA (A.) 
or RelB (B.) depletion, combined with the depletion of the other NF-κB subunits. 
C. cRel and p50 depletion, separately or combined. Error bars show the 
standard error of at least 3 independent experiments. * P<0,05 
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4.2.10 Differential effect of RelB depletion with PLK4 promoter deletions 
As the RelB shRNA was the only one to affect PLK4 promoter activity in 
a luciferase assay (Figure 4.9.B), I investigated the effect of depleting this 
subunit on the various PLK4 promoter deletions constructs (Figure 4.8). As 
observed in Figure 4.12, RelB depletion affected all PLK4 constructs, increasing 
their activity. However, the effect was the strongest for the construct prPLK4+1, 
which contained only the region flanking the transcription initiation start. 
However, when the PLK4 promoter was deleted of all κB sites 5’ to the 
transcription initiation start, but leaving the κB sites downstream intact, RelB 
depletion had only a minimal effect (Figure 4.12).  
 
4.2.11 NF-κB subunit effects on the PLK4 promoter deletion constructs 
As overexpression of all NF-κB subunits increased PLK4 promoter 
activity with varying intensity (Figure 4.9.A), I next investigated their effect on 
the PLK4 promoter deletion constructs. U2OS cells were transfected with 
plasmids overexpressing the various NF-κB subunits, along with the PLK4 
promoter deletion luciferase reporter plasmids. The most interesting effect was 
once again seen with c-Rel overexpression (Figure 4.13). Here, c-Rel 
overexpression increased full length promoter activity by three fold but all the 
deletion constructs exhibited a 4 fold increase in activity. Similar effects were 
seen with p50 and RelB overexpression, where promoter deletions had little 
effect on their ability to induce PLK4 promoter activity.  
By contrast, the effects of p52 and RelA overexpression did show some 
selectivity. Here, the full length promoter and the prPLK4-Δ3587 and prPLK4-
Δ1256 mutants were induced but the effect on the two other constructs 
(prPLK4+1 and prPLK4-2634-1256) was significantly reduced compared to the 
full length promoter. This suggests that with these subunits, some contribution 
to regulation of PLK4 promoter activity derives from both the upstream and 
downstream κB sites.  
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Figure 4-12: RelB depletion regulates the different PLK4 promoter 
constructs 
U2OS cells were subjected to transient DNA transfection to down-regulate the 
RelB NF-κB subunit, along with a plasmid encoding the luciferase reporter 
gene, under the control of the various PLK4 promoter constructs. 48h later, 
cells were processed for a luciferase assay. Results were normalized to protein 
yield and then shown relative to a plasmid control. Error bars show the standard 
error of at least 3 independent experiments. ** P<0,001 
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Figure 4-13: Effects of NF-κB subunits on the different PLK4 promoter 
constructs 
U2OS cells were subjected to transient DNA transfection to overexpress NF-κB 
subunits, along with a plasmid encoding the luciferase reporter gene, under the 
control of the various PLK4 promoter constructs. 48h later, cells were 
processed for a luciferase assay. Results were normalized to protein yield and 
then shown relative to a plasmid control. Error bars show the standard error of 
at least 3 independent experiments. * P<0,05; ** P<0,001; *** P<0,0001 
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4.3 Discussion 
 
Previous results in chapter 3 showed that the p52 NF-κB subunit 
regulates the expression of genes involved in centrosome duplication. Further 
studies demonstrated that one of these genes, PLK4, is a target gene for all 
NF-κB subunits. The next investigation was to determine whether this regulation 
is direct, through NF-κB binding to the PLK4 promoter, or indirect, through 
association with other transcription factors.  
Consensus κB sites have been previously described in the literature 
(Natoli et al, 2005) and analysis of the PLK4 promoter revealed seven such 
potential κB sites. ChIP analysis in human cell lines (U2OS cells and Hela cells) 
demonstrated that NF-κB subunits bind to the PLK4 promoter, mainly on three 
of these potential κB sites, the -2634, -1947 and -1256 sites (Figure 4.2). 
Quantification showed that the NF-κB subunits bind to the PLK4 promoter with 
various intensities (Figure 4.3.A).  
One of the main issues encountered during this thesis was experimental 
variability. As seen in Figure 4.3.B, final quantification of NF-κB binding to the 
PLK4 promoter was hard to determine, as two sets of data seems to be 
available for each subunit. For some experiments, NF-κB binding to the κB sites 
in the PLK4 promoter is very strong, for other experiments, binding is just 
slightly above the IgG negative control. Interestingly, for the prPLK4-2634 κB 
site, p52 displayed very strong binding, whereas for the prPLK4-1947 κB site, 
RelA, RelB and c-Rel have stronger binding in U2OS cells (Figure 4.3.B). The 
prPLK4-1256 κB site does not show any preference for a particular NF-κB 
subunit. However, binding was different in H1299 cells, where RelB seemed the 
more important subunit as it was associated with all three κB sites in the PLK4 
promoter. However, these results in H1299 cells are preliminary, as more 
repeats are needed, so no final conclusion can be drawn from them. Despite 
multiple repeats, changes in experimental conditions or modifications of the 
ChIP protocol, the variability observed could not been resolved. Other 
modifications of the ChIP protocol will be performed with more repeats in order 
to have definitive and publishable results. However, despite the reproductibility 
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issue in the quantification of NF-κB binding to the PLK4 promoter, the results 
demonstrate that PLK4 is a direct NF-κB target gene. 
Specificity of binding for the p52 subunit was confirmed using siRNA 
depletion in U2OS cells and Hela cells (Figure 4.5). After p100/p52 siRNA 
treatment, p52 binding was reduced by half in both cell lines for all κB sites 
tested. Similar experiments are also ongoing to validate the binding specificity 
of the other NF-κB subunits. Moreover, the binding of the various NF-κB 
subunits will be quantified after deletion of one or several of the subunits, to 
underline the influence of NF-κB subunits on others’ binding to the PLK4 
promoter. Moreover, exogenous HA-tagged p52 transfection in Hela cells 
allowed p52 binding to be validated using an HA antibody (Figure 4.6). 
Overexpression of a DNA binding mutant of p52 unable to bind DNA but still 
able to dimerize and associate with other transcription factors (Schumm et al, 
2006), showed a decrease in p52 binding but not a complete depletion. This 
suggests that association with another NF-κB subunit or interaction with 
heterologous transcription factor seems to be sufficient for p52 binding. Thus it 
will be necessary to determine exactly which complexes are involved in NF-κB 
regulation of PLK4. To facilitate this, ChIP reverse (ReChIP) analysis will be 
performed in various cell lines. Along with siRNA depletion experiments, 
ReChIP analysis should allow us to determine the main complexes involved in 
NF-κB regulation of PLK4 expression. 
In order to validate PLK4 as a NF-κB target gene, the orthologous mouse 
promoter was studied and three putative κB sites were identified. Interestingly, 
the first thing to note is the placement of these κB sites (Figure 4.7). None of 
them are situated in a region analogous to the human promoter. Instead, they 
can be found closer to the transcription initiation start. ChIP analysis in wild type 
MEFs demonstrated p52 binding to the three putative κB sites, whereas the p50 
subunit was only present in the mprPLK4+135 site and RelA bound to the 
mprPLK4-21 and mprPLK4+135 PLK4 κB sites (Figure 4.7.B). RelB and cRel 
did not appear to bind to the PLK4 promoter in these conditions. By contrast, it 
is interesting to note that when p52 was absent (obtained with nfkb2 -/- MEFs, 
Figure 4.7.C), RelB and cRel were able to bind to the PLK4 promoter. Further 
experiments will be required to quantify this NF-κB binding and determine if p52 
has a negative effect on c-Rel and RelB binding. Nonetheless, these 
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experiments validated PLK4 as a NF-κB target gene, whether in human cancer 
cells or in murine fibroblasts.  
As nfkb2 -/- MEFs were at our disposal, it was then interesting to study 
basal mRNA levels for PLK4. In nfkb2 -/- MEFs, PLK4 mRNA levels increased 
two fold compared to wild type MEFs. This implies that p52 can also be a 
negative regulator of PLK4 expression, in addition to the seemingly positive 
regulatory role found in human cell lines (Figures 3.4 and 3.6). Unquantified 
observations showed that nfkb2 -/- MEFs proliferated faster than wild type 
MEFs (data not shown), meaning that nfkb2 -/- MEFs overcame the absence of 
p52 for proliferation. This increased PLK4 mRNA levels in nfkb2 -/- MEFs 
correlate with this, suggesting other NF-κB subunits can compensate for p52 
absence in regulating PLK4 expression. The finding that other subunits also 
bind to the PLK4 promoter in the absence of p52 is consistent with this. 
However, the exact mechanism still needs to be identified. 
To help understand the mechanism of NF-κB regulation of the PLK4 
gene, various deletions of the human promoter were created in luciferase 
reporter plasmids. These deletions removed one or more of the κB sites 
previously identified. Luciferase assays on the basal PLK4 promoter activity 
showed that suppressing the upstream κB site did not have an effect on PLK4 
promoter activity, but keeping only a minimal promoter without any κB sites 
decreased the basal activity by two (Figure 4.8).  
Overexpression of the NF-κB subunits increased the full length PLK4 
promoter activity to various degrees, with the p50 subunit having the strongest 
effect. This corroborates results seen at the protein levels (Figure 3.7), where 
overexpression of the NF-κB subunits increased endogenous PLK4 protein 
levels, p50 overexpression having a strong effect on endogenous PLK4 levels. 
Furthermore, overexpression of the NF-κB subunits with the various PLK4 
deletions constructs did not reveal a specific NF-κB responsive region (Figure 
4.13). This suggests that despite NF-κB binding these regions (shown in 
Figures 4.2 and 4.3), the critical sites for regulation happen somewhere else, 
the luciferase reporter plasmids do not accurately reflect the occupation of the 
endogenous genes.  
 115 
Experiments to look at NF-κB subunit cooperation demonstrated that 
induction of the full length PLK4 promoter activity is stronger in case of 
overexpression of multiple NF-κB subunits than the overexpression of only one 
subunit (Figure 4.10). Higher induction of the PLK4 promoter activity was 
obtained after co-overexpression of c-Rel with p52, RelB or p50. Interestingly, 
c-Rel/RelA overexpression did not have a different effect than overexpression 
of RelA or c-Rel separately, suggesting that this hetero-dimer does not regulate 
PLK4 promoter activity. These experiments illustrate the complexity of NF-κB 
regulation of the PLK4 promoter, as not one hetero-dimer appeared to be more 
important than another. However, it seems that whenever c-Rel consistently 
was a strong inducer of promoter activity when co-expressed with another NF-
κB subunit. 
Surprising results were obtained on the PLK4 promoter activity after NF-
κB shRNA depletion. Indeed, the only subunits showing an effect were RelA, 
with a small decrease in PLK4 promoter activity, and RelB, where depletion 
induced an increase in PLK4 promoter activity (Figure 4.9.B). These results are 
the opposite to the effect seen after siRNA depletion, which decreased 
endogenous PLK4 mRNA and protein levels (Figure 3.6). Other NF-κB subunit 
depletion did not have an effect on the PLK4 promoter, as did depletion of all 
NF-κB subunits at once with the pan-NF-κB shRNA (data not shown). Depletion 
of combinations of NF-κB subunits also did not show any significant effect for 
potential RelA or RelB hetero-dimers (Figure 4.11). However, it is interesting to 
note that, although single c-Rel or p50 shRNA depletion did not affect PLK4 
promoter activity, dual depletion of these two subunits increased full length 
promoter activity (Figure 4.11.C). c-Rel/p50 co-depletion also had the same 
effect on the PLK4 promoter activity as overexpressing the c-Rel/p50 
heterodimer, suggesting a major influence of this dimer on the PLK4 promoter 
activity regulation. However, these results suggest that the luciferase reporter 
plasmid does not accurately mimic the activity of the endogenous PLK4 
promoter. 
RelB depletion also increased the activity of all PLK4 constructs (Figure 
4.12), with the strongest activation being seen for the minimal promoter, and a 
reduced effect when the PLK4 promoter lacked the κB sites upstream of the 
transcription start. This data suggests that RelB repression of the PLK4 
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promoter happens through the core promoter region and results either from the 
presence of a cryptic unidentified κB site or occurs through an indirect 
mechanism. Previous results support both hypotheses. Indeed, the trouble with 
ChIP reproductibiliy, showing either very high binding of NF-κB subunits 
(including RelB, Figure 4.3) or reduced binding could be explained by the 
presence of an unknown κB site. Unpredictable sonication during the ChIP 
protocol could sometimes produce DNA fragments containing this unknown κB 
site but recognized with the primers designed to the other κB sites, while at 
other times these sites were excluded. Alternatively, ChIP signals could result 
from DNA looping between this distal κB site and the promoter regions detected 
using PCR. However, the hypothesis of regulation luciferase assays not 
accurately reporting endogenous activity is supported by the opposing effects 
seen between PLK4 promoter activity (Figure 4.9) and PLK4 expression (Figure 
3.6) following RelB depletion. Indeed, RelB depletion increased PLK4 promoter 
activity but reduced endogenous PLK4 mRNA and protein expression. To date, 
experiments do not allow us to completely discard any of these hypotheses so 
more investigation will be necessary to either identify this unknown κB site or to 
explain the indirect mechanism. However, luciferase assays support the 
hypothesis that, so far, I have been looking at a wrong κB sites and that NF-κB 
regulation probably happens somewhere else within the PLK4 gene. 
Unfortunately, these assays were performed at the end of the study, not 
allowing me the time to re-analyze the PLK4 promoter and identify potential 
new κB sites responsible for NF-κB binding to the promoter. Another 
observation to support the hypothesis of investigating the wrong κB sites is the 
study of the mouse promoter. The human and mouse promoters share a high 
sequence homology, especially close to the transcription initiation start and 
close to the identified κB sites in mice. Therefore, it is possible that the human 
PLK4 promoter posseses cryptic NF-κB binding sites closer to the initiation 
transcription start analogous to the sites in the mouse promoter, which are 
involved in its regulation. Investigating this will be a priority to complete this 
study. 
The absence of an effect after depletion of other NF-κB subunits on 
PLK4 promoter activity in the luciferase assays has various explanations. Even 
though the shRNA plasmids have been validated, it is possible that the level of 
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NF-κB depletion encountered is not enough to affect PLK4 promoter activity, 
with the exception of RelB. Indeed, RelB is the subunit seen to bind more 
strongly the PLK4 promoter (Figures 4.3. and 4.4), so even a small change in 
the expression of RelB could affect promoter activity. Alternatively, as discussed 
above, it is possible that the luciferase reporter plasmid does not correctly 
mimic PLK4 promoter activity. This could results either from the exclusion of a 
distal enhancer region that mediates NF-κB effects with the endogenous gene. 
Alternatively, NF-κB may mediate effects on chromatin structure that have little 
effect with a transiently transfected reporter plasmid, as luciferase reporter 
plasmids are not properly chromatinized.  
 
4.4 Conclusion 
 
This chapter allowed us to determine that PLK4 is a direct target gene for 
NF-κB regulation and that NF-κB subunits bind to various κB sites on the 
promoter. However, PLK4 promoter activity analysis, due to a variety of 
sometimes opposing effects, raises the possibility of either an unidentified κB 
sites or an indirect mechanism being involved in NF-κB regulation of PLK4 
expression. Since PLK4 is a tightly cell cycle regulated gene, the next chapter 
will describe attempts to determine the NF-κB’s regulation during the cell cycle 
and potentially identify opposite effects during various cell cycle phases. 
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5 – Results Chapter 3: Cell cycle regulation 
 
5.1 Introduction 
 
As seen previously, PLK4 is a direct target for NF-κB regulation. Indeed, 
all NF-κB subunits bind to various κB sites on the PLK4 promoter. Moreover, 
NF-κB overexpression or depletion affects PLK4 expression, as well as PLK4 
promoter activity. However, so far, it has not been possible to determine a 
regulatory mechanism for NF-κB on the PLK4 promoter. 
A possible explanation arises from the tight regulation of PLK4 during the 
cell cycle. Experiments in murine fibroblasts showed that SAK (PLK4 murine 
orthologous form) mRNA levels were minimal in G1 phase, increased in late G1 
to be maximal through S phase and mitosis, before decreasing in early G1 
(Fode et al, 1996). This was demonstrated using a nocodazole-induced mitotic 
arrest or restart of cell growth after quiescence. However, regulation of protein 
levels or kinase activity during the cell cycle has not yet been studied (Winkles 
& Alberts, 2005). 
To investigate whether NF-κB subunits have potentially different effects 
on PLK4 regulation during the cell cycle, cell cycle synchronization was 
performed. Various agents were tested to optimize cell synchronization. DNA 
profile analysis allowed me to determine the various phases of the cell cycle in 
order to study PLK4 and p100/p52 mRNA and proteins level variability.  
ChIP analysis for each phase of the cell cycle was then performed, to 
determine variation in the binding of the NF-κB subunits to the PLK4 promoter. 
Two synchronization agents were used to validate the results. Different NF-κB 
binding to the PLK4 promoter during the phases of the cell cycle could explain 
the interesting effects seen on the PLK4 promoter activity after NF-κB depletion, 
which were opposite to the effects seen at mRNA levels. 
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5.2 Results 
 
5.2.1 Cell synchronization  
In order to study the effect of the cell cycle on NF-κB regulation of PLK4 
and consequent variations in mRNA expression, several agents were used to 
synchronize the cells. U2OS cells were treated with different drugs, as stated in 
Material and Methods, washed and released in fresh media. Different time-
points were then harvested, as indicated in Figure 5.2, and the DNA profile was 
checked by flow cytometry. Three of the agents did not give successful 
synchronization, while two others gave good synchronization and progression 
through the cell cycle after release. These are described below. 
The first trial used aphidicolin, which stops the cells in late G1 by 
inhibiting DNA polymerase α, thus blocking DNA synthesis (Figure 5.1). Before 
washing and release, 60% of the cells were blocked in G1, which was not 
sufficient for a robust synchronization (Figure 5.2.A). Moreover, after release 
the cells did not show correct progression through S and G2/M phases. 
Serum starvation, which blocks the cells in G0/G1 by forcing the cells to 
go into G0 quiescence due to nutritional deprivation (Figure 5.1), induced a 
60% accumulation of the U2OS cells in G0/G1 phase but they did not re-enter 
the cell cycle after washing and release, even after 24h (Figure 5.2.B).  
The last unsuccessful agent was nocodazol. It blocks the polymerization 
of microtubules, and as a consequence, cells that enter into mitosis fail to form 
a correct mitotic spindle and therefore remain in G2/M (Figure 5.1). U2OS cells 
treated in this way were indeed blocked in G2/M but did not progress into the 
cell cycle after release (Figure 5.2.C).  
Synchronization was more efficient using two agents that block in late G1 
– early S phase. Hydroxy-urea decreases the production of dNTPs by inhibition 
of ribonucleotide reductase and thymidine induces an imbalance of dNTPs and 
thus blocks DNA synthesis (Figure 5.1). 
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Drugs used Mode of Action Block 
Hydroxy-urea Decreases the production of dNTPs by 
inhibition of ribonucleotide reductase 
(Ma & Poon, 2011) 
 
Late G1/ early S 
phase 
Thymidine  Inhibition of DNA synthesis by creation 
of an imbalance of dNTPs (Ma & 
Poon, 2011) 
 
early S phase 
Serum starvation Nutritional deprivation, forcing the cells 
to go into G0 quiescence phase (Kues 
et al, 2000) 
 
G0/G1 
Aphidicolin Inhibitor of the DNA polymerase a: 
blocks DNA synthesis (Ma & Poon, 
2011) 
 
Late G1 
Nocodazole Blocks the polymerization of 
microtubules: cells enter into mitosis 
but can not form the mitotic spindle 
(Jordan et al, 1992) 
 
G2/M (prophase) 
 
Table 5-1: Overview of drugs tested for synchronization 
Table summarizing the drugs tested for synchronization, as well as their 
mechanism of action and blocking point during the cell cycle. 
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Figure 5-2: cell cycle analysis after synchronization using the various 
drugs tested 
Cells were treated by the indicated synchronization agents: A aphidicolin (1 nM 
for 12h), B. serum starvation (growth overnight in 0.5%FBS), C. nocodazol (2 
mM for 20h), D. hydroxy-urea (2 mM overnight), E. and F. double-thymidine 
block (2 mM for 18h, release for 9h, 2 mM for 14h) as described in Material and 
Methods and the DNA profile was analyzed by flow cytometry. Data presented 
shows the DNA profile at different times after release in comparison to 
untreated cells (control cells) 
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After hydroxy-urea treatment, cells were blocked between 65% and 74% 
in G1 phase. After release, the cells then progressed in a synchronized fashion 
through the cell cycle, to reach between 60% and 75% in G2/M phase, 10 hours 
after release (Figure 5.2.D and Figure 5.3.A). Good results were also obtained 
using a double-thymidine block. Cells were harvested every hour after release 
from the double-thymidine block, and cell cycle analysis demonstrated a 60% 
block in G1 phase that progressed to 70% of the cells ending up in G2/M, 10 
hours after release (Figure 5.2.E). Best results were obtained by pooling cells 
from two time-points, such as mixing cells from 1h and 2h after release, or 3h 
and 4h after release (Figure 5.2.F). This allowed for an improved 
homogenization of the cells and better DNA profile (Figure 5.3.B). Thus this 
technique will be used later. 
 
5.2.2 PLK4 and p52 levels during the cell cycle 
As PLK4 is a tightly regulated gene during the cell cycle (Pearson & 
Winey, 2010; Winkles & Alberts, 2005), and the p52 NF-κB subunit is involved 
in this regulation, U2OS cells were synchronized using hydroxy-urea or a 
double-thymidine block and mRNA and protein levels were investigated at each 
phase of the cell cycle. As seen in Figure 5.4.A, p100 mRNA levels increased to 
reach a maximum in G1/S and S phases, before slowly decreasing to go back 
to the initial level. By contrast, PLK4 levels decreased to reach a minimum in S 
phase and then quickly rose to be at a maximum in S/G2 and G2/M phases. 
Treatment of the cells by hydroxy-urea (Figure 5.4.A, left panel) gave clearer 
results than the double-thymidine block (Figure 5.4.B, right panel), but this is 
probably only due to the fact that more results were available for the first 
technique, and mRNA levels have the same profile with both types of 
synchronization, confirming my results.  
Protein levels were then studied using the double-thymidine block. 
Generally p100 and p52 protein levels did not vary much during the cell cycle 
(Figure 5.4.B). However, PLK4 protein levels were almost undetectable prior to 
S phase, where it slightly increased and then reached a maximum in S/G2 
phase, before once again decreasing slightly.  
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Figure 5-3: DNA profiles after synchronization with hydroxy-urea or 
double-thymidine block 
Cells were treated with hydroxy-urea (A.) or double-thymidine block (B.) as 
described in Material and Methods and the DNA profile was analyzed by flow 
cytometry. Data show the DNA profile at different times after release and is 
representative of 3 independent experiments. 
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Figure 5-4: PLK4 and p52 levels during the cell cycle 
A. Cells were synchronized with hydroxy-urea (left panel) or double-thymidine 
block (right panel), released as described in Material and Methods and. mRNA 
expression was analyzed by quantitative PCR, compared to the housekeeper 
gene GAPDH and related to the expression at the G1 phase of the cell cycle. 
Error bars represent the standard deviation for at least 3 independent 
experiments. B. Cells were synchronized with a double-thymidine block, 
released as described in Material and Methods and analyzed by Western Blot 
for PLK4 expression and S222-p52 protein phosphorylation.  
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Similar results were found after hydroxy-urea treatment (data not shown). 
These results, together with the mRNA profile, indicate that post-transcriptional 
modification is likely to be involved after the regulation by transcription factors.  
A phosphoproteomic study demonstrated, in 2008, that p52 can be 
phosphorylated at Ser222 and this phosphorylation is specific for mitosis 
(Dephoure et al, 2008). Being interested in post-transcriptional modifications on 
the NF-κB subunits, our laboratory produced an antibody for the phosphorylated 
form of Ser222-p52. Looking at the various phases of the cell cycle, I confirmed 
that phosphorylation at Ser222 of p52 slowly increases and reaches its maximal 
level in G2/M phase (Figure 5.4.B).  
 
 
5.2.3 Cyclin and CDKs levels during the cell cycle 
A part of my project was to characterize the effect of p52 on cell 
proliferation, I thus decided to look at cyclin and CDK mRNA levels during the 
different phases of the cell cycle following cell synchronization. CDK1, CDK2 
and CDK4 mRNA levels did not vary much during the cell cycle (Figure 5.5). 
The strongest result can be seen for cyclin B1 expression, where a clear 
increase was detected during the cell cycle with a maximum being seen in 
G2/M phase, compared to the basal level at G1. Cyclin E mRNA peaked at the 
G1/S transition, where its protein is needed and then decreased slowly. Cyclin 
D1 levels did not vary much during the cell cycle and cyclin A mRNA had a 
similar profile as cyclin B1, with an increase through the cell cycle to reach the 
highest level in S/G2 and G2/M. This is to be expected because cyclin A forms 
a complex with CDK1 to promote entry into mitosis (Deshpande et al, 2005). 
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Figure 5-5: cyclin and CDK mRNA expression during the cell cycle 
U2OS cells were synchronized using a double-thymidine block and released as 
described in Material and Methods. mRNA expression was analyzed by 
quantitative PCR, compared to the housekeeper gene GAPDH and related to 
the expression at the G1 phase of the cell cycle. Errors bars represent the 
standard deviation for at least 3 independent experiments.  
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5.2.4 NF-κB binding to the PLK4 promoter during the cell cycle 
Earlier I determined that PLK4 was a NF-κB target gene but that NF-κB 
binding on the PLK4 promoter was difficult to quantify due to high variability. I 
also showed, in agreement with other published data, that PLK4 expression is 
tightly regulated during the cell cycle. A possible explanation of these effects is 
that NF-κB binding to the PLK4 promoter is cell cycle dependent, which could 
explain the problems with variability, as the cells studied were asynchronous. 
 To investigate this hypothesis, U2OS cells were synchronized in G1 
phase using hydroxy-urea and released as described in Material and Methods. 
ChIP assays were performed for each phase of the cell cycle, with antibodies 
against each NF-κB subunit and using IgG as a negative control. Quantification 
was performed using qPCR with primers against the PLK4 promoter κB sites 
previously studied (Figure 5.6). The first observation of the overall data is, with 
few exceptions (the p52 and p50 subunits for example), NF-κB subunits behave 
similarly for the various κB sites tested at each phase of the cell cycle (Figure 
5.6). After hydroxy-urea synchronization, p52 binding was higher in G1/S for the 
prPLK4-2634 κB site, whereas it was higher in S phase for the prPLK4-1947 κB 
site and at the same level for the prPLK4-1256 site (Figure 5.6). RelA seemed 
to mainly bind the three κB sites in S/G2 phase. The binding of the RelB subunit 
to the PLK4 promoter is higher in G2/M, but RelB’s presence was also detected 
at the prPLK4-1947 site in S phase and at the prPLK4-1256 site in G1/S phase. 
c-Rel showed preferential binding at the end of the cell cycle (from S phase to 
G2/M phase), with the exception of the prPLK4-1256 κB site. The p50 subunit 
mainly bound in S phase, except for the prPLK4-2634 site where maximal 
occupancy was seen in G2/M phase (Figure 5.6). However, despite numerous, 
reproducibility was still an issue during the experiment, so another type of cell 
synchronization was investigated, with the hope of decreasing the variability of 
the results. 
Results were clearer with synchronization with the double-thymidine 
block, but this other type of synchronization did not solve all the issues with 
reproducibility. In Figure 5.7, it can be seen that p52 was bound primarily in G1 
phase to both the prPLK4-1947 and prPLK4-1256 sites, and in G1 and G1/S 
phases at the prPLK4-2634 site (Figure 5.7).  
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Figure 5-6: NF-κB binding on the PLK4 promoter during the cell cycle 
after hydroxy-urea treatment 
U2OS cells were synchronized with hydroxy-urea, released as described in 
Material and Methods, fixed by paraformaldehyde and processed for a ChIP 
assay for each phase of the cell cycle, using antibodies against the various NF-
κB subunit and IgG as a negative control. qPCR was performed with primers for 
the NF-κB binding sites, -1947 and -1256. Error bars show the standard error of 
at least 3 independent experiments. * P<0,05 
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Figure 5-7: NF-κB binding on the PLK4 promoter during the cell cycle 
after double-thymidine block 
U2OS cells were synchronized with a double-thymidine block, released as 
described in Material and Methods, fixed by paraformaldehyde and processed 
for a ChIP assay for each phase of the cell cycle, using antibodies against the 
various NF-κB subunit and IgG as a negative control. qPCR was performed with 
primers for the NF-κB binding sites, -1947 and -1256. Error bars show the 
standard error of at least 3 independent experiments. * P<0,05 
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The RelA subunit showed the same pattern of binding for the prPLK4-
2634 and prPLK4-1256 sites, with main binding being early in the cell cycle, 
whereas RelA was present at the prPLK4-1947 site during G2/M. RelB mainly 
associated with the prPLK4-2634 site in G1/S phase, to the prPLK4-1947 site in 
S phase and S/G2, while binding was slightly earlier in G1/S for the prPLK4-
1256 site. c-Rel binding mainly occurred in G1/S phase for all three κB sites, 
whereas p50 seemed more important in S phase (Figure 5.7). 
However, as it can been seen in Figures 5.6 and 5.7, error bars for each 
experiment were very large. Therefore, whit this thesis, I have included two 
independent, representative, experiments for the cell synchronization using 
double-thymidine block (Appendix A to E). These experiments illustrate the 
problems seen with variability between experiments. The p52 subunit, in one 
experiment, mainly bound to the three κB sites in G1 and S phase, whereas in 
the second experiment, the binding occurred in G1/S and S/G2, almost as if the 
timing for cell synchronization was altered (Appendix A). RelA showed a 
different profile between the two experiments (Appendix B), with the main 
binding for the three κB sites in G2/M for the exp2, whereas the first experiment 
demonstrated strong binding in S/G2 for the prPLK4-2634 and prPLK-1256 
sites and in S phase for the prPLK4-1947 site. RelB binding occurred either in S 
phase or S/G2 phase (Appendix C). Binding of c-Rel was strongly detected in 
G2/M for the three κB sites in one experiment, and in G1/S phase in the other 
(Appendix D). The p50 subunit was the one with the most variation between 
experiments. In one experiment, very strong binding occurred in G2/M phase 
for the prPLK4-1947 site (Appendix E, experiment 2), whereas in the other 
experiment, no significant binding could be detected (Appendix E, experiment 
1). p50 either bound, to the same extent, the prPLK4-2634 site in G1 phase 
(Appendix E, Experiment 1) or in S/G2 (Appendix E, Experiment 2). Regarding 
the prPLK4-1256 site, the two independent experiments showed p50 binding 
either in G1 phase or in S/G2 and G2/M phases. These variations of results 
were not reduced, regardless of the changes in experimental conditions that 
were tried. 
Figure 5.8 summarizes the percentage of experiments in which binding 
of NF-κB subunits to the various PLK4 promoter κB sites was higher than the 
IgG control, for each phase of the cell cycle. In red are those with a percentage 
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higher than 50%. It is interesting to note that the prPLK4-2634 and prPLK4-
1256 sites have a very similar pattern. p52 was the main subunit binding during 
the G1 and S phases but the other subunits were more involved in the rest of 
the cell cycle, specifically p50 during the transition phase (83.3% and 100% of 
binding on both sites during G1/S and 66.7 and 83.3% during S/G2) (Figure 
5.8). At the prPLK4-1256 site, c-Rel and RelB were always bound in G2/M (and 
half the time for prPLK4-2634). This finding indicates that those proteins are 
likely to form a complex with p50, which was also detected in this time point. 
The prPLK4-1947 site had a different pattern early in the cell cycle, but the 
G2/M phase was similar (binding of RelB and c-Rel) (Figure 5.8).  
Based on the correlations between the binding patterns of individual NF-
κB subunits, some potential dimers regulating PLK4 expression during the cell 
cycle can be hypothesized. In S phase a dimer of p52-RelB seems to be 
forming, whereas in S/G2 there appears to be a hetero-dimer of p52-RelA (p52 
always binds in S and S/G2 phases, and c-Rel seems mainly in G2/M phase). 
ReChIP analysis needs to be performed to confirm these observations. 
 
5.3 Discussion 
 
As seen previously, NF-κB binds to the PLK4 promoter and affects its 
activity. However, these results suggest that the mechanism involved is more 
complex than expected. As PLK4 is a tightly cell cycle regulated gene, it was 
investigated whether the cell cycle affects NF-κB regulation of the PLK4 
expression. To this extend, cell synchronization was optimized in U2OS cells 
and several agents were tested. 
Nocodazole treatment, which induces a mitotic arrest by blocking 
microtubule polymerization (Figure 5.1), resulted in more than 70% of cells 
becoming arrested in G2/M phase. However, it could not be use for our 
experiments, as the cells did not re-enter the cell cycle when nocodazole was 
removed (Figure 5.2). Similarly, it has been published that nocodazole is not 
suitable for synchronizing Hela cells (Cooper et al, 2006).  
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Figure 5-8: percentage of positive NF-κB binding on the PLK4 promoter 
Tables summarizing the percentage of positive binding for the NF-κB subunits 
on the PLK4 promoter during the cell cycle. 5 or more experiments were done 
for each NF-κB subunit and percentage was calculated for each binding higher 
than IgG control related to n total of experiments. U2OS cells were 
synchronized double-thymidine block, released as described in Material and 
Methods, fixed by parafornaldehyde and processed for a ChIP assay for each 
phase of the cell cycle. In red, the case where a positive binding was detected 
in more than 50% of the experiments performed. 
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Serum starvation, which forces the cell to go into G0 quiescence phase 
due to lack of nutriments, also did not work in our conditions (Figure 5.2). This 
result was surprising, as serum starvation was previously used in the lab to 
synchronize U2OS cells (Barre & Perkins, 2007; Roche et al, 2004). It does 
illustrate, however, how experimental conditions can affect the outcome of 
experiments. The use of a new batch of cells or different culture conditions such 
as different serum can affect results. Cell passage number can also have an 
effect, as demonstrated with regulation of oxygen consumption by RelA in 
U2OS cells, where different results were obtained depending on whether the 
cells were from an early or late passage (Johnson et al, 2011). Cell 
synchronization using aphidicolin, thereby blocking the cells in late G1 phase by 
inhibition of DNA polymerase α, thus stopping DNA synthesis (Figure 5.1). 
Aphidicolin was known to be efficient for cell synchronization (Pedrali-Noy et al, 
1980). Treatment of U2OS cells resulted in 60% of cells synchronized in G1 
phase, while release did lead to progression through the cell cycle (Figure 5.2). 
However, the proportions of cells in each phase were too low for our purpose, 
as we did not obtain more than 50% of cells in G2/M phase. Therefore, this 
technique was also discarded for later experiments.  
Two techniques were optimized successfully, both blocking cells in late 
G1 or early S phase. Double-thymidine block inhibits DNA synthesis by creation 
of an imbalance of dNTPs, whereas hydroxy-urea decreases the production of 
dNTPs available for DNA synthesis by inhibition of ribonucleotide reductase 
(Figure 5.1). Both techniques allowed good synchronization of cells in G1 
phase, as well as progression through the cell cycle (Figures 5.2 and 5.3), 
corresponding to what has been published for these agents (Ma & Poon, 2011). 
However, it is important to note that all these synchronization techniques used 
chemical agents that can induce stress responses and possibly DNA damage 
responses in the cells. Consequently, they are not as efficient or as 
reproducible as elutriation. Elutriation is a centrifugation technique that 
separates the cells depending on their size and had been used previously with 
success on U2OS cells to enrich cells at different cell cycle stages (Barre & 
Perkins, 2007). Nonetheless, despite its attractiveness, synchronization by 
elutriation was not possible due to the lack of equipment available. Therefore, 
the results obtained with hydroxy-urea or double-thymidine block must be 
considered with some caution. 
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Analysis of the nfkb2 and PLK4 genes reveal that they display opposing 
patterns of expression during the cell cycle (Figure 5.4). Indeed, nfkb2 is 
maximal in G1/S, which is expected due to the involvement of p52 at the G1/S 
transition (Hinz et al, 1999; Rocha et al, 2003b; Schumm et al, 2006). By 
contrast, PLK4 levels started to rise in S phase to be maximal in G2/M, in 
accordance with what has been previously published (Pearson & Winey, 2010). 
These results were detected by both means of synchronization, hydroxy-urea 
and double-thymidine block. Protein levels were slightly different (Figure 5.4.B), 
with maximal levels being reached in S/G2 phase followed by a rapid decrease 
in G2/M, suggesting post-transcriptional regulation. This result would be in 
accordance with the fact that PLK4 is a short-live protein (Sillibourne & 
Bornens, 2010b). The absence of PLK4 protein detected in G1 and G1/S 
phases is contradicted by literature stating that maximal PLK4 kinase activity is 
found in G1/S phase at the duplicating mother centriole (Pearson & Winey, 
2010). Further analysis would need to be required to explain this result but it is 
possible that, PLK4 being located at the centriole, the level of proteins was too 
low to be detected by western blot. 
In 2008, a phospho-proteomic study identified some phospho sites in 
p100/p52 specifically phosphorylated during G2/M phase (Dephoure et al, 
2008). Our lab is particularly interested in the p52 Ser222 phosphorylation; 
therefore it was investigated in the synchronized U2OS cells. Ser222 
phosphorylation has also been shown to be carried out by GSK3β and be 
responsible for the repression of the Skp2 promoter by p52 (Barre & Perkins, 
2010). My results showed an increase of Ser222 phosphorylation during the cell 
cycle, with a maximum level in G2/M phase (Figure 5.4), concurring with 
published data (Dephoure et al, 2008). Besides GSK3β, little is known about 
kinases responsible for Ser222-p52 phosphorylation, and it will be interesting to 
identify the kinases involved during mitosis. I also investigated the effect of a 
few G2/M kinase inhibitors, such as a PLK inhibitor, to block PLK1 and PLK3 
kinase activity; roscovitin, a CDK inhibitor and RO-3306, an inhibitor specific to 
CDK1, under the conditions recommended by the manufacturers. However, no 
apparent effect was detected on Ser222 p52 phosphorylation after these 
treatments, possible indication that these kinases are not involved in p52 
modification (data not shown). However, these results have to be treated 
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carefully, as no positive control was performed to confirm the experimental 
conditions.  
Our laboratory will soon be in possession of transgenic mice mutated at 
Ser222 in the nfkb2 gene: S222A mice which will lack the ability of being 
phosphorylated at Ser222, and S222D mice, which are phospho-mimetic 
mutants of the wild type mice.  It will be interesting to determine PLK4 levels in 
these mice, and determine whether Ser222 p52 phosphorylation is involved in 
PLK4 regulation of centrosome duplication or affects p52’s functions in G2/M 
phase. 
ChIP analyses were performed on each phase of the cell cycle for the 
three κB sites previously identified (Figures 5.6 to 5.9 and Appendix A to E), 
either after hydroxy-urea or double-thymidine block. Both types of 
synchronization did not show the same results and furthermore, all results 
demonstrated a high variability between experiments (Figures 5.6. and 5.7). 
Detailed analysis of two independent experiments (Appendix A to E) showed a 
shift of the phase of binding in many of the cases, with, for example, the p52 
subunit binding to the prPLK4-2634 site mainly in G1 and S phases for 
experiment 1 and in G1/S and S/G2 phases for experiment 2 (Appendix A). This 
shift was also found for the RelB subunit at the prPLK4-2634 site, with binding 
in S or S/G2 phase (Appendix C).  
 A possible explanation for this shift in binding in different phases of the 
cell cycle is that despite our careful analysis of the cell DNA profile to separate 
the various phases, it is possible that cell cycle progression varied between 
experiments and FACS analysis was not sensitive enough to detect this. A 
possible way to overcome this would be to base the separation between phases 
not on the DNA profile but on a biochemical analysis. We could, for example, 
use one of the cyclins, such as cyclin B1, as a reference with the highest 
mRNA/protein expression being used as a marker for G2/M phase, whereas the 
lowest would mean G1 phase. Now that the PLK4 levels have been described, 
they could also be used as reference. This could lead to reduced variation 
between experiments. Another possibility is to perform cell synchronization 
based on cell size by using elutriation. Other factors can also be involved to 
explain these results. For example, although experiments were repeated as 
closely as possible, external factors such as cell confluency within the plate or 
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the passage number could affect the cell culture conditions and thus the 
response to the synchronization agent. Chapter 4 also raised also some issues 
of reproducibility and it was suggested that potential unknown κB sites were still 
to be identified, situated closer to the initiation transcription start. If this was the 
case, it could also explain the variation between the results obtained with 
independent experiments. More careful analysis will be performed in the future 
to remedy these issues. 
Importantly, this shift between phases of the cell cycle did not always 
happen and some results were more reproducible, such as c-Rel binding in 
G1/S phase to the prPLK4-1947 and prPLK4-1256 sites (Appendix D). 
Consequently, it was possible to determine the percentage of experiments in 
which NF-κB binding was higher than IgG control (Figure 5.8). The general 
pattern showed that, assuming the κB sites were correct, NF-κB binds to the 
prPLK4-2634 site mainly during the early cell cycle (G1 to S), whereas for the 
prPLK4-1947 site, later binding, from S to G2/M phases can be detected. 
However, for the prPLK4-1256 κB site, no conclusion could be made, as 
various NF-κB subunits bind at different times of the cell cycle. This suggests 
that NF-κB regulation of the PLK4 promoter is more complex than expected, as 
potentially the same subunit could bind at different κB sites during various 
stages of the cell cycle, and possibly induce different response of the promoter. 
This hypothesis could also explain the effect seen on the PLK4 promoter 
activity in luciferase assays, where NF-κB depletion had very little effect, 
whereas it had a strong effect on expression of the endogenous gene.  
  
 137 
5.4 Conclusion 
 
In this chapter, I studied the expression of the nfkb2 and PLK4 genes 
during each phase of the cell cycle and I determined that they have opposing 
mRNA patterns. I also studied NF-κB binding to the various κB sites in the 
PLK4 promoter during the cell cycle. Although this generated some hypotheses 
about the potential mechanism involved, the data is still too preliminary to fully 
understand the NF-κB regulation of the PLK4 promoter and further experiments 
will be required. 
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6  Discussion 
 
 
6.1 Introduction 
 
The aim of this thesis was to investigate the regulation of cancer cell 
proliferation and mitosis by NF-κB. I was especially interested in the 
characterization of the effect of the p52 subunit on the cell cycle and to explore 
its regulation of centrosome duplication. To support this purpose, I based my 
research on previous data obtained in the lab, including both published and 
unpublished observations. These data demonstrated that p52 was involved in 
cell proliferation through the regulation of cyclin D1 expression. The p52 NF-κB 
subunit also appeared to be involved in regulation of the centrosome, as its 
depletion induced major defects in centrosome structure in the cell but no 
further analysis had been performed to determine the mechanism of regulation. 
Therefore, it was interesting to try to resolve how p52 might regulate both 
centrosome structure and duplication. The results presented in this thesis link 
p52 to the centrosome and suggest that this NF-κB subunit regulates the 
expression of genes involved in centrosome duplication. More importantly, one 
of these genes, PLK4, is identified in this thesis as a new NF-κB target gene 
that could provide a link between NF-κB and the mitotic events. These 
implications will be discussed in this section and possible future experiments 
will be highlighted. 
 
6.2 The p52 NF-κB subunit and the cell cycle 
 
The link between NF-κB and regulation of the cell cycle is now well 
known. Indeed, in 1998, Grumont et al described that c-Rel -/- or nfkb1 -/- B 
cells failed to proliferate in response to mitogen activation and induced an 
accumulation of cells in G1 phase (Grumont et al, 1998). A few months later, 
Guttridge et al made the link with the cyclin D1 regulation by NF-κB (Guttridge 
et al, 1999). From then on, a lot of research was invested in this area and soon, 
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various links were found. For example, c-Rel induces an increase in cyclin D1 
expression and promotes mammalian tumorigenesis (Romieu-Mourez et al, 
2003), while the p50 subunit could have an opposite effect. Formation of c-
Rel/p50 heterodimers induces cyclin D1 expression (Romieu-Mourez et al, 
2003), whereas in TNF-α stimulated cells, p50 could associate to the cyclin D1 
promoter and repress its transcription (Witzel et al, 2010). In the cell lines 
investigated in the Perkins lab, the main NF-κB subunit involved in cyclin D1 
regulation is p52. As described before, p52 depletion by siRNA treatment 
induces G1/S arrest through the loss of cyclin D1 expression (Schumm et al, 
2006). My data confirmed p52 regulation of cyclin D1 protein and mRNA 
expression (Figure 3.3). The expression of other cyclin genes was not affected 
by the p100/p52 siRNA depletion; although, CDK2 and CDK4 expression were 
seen to be reduced.  This was supported by recent results in the Perkins lab 
showing the down-regulation of CDK4 expression upon p100/p52 siRNA 
depletion in human fibroblast (Figure 3.9) (A. Iannetti, unpublished micro-array 
data). Therefore, future experiments will try to determine, using ChIP analysis, 
whether CDK4 is a direct NF-κB target and what are the dimers involved in its 
regulation. To date, no connection has been made between p52 and CDK2 but 
RelA has been shown to regulate CDK2 expression in laryngeal squamous 
cancer cell (Liu et al, 2011). It is probable that CDK2 and CDK4 regulation is 
involved in the p52 regulation of the G1/S transition, but nothing more have 
been described yet. It would be interested to test whether CDK2 or CDK4 
downregulation blocks the cells in G1/S phase and in what extent this can be 
linked solely to regulation by p52. Ultimately, this would help to clarify the 
oncogene and tumor suppressor roles of NF-κB. 
 
6.3 NF-κB and centrosomes 
 
Centrosomal abnormalities are frequently found in cancer, especially in 
the early events of tumorigenesis and these usually lead to chromosome 
missegregation. They usually trigger multinucleate cells and chromosomal 
instability and can be used as prognostic indicator for tumor progression 
(Gustafson et al, 2000; Kuo et al, 2000; Pihan et al, 2001). An important but 
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hypothetical link between centrosome abnormalities and NF-κB was made 
when these were commonly found in hematologic malignancies, tumours often 
overexpressing p52 (Rayet & Gelinas, 1999). However, some of our preliminary 
data (K.Schumm, unpublished observations) suggested that p52 down-
regulation also induces such centrosome abnormalities, as it was observed by 
immunofluorescence and electron microscopy. Although I was not able to 
repeat these observations, I was able to localize p100/p52 to the centrosome. 
As U2OS cells undergo cell cycle arrest upon p100/p52 depletion, an effect on 
centrosome is unlikely to be seen since a consequence of this is also the arrest 
of the centrosome duplication cycle. Further experiments, using stable cell lines 
depleted for p100/p52 that have overcome the arrest in cell cycle, will be used 
to confirmed these effects 
 
6.4 Regulation of the centrosome duplication by NF-κB 
 
CDK2 and CDK4 have been described as regulators of centrosome 
duplication. Indeed, Adon et al demonstrated that in case of p53 -/- MEFs, 
CDK2 and CDK4 were hyperactive and, through hyperphosphorylation of Rb 
and uncontrolled E2F-dependent transcription, lead to the aberrant expression 
of molecules involved in centrosome duplication (Adon et al, 2010). However, in 
case of these p53-/- MEFS, when either CDK2 or CDK4, or both, were 
depleted, normal centrosome duplication was restored (Adon et al, 2010). 
These results confirmed the importance of CDK proteins for normal centrosome 
regulation. My data showing that p52 (and possibly other NF-κB subunits, but it 
will need to be confirmed) participates in the regulation of CDK2 and CDK4 
expression could then suggest NF-κB involvement in the regulation of 
centrosome duplication in the case of the absence of p53. This idea will be 
further investigated using Hela cells, which express a non functional p53 
protein, or H1299 cells, which are p53 depleted. H1299 cells are a particularly 
interesting system for investigation, as my laboratory possesses a p53 inducible 
variation of this cell line. Using this cell line, I would be able to determine if p52 
depletion is involved in CDK2 and CDK4 regulation of centrosome duplication 
and any p53 involvement in this process. This hypothesis is supported by a 
recent study demonstrating that CDK2 is a RelA target gene and that inducing 
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RelA upregulates CDK2 expression and promotes centrosome amplification 
(Liu et al, 2011). Overepressing the p52 subunit will be an important experiment 
to perform, in order to determine possible aberrant centrosome number. 
PLK4, whose down-regulation reduces centriole number and thus induces 
aneuploidy, was recently described to be associated with a poor survival 
prognosis in hepatocellular carcinoma (Liu et al, 2012). My results showed that 
NF-κB is essential for PLK4 expression regulation and its promoter activity in 
some cell types. Among the defects in mitosis previously detected after 
p100/p52 depletion in U2OS cells, a failure in cytokinesis and multinucleate 
cells could be seen. These results can be linked to my regulation of PLK4 
expression by p52. This hypothesis is supported by the fact that PLK4+/- MEFs 
exhibit defective cytokinesis, an increase in centrosome number and 
multinucleate cells (Rosario et al, 2010). So PLK4 could be the link between the 
p52 subunit and the phenotypes of aberrant centrosome structure, mitotic 
spindle, multinucleate cells and chromosomal instability previously observed.  
This will be investigated further, with the help of wild type or nfkb2-/- 
MEFs. Observations in these cells will determine whether they have increased 
centrosome number, which is the expected result due to the upregulation of 
PLK4 detected in these cells (Chapter 4). Previous unpublished data suggested 
that p52 siRNA depletion did not increase centrosome number. This is 
consistent with my data, shown either by immunofluorescence (Figure 3.2) or 
with the p52 regulation of PLK4. Indeed, p100/p52 siRNA depletion decreases 
PLK4 expression (Figure 3.4), and PLK4 reduction has been shown to block the 
centrosome duplication (Bettencourt-Dias & Glover, 2007). It has also been 
shown that PLK4 overexpression induces centriole overamplification (Kleylein-
Sohn et al, 2007), therefore the effect of overexpressing p52 and other NF-κB 
subunit will be studied.  
It is interesting to note that CDK2 and CDK4 down-regulation, induced by 
p100/p52 depletion in my model, is thought to amplify centrosome duplication 
(Adon et al, 2010), whereas centrosome overamplification will be inhibited by 
reduced PLK4 expression (Bettencourt-Dias & Glover, 2007), also regulated by 
NF-κB. My own observations determined that p100/p52 depletion did not 
increase the number of centrosome (Figure 3.2 and K.Schumm unpublished 
observation), therefore supporting PLK4 regulation effect. It is possible that 
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centrosome overamplification expected after CDK2 and CDK4 down-regulation 
is overcome by the p52 effect on PLK4, key factor for centriole duplication. 
However, further analysis will be required to confirm this hypothesis.  
 
6.5 Cell cycle effect 
 
My data suggests that p52’s main effect on the cell cycle is regulation of 
the G1/S transition, through the regulation of CDKs and cyclin D1. It is also the 
start of the centrosome duplication cycle, which supports my hypothesis of p52 
involvement in this process. To emphasize this, PLK4 is mainly active in late 
G1/early S phase, to initiate centriole duplication. However, my experiments 
demonstrated that PLK4 mRNA was maximal towards the end of the cell cycle, 
from late S phase to G2/M, which was confirmed by published data (Winkles & 
Alberts, 2005). I then investigated whether p52 and NF-κB regulation vary 
during the cell cycle. To achieve this, I used synchronized cells and studied the 
binding of NF-κB to the PLK4 promoter. Although unfortunately no definitive 
mechanism could be concluded, due to the in the binding seen, my analysis 
showed that NF-κB appears to mainly bind to one κB site, the prPLK4-2634 
site, during the early cell cycle (G1 to S phases) and to another, prPLK4-1947, 
during the late cell cycle (S to G2/M phases). It is possible that this change of 
binding sites induces different responses in PLK4 promoter activity, but this will 
need to be investigated further, possibly using reporter gene assays on 
synchronized cells. This altered effect of p52 during the cell cycle has already 
been described for the regulation of c-myc, cyclin D1 and Skp2 expression 
(Barre & Perkins, 2007) and is linked to the phosphorylation of RelA inducing 
the formation of different activator or repressor heterodimers. It is a mechanism 
that could possibly be applied to PLK4, a tightly cell cycle regulated gene, 
especially as p52 is known to possess cell cycle-dependent phosphorylation 
sites, such as Ser222.  
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6.6 NF-κB phosphorylation 
 
The Ser222 phosphorylation of the p52 subunit has been described 
previously as a specific event of mitosis (Dephoure et al, 2008), which was 
confirmed in this study (Chapter 5). However, no mitotic kinase has yet been 
identified as being responsible for this phosphorylation. A phospho-proteomic 
study identified the p52 subunit as a potential target for PLK1 phosphorylation 
(Grosstessner-Hain et al, 2011) and sequence analysis of the p100 sequence 
found consensus sites for the Aurora A, CDK and PLK kinases. Nonetheless, 
my analysis suggests that in my conditions, the PLK1 and CDKs kinases were 
not responsible for Ser222 phosphorylation of p52 (Chapter 5), as inhibiting 
their kinase activity had no effect (data not shown). It will be interesting as to 
investigate whether PLK4 depletion reduces Ser222 p52 phosphorylation and 
also to determine if Ser222 phosphorylation affects p52 regulation of PLK4. 
This will be helped by the creation of Ser222 p52 mutant mice, soon available in 
the lab. These mice, containing mutations at the Ser222 residue that will render 
Ser222 either non phosphorylable (S222A mice) or phospho mimicking but 
insensible to Ser/Thr kinases (S222D mice), will aid in the determination the 
mechanism behind p52-dependent regulation of G2/M phase. Other data 
suggests that NF-κB’s phosphorylation state may be important in the regulation 
of PLK4. For example, the RelA subunit is phosphorylated at the Thr505 in S 
phase (Barre & Perkins, 2007), inhibiting its transcriptional activity. An ongoing 
project in the lab found that transgenic T505A mice displayed multiple mitotic 
defects in the liver and that PLK4 mRNA levels were higher than in wild-type 
mice (personal communication), suggesting that Thr505 RelA phosphorylation 
is involved in RelA regulation of PLK4. This mouse model reinforce our 
hypothesis of differential effects due to the phosphorylation state of NF-κB and 
will be used for further experiments, in parallel with the S222 mouse models. 
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6.7 Final conclusion 
 
This thesis aimed to explain the role of the p52 NF-κB subunit in cell 
proliferation and centrosome duplication. Although no final explanation was 
found, some interesting leads were discovered. First, I determined that p52 
regulates other genes involved in the cell cycle in addition to cyclin D1. It also 
became apparent that p52 is involved in the regulation of centrosome 
duplication genes and that one of these genes, PLK4, is a direct NF-κB target 
gene. I demonstrated that multiple κB sites mediate NF-κB binding to the PLK4 
promoter and that these sites can differentially regulate NF-κB binding during 
the cell cycle, resulting in various effects on promoter activity. Further analysis 
will be required to fully identify these effects, to complete the characterization of 
NF-κB regulation of the PLK4 promoter and ultimately, NF-κB regulation of 
centrosome duplication.  
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7 Appendixes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 7-1: the p52 subunit binds the PLK4 promoter during the cell 
cycle 
U2OS cells were synchronized double-thymidine block, released as described 
in Material and Methods, fixed by parafornaldehyde and processed for a ChIP 
assay for each phase of the cell cycle, using antibodies against the p52 subunit 
and IgG as a negative control. qPCR was performed with primers for the NF-κB 
binding sites -2634, -1947 and -1256. Data show a representation of 2 
independent experiments, demonstrating the variation of results obtained 
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Appendix 7-2: the RelA subunit binds the PLK4 promoter during the cell 
cycle 
U2OS cells were synchronized double-thymidine block, released as described 
in Material and Methods, fixed by parafornaldehyde and processed for a ChIP 
assay for each phase of the cell cycle, using antibodies against the RelA 
subunit and IgG as a negative control. qPCR was performed with primers for 
the NF-κB binding sites -2634, -1947 and -1256. Data show a representation of 
2 independent experiments, demonstrating the variation of results obtained 
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Appendix 7-3: the RelB subunit binds the PLK4 promoter during the cell 
cycle 
U2OS cells were synchronized double-thymidine block, released as described 
in Material and Methods, fixed by parafornaldehyde and processed for a ChIP 
assay for each phase of the cell cycle, using antibodies against the RelB 
subunit and IgG as a negative control. qPCR was performed with primers for 
the NF-κB binding sites -2634, -1947 and -1256. Data show a representation of 
2 independent experiments, demonstrating the variation of results obtained 
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Appendix 7-4: the cRel subunit binds the PLK4 promoter during the cell 
cycle 
U2OS cells were synchronized double-thymidine block, released as described 
in Material and Methods, fixed by parafornaldehyde and processed for a ChIP 
assay for each phase of the cell cycle, using antibodies against the cRel subunit 
and IgG as a negative control. qPCR was performed with primers for the NF-κB 
binding sites -2634, -1947 and -1256. Data show a representation of 2 
independent experiments, demonstrating the variation of results obtained 
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Appendix 7-5: the p50 subunit binds the PLK4 promoter during the cell 
cycle 
U2OS cells were synchronized double-thymidine block, released as described 
in Material and Methods, fixed by parafornaldehyde and processed for a ChIP 
assay for each phase of the cell cycle, using antibodies against the p50 subunit 
and IgG as a negative control. qPCR was performed with primers for the NF-κB 
binding sites -2634, -1947 and -1256. Data show a representation of 2 
independent experiments, demonstrating the variation of results obtained. 
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